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ABSTRACT	
The	 »600kb	 16p11.2	 CNVs	 (breakpoints	 4–5,	 29.6-30.2	 Mb-Hg19)	 are	 among	 the	 most	
frequent	genetic	 risk	 factors	 for	neurodevelopmental	and	psychiatric	 conditions:	A	10-fold	
enrichment	 of	 deletions	 and	 duplications	 is	 observed	 in	 autism	 cohorts	 and	 a	 10-fold	
enrichment	of	duplications	in	schizophrenia	cohorts.	Previous	studies	demonstrated	“mirror”	
effects	 of	 both	 CNVs	 on	 body	 mass	 index	 and	 head	 circumference	
(deletion>control>duplication).	However,	the	large	global	effect	of	brain	size	and	the	sample	
size	of	the	two	previous	neuroimaging	studies	limited	the	interpretation	of	the	analyses	on	
regional	brain	structures,	any	estimate	of	the	effect	size,	and	the	generalizability	of	the	results	
across	different	ascertainments	of	the	patients.	
In	 the	 first	part	of	my	Ph.D.,	 I	 analyze	 structural	magnetic	 resonance	 imaging	 (MRI)	on	78	
deletion	carriers,	71	duplication	carriers,	and	212	controls.	I	show	that	both	CNVs	affect	in	a	
“mirror”	way	the	volume	and	the	cortical	 surface	of	 the	 insula	 (Cohen’s	d>1),	whilst	other	
brain	regions	are	preferentially	altered	 in	either	 the	deletion	carriers	 (calcarine	cortex	and	
superior,	middle,	transverse	temporal	gyri,	Cohen’s	d>1)	or	the	duplication	carriers	(caudate	
and	 hippocampus,	 Cohen’s	 d	 of	 0.5	 to	 1).	 Results	 are	 generalizable	 across	 scanning	 sites,	
computational	 methods,	 age,	 sex,	 ascertainment	 for	 psychiatric	 disorders.	 They	 partially	
overlap	with	results	of	meta-analyses	performed	across	psychiatric	disorders.	
In	the	second	part,	 I	characterize	the	developmental	 trajectory	of	global	brain	metrics	and	
regional	 brain	 structures	 in	 the	 16p11.2	 CNV	 carriers.	 I	 adapt	 a	 previously	 published	
longitudinal	 pipeline	 and	 normalizing	 method,	 derived	 from	 339	 typically	 developing	
individuals	aged	 from	4.5	 to	20	years	old.	From	this	population	of	 reference,	 I	Z-score	our	
cross-sectional	16p11.2	dataset	and	show	that	all	the	brain	alterations	in	the	16p11.2	carriers	
are	already	present	at	4.5	years	old	and	follow	parallel	trajectories	to	the	controls.	
In	summary,	my	results	suggest	that	brain	alterations,	present	in	childhood	and	stable	across	
adolescence	and	adulthood,	are	related	to	the	risk	conferred	by	the	16p11.2	CNVs,	regardless	
of	the	carriers’	symptoms.	Additional	factors	are	therefore	likely	required	for	the	development	
of	 psychiatric	 disorders.	 I	 highlight	 the	 relevance	 of	 studying	 genetic	 risk	 factors	 and	
mechanisms	 as	 a	 complement	 to	 groups	 defined	 by	 behavioral	 criteria.	 Further	 studies	
comparing	multiple	CNVs	and	monogenic	conditions,	from	the	earliest	age,	are	required	to	
understand	 the	 onset	 of	 neuroanatomical	 alterations	 and	 their	 overlap	 between	 different	
genetic	risk	factors	for	neurodevelopmental	disorders.	 	
 	 7	
RÉSUMÉ	
Les	variations	en	nombre	de	copies	(CNV),	au	locus	16p11.2	et	d’une	taille	d’»600kb	(points	
de	cassure	4–5,	29.6-30.2	Mb-Hg19)	représentent	un	des	facteurs	de	risque	génétique	les	plus	
fréquents	parmi	les	troubles	psychiatriques	:	10%	d’enrichissement	en	délétion	et	duplication	
pour	 les	 troubles	 du	 spectre	 autistique,	 10%	 d’enrichissement	 en	 duplication	 pour	 la	
schizophrénie.	 Les	 effets	 «	miroirs	 »	 des	 deux	CNVs	 sur	 l’indice	 de	masse	 corporelle	 et	 le	
périmètre	 cranien	ont	déjà	été	démontrés	 (délétion>contrôle>duplication).	Cependant,	 les	
différences	en	taille	de	cerveau	et	 les	échantillons	des	deux	précédentes	études	de	neuro-
imagerie	ont	limité	les	analyses	des	régions	cérébrales,	l’estimation	de	la	taille	des	effets,	et	
la	généralisation	des	résultats	selon	les	modes	de	recrutement	des	patients.	
Dans	cette	thèse,	j’analyse	les	images	par	résonance	magnétique	(IRM)	de	78	porteurs	de	la	
délétion,	71	porteurs	de	la	duplication	et	212	participants	contrôles.	Je	montre	que	les	deux	
CNVs	sont	associées	à	des	différences	«	en	miroir	»	du	volume	et	de	la	surface	corticale	de	
l’insula	(Cohen’s	d>1),	tandis	que	le	cortex	calcarin,	les	gyri	temporaux	supérieur,	moyen	et	
transverse	sont	préférentiellement	altérés	par	la	délétion	(Cohen’s	d>1),	les	noyaux	caudés	et	
l’hippocampe	 sont	 préférentiellement	 altérés	 par	 la	 duplication	 (0.5<Cohen’s	 d<1).	 Les	
résultats	 sont	 généralisables	 à	 travers	 les	 differents	 sites	 d’IRM,	 les	 méthodes	 d’analyse	
computationnelle,	les	âges,	les	sexes	et	les	divers	diagnostiques	psychiatriques	des	patients.	
Les	résultats	chevauchent	partiellement	ceux	d’une	méta-analyse	sur	plusieurs	diagnostiques	
psychiatriques.	Dans	un	second	temps,	je	caractérise	la	trajectoire	développementale	de	ces	
différences	cérébrales.	J’adapte	un	pipeline	longitunal	et	une	méthode	de	normalisation	déjà	
publiés,	construits	à	partir	de	339	participants	contrôles	de	4.5	à	20	ans.	Je	calcule	des	Z-scores	
pour	nos	données	transversales	et	montre	que	les	différences	cérébrales	liées	aux	CNVs	sont	
déjà	 présentes	 à	 4.5	 ans,	 avec	 les	 mêmes	 tailles	 d’effet	 et	 une	 trajectoire	 parallèle	 aux	
contrôles.	En	résumé,	mes	résultats	suggèrent	que	les	différences	cérébrales,	présentes	dans	
la	jeune	enfance	et	stables	à	l’adolescence	et	l’âge	adulte,	sont	liées	au	risque	conféré	par	les	
CNVs	 en	 16p11.2,	 quelque	 soient	 les	 symptômes.	 Des	 facteurs	 additionnels	 sont	
probablement	nécessaires	pour	le	développement	de	maladies	psychiatriques.	Je	montre	la	
pertinence	 d’étudier	 les	 facteurs	 de	 risque	 génétiques	 en	 complément	 des	 groupes	 de	
patients	définis	sur	des	critères	comportementaux.	Des	études	comparant	diverses	conditions	
génétiques,	dès	la	naissance,	sont	nécessaires	pour	comprendre	le	début	et	le	chevauchement	
des	différences	neuro-anatomiques	observées	pour	différents	facteurs	de	risque	génétiques.	 	
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LIST	OF	ABBREVIATIONS	
CNV	 	 copy	number	variant	
ASD	 	 autism	spectrum	disorder	
SCZ	 	 schizophrenia	
NDD	 	 neurodevelopmental	disorder	
ID	 	 intellectual	disability	
DSM-5		 diagnostic	and	statistical	manual	of	mental	disorder,	5th	version	
Simons	VIP	 Simons	variation	in	individuals	project	
BMI	 	 body	mass	index	
HC	 	 head	circumference	
FSIQ	 	 full	scale	intelligence	quotient	
VIQ	 	 verbal	intelligence	quotient	
NVIQ	 	 non-verbal	intelligence	quotient	
MRI	 	 magnetic	resonance	imaging	
TIV	 	 total	intracranial	volume	
GM	 	 grey	matter	
WM	 	 white	matter	
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1.	INTRODUCTION	
1.1	Copy	Number	Variants	and	psychiatric	disorders	
1.1.1	Definition	of	copy	number	variants	
Copy	 number	 variants	 (CNVs)	 are	 variations	 of	 chromosomal	 structure,	widespread	 in	 the	
human	 genome	 (>1000	 CNVs),	 including	 deletion,	 duplication,	 inversion	 and	 translocation	
(Malhotra	 &	 Sebat	 2012).	 Thanks	 to	 the	 recent	 key	 evolution	 of	 technologies	 (as	 the	
chromosomal	microarray	analysis,	and	most	recently	the	whole-genome	sequencing)	and	the	
clinical	 application	 of	 these	 genomic	 arrays,	 we	 begin	 to	 understand	 their	 essential	
contribution	to	inter-individual	genetic	and	phenotypic	variations.	Many	CNVs	are	probably	
benign,	underlying	common	normal	traits,	and	some	of	them	are	associated	with	common	
Mendelian	 conditions,	 such	 as	 colorblindness,	 Charcot–Marie–tooth	 disease	 type	 1A,	 etc.	
Some	variations	can	influence	susceptibility	to	complex	diseases	such	as	Alzheimer’s	disease,	
Crohn’s	disease,	and	to	infection	such	as	the	Human	Immunodeficiency	Virus	(Lupski	2007).	
Therefore,	 they	are	 thought	 to	play	a	major	 role	 in	 the	etiology	of	common	disorders	and	
complex	multifactorial	 traits,	 and	 they	 could	 explain	 the	 variable	 penetrance	 of	 inherited	
diseases	(Beckmann	et	al.	2007).	
In	 this	 thesis,	 I	 focus	on	the	deletion	and	duplication	of	a	 recurrent	CNV,	 identified	as	 risk	
factors	 for	 intellectual	disabilities	 (ID),	 autism	spectrum	disorders	 (ASD)	and	 schizophrenia	
(SCZ).	The	recurrence	is	based	on	the	consistent	breakpoints	of	the	CNVs	among	individuals,	
and	they	occur	in	specific	locations	in	the	genome,	at	the	level	of	segmental	duplications,	also	
called	low-copy	repeat-LCR	sequences	(large	stretches	of	DNA	with	similar	sequences).	If	these	
LCR	are	misaligned	during	meiosis,	this	leads	to	a	crossing	over	between	two	chromosomal	
sites	 and	 products	 a	 recurrent	 CNV:	 this	 process	 is	 called	 nonallelic	 homologous	
recombination	(Moreno-De-Luca	&	Cubells	2011).	Recurrent	reciprocal	CNVs	allow	studying	
the	effect	of	gene	dosage	 in	 individuals	carrying	1,	2	or	3	copies	of	a	genomic	 region.	The	
deletion	(1	copy	of	the	genomic	segment)	and	the	duplication	(3	copies)	can	disrupt	a	variable	
number	 of	 genes.	 Aberrations	 in	 the	 number	 of	 copies,	 haplo-insufficiency	 and	 over-
expression	of	the	genes,	represent	unique	paradigms	to	identify	pathways	sensitive	to	gene	
dosage	in	humans.	They	open	a	new	way	for	the	study	of	diseases	mechanisms	and	some	new	
approaches	to	potential	treatments,	in	which	the	goal	is	not	to	correct	abnormal	or	mutant	
proteins	but	to	modify	their	abnormal	dosage.	
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1.1.2	Psychiatric	diagnoses	
Psychiatric	disorders	are	diagnosed	based	on	clinical	criteria	from	the	5th	version	of	diagnostic	
and	statistical	manual	of	mental	disorder	(DSM-5,	American	Psychiatric	Association)	or	from	
the	 10th	 revision	 of	 the	 international	 classification	 of	 diseases	 (ICD-10,	 World	 Health	
Organisation).	
According	to	DSM-5,	neurodevelopmental	disorders	(NDDs)	are	a	group	of	conditions	with	an	
onset	 early	 in	 development.	 They	 are	 characterized	 by	 a	 series	 of	 developmental	 deficits,	
producing	impairments	of	social,	academic	and/or	occupational	functioning:	they	include	ID	
(prevalence	of	about	1%)	and	ASD.	Three	criteria	must	be	met	to	fill	in	the	diagnostic	of	ID:	1-
deficits	in	intellectual	functions,	2-deficits	in	everyday	adaptive	functioning	to	reach	personal	
independence	 and	 social	 responsibility,	 3-onset	 during	 the	 developmental	 period.	 ASD	
diagnosis	 is	 based	on	 characteristic	 deficits	 in	 social	 communication	 and	 social	 interaction	
across	multiple	context,	as	well	as	an	excess	of	repetitive	behaviours	and	restricted	interests.	
ASD	frequently	co-occur	with	 ID	and	 language	 impairment.	The	prevalence	 is	estimated	to	
affect	up	to	than	1	in	68	children	(Christensen	et	al.	2012)	and	males	have	a	>3-fold	higher	risk	
for	ASD	than	females	(Volkmar	et	al.	2004).		
SCZ	belongs	to	the	“Schizophrenia	spectrum	and	other	psychotic	disorders”	conditions.	SCZ	
involves	a	large	range	of	cognitive,	behavioural	and	emotional	dysfunctions.	Individuals	meet	
at	least	two	of	these	active-phase	symptoms	during	1	month:	first	delusions,	hallucinations,	
disorganized	 speech,	 and	 also	 disorganized	 or	 catatonic	 behaviour,	 negative	 symptoms	
affecting	emotional	expression	or	volition.	These	symptoms	affect	every	day	functioning	and	
the	 disturbance,	 including	 prodromal	 or	 residual	 symptoms,	 has	 to	 persist	 for	 at	 least	 6	
months.	
1.1.3	The	contribution	of	copy	number	variants	to	psychiatric	disorders	
The	 psychiatric	 disorders	 present	 an	 important	 heterogeneity	 and	 a	 complexity	 of	 the	
symptoms	 in	 clinics.	 Instead	 of	 considering	 this	 heterogeneity	 as	 noise,	 it	 represents	 a	
challenge:	 understanding	 them	 is	 a	 mandatory	 step	 to	 classify	 the	 diagnostic	 criteria	 in	
biologically	relevant	categories	and	to	advance	our	understanding	of	underlying	mechanisms.		
The	genetic	architecture	of	these	conditions	has	proven	to	be	complex.	In	the	example	of	ASD,	
twin	and	family	studies	report	up	to	90%	of	heritability,	although	there	is	a	broad	variance	
according	to	the	studies	and	the	contribution	of	shared	environmental	factors	could	be	higher	
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than	previously	estimated.	Despite	this	high	heritability,	a	genetic	cause	can	be	identified	in	
maximum	25%	of	cases,	such	as	the	presence	of	chromosomal	rearrangements,	rare	and	de	
novo	CNVs	or	coding-sequence	mutations	(Huguet	et	al.	2013).	The	rare	variants	bring	a	new	
understanding	of	the	diseases	and	an	entry	point	for	investigations	into	the	mechanisms	of	
brain	function	and	dysfunction.	They	offer	an	opportunity	to	study	their	effects	separate	from	
that	 of	manifest	 phenotypic	 traits.	 However,	 even	when	 ASD	 is	 associated	with	 a	 genetic	
mutation,	expressivity	of	this	mutation	is	often	variable	and	not	totally	penetrant.	Most	of	the	
NDDs	are	thought	to	be	polygenic	or	multifactorial,	influenced	by	genetic	and	environmental	
factors	(Torres	et	al.	2016).	
A	growing	number	of	studies	demonstrates	the	association	of	deletions	and	duplications	with	
NDDs	(Merikangas	et	al.	2009).	“Pathogenic”	CNVs,	that	are	rare	and	large	CNVs	contributing	
significantly	 to	diseases	 (>250	Kb	with	a	 frequency	<0.1%),	 are	 identified	 in	10	 to	15	%	of	
children	referred	for	NDDs	(Miller	et	al.	2010;	Battaglia	et	al.	2013).	Such	alleles	arise	by	de	
novo	mutation	 in	 the	 individual	or	 the	 recent	ancestry.	 Sanders	et	al.	 (2011)	estimate	 the	
presence	of	130-234	distinct	ASD-related	CNVs	across	the	genome,	Levy’s	estimate	(Levy	et	
al.	2011)	goes	up	to	250-300	target	loci.	Large	de	novo	CNVs	carry	substantial	risk,	and	the	
same	 CNVs	 can	 increase	 the	 risk	 for	 multiple	 cognitive	 and	 psychiatric	 disorders.	 Recent	
genome-wide	association	studies	show	enrichment	of	CNV	burden	in	SCZ	(odds	ratio	of	1.11),	
especially	 for	 genes	 associated	with	 synaptic	 function	 and	 neurobehavioral	 phenotypes	 in	
mice	(Marshall	et	al.	2016).	
In	table	1,	we	present	the	largest	and	most	pathogenic	risks	alleles,	associated	with	ID,	SCZ	
and	ASD	(Malhotra	&	Sebat	2012).	These	genomic	hotspots	are	important	candidate	loci	in	
genetic	 studies	 of	 psychiatric	 disorders,	 even	 if	 they	probably	 represent	 a	minority	 of	 risk	
variants.	Beyond	their	association	with	a	broad	range	of	NDDs,	we	have	only	a	few	pieces	of	
knowledge	on	the	effect	of	these	CNVs	on	neurodevelopmental	mechanisms.	
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CNV	locus	 Position	(Mb)	
Disease	
category	
Odds	Ratio	
[95%	CI]	
1q21.1	deletion	 145.0–146.3	 ID	SCZ	
12.6	[7.4–21.3]	
8.1	[4.3–15.6]	
1q21.1	duplication	 145.0–146.3	
ID	
ASD	
SCZ	
4.4	[2.6–7.4]	
8.0	[3.5–18.4]	
4.2	[2.1–8.6]	
3q29	deletion	 197.2–198.4	 ID	SCZ	
41.8	[5.6–311.6]	
63.0	[8.1–491.7]	
7q11.23	Williams-Beuren	
syndrome	deletion	 72.4–73.8	 ID	 Frequency:	0.27%	
7q11.23	Williams-Beuren	
syndrome	duplication	 72.4–73.8	
ID	
ASD	
16.5	[2.2–124.5]	
30.7	[3.4–275.1]	
VIPR2	(7q36.3)	
duplication	 158.4–158.8	 SCZ	 3.2	[1.5–7.1]	
15q11.2	deletion	 20.3–20.6	 ID	SCZ	
1.9	[1.6–2.3]	
2.1	[1.6–2.8]	
15q11.2-13.1	duplication	
including	Prader	Willy	
syndrome	critical	region	
20.8–26.2	
ID	
ASD	
SCZ	
18.5	[7.1–47.9]	
42.6	[15.7–115.5]	
5.1	[1.4–19.1]	
15q13.3	deletion	 28.7–30.2	
ID	
ASD	
SCZ	
15.1	[8.4–27.4]	
10.8	[3.5–33.1]	
10.7	[5.4–21.3]	
16p13.11	duplication	 15.4–16.2	 ID	SCZ	
2.4	[1.8–3.2]	
2.0	[1.1–3.5]	
16p11.2	deletion	 29.5–30.2	 ID	ASD	
9.2	[5.8–14.7]	
9.5	[5.2–17.4]	
16p11.2	duplication	 29.5–30.2	
ID	
ASD	
SCZ	
3.4	[1.8–6.5]	
11.8	[6.1–22.7]	
9.4	[5.3–16.6]	
17p12/HNPP	deletion	 14–15.4	 SCZ	 5.7	[2.4–13.7]	
17q12	deletion	 31.9–33.2	
ID	
ASD	
SCZ	
17.3	[6.1–49.0]	
16.0	[2.9–87.9]	
9.5	[2.4–38.2]	
22q11.21	deletion	 17.1–18.7	
ID	
ASD	
SCZ	
Frequency:	0.61%	
Frequency:	0.07%	
Frequency:	0.3%	
22q11.2	duplication	 17.1–18.7	 ID	ASD	
3.7	[2.3–6.1]	
3.3	[1.6–6.6]	
	
	
	
	
Among	the	11	pathogenic	CNV	loci	in	table	1,	the	16p11.2	CNVs	are	among	the	most	frequent	
hotspots	for	recurrent	rearrangements	in	association	with	ID,	ASD	and	SCZ	(Weiss	et	al.	2008).	
They	are	also	associated	with	a	range	of	phenotypic	variability	and	severity.	In	this	thesis,	I	
Table	 1:	 Eleven	 pathogenic	 CNV	 loci	 across	 multiple	 diagnostic	 categories:	
intellectual	ability	(ID),	autism	spectrum	disorders	(ASD),	schizophrenia	(SCZ).	In	
case	odds	ratio	were	not	available,	the	frequency	of	each	CNV	is	reported.	Only	
significant	 scores	 are	 shown	 in	 the	 table.	 Adapted	 from	Malhotra	 and	 Sebat.	
(Malhotra	&	Sebat	2012).	
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investigate	intermediate	phenotypes	in	carriers	of	the	16p11.2	reciprocal	CNVs,	ascertained	
through	large	clinical	cohorts.	
1.2	The	16p11.2	Copy	Number	Variants	
The	16p11.2	 locus	encompasses	several	distinct	 structural	variants,	as	 shown	 in	Figure1.A.	
Here,	 I	 focus	on	 the	most	 frequent	ones,	 the	proximal	600	kb	 recurrent	CNVs,	defined	by	
breakpoints	4	and	5	(BP4-5),	at	genome	sequence	coordinates	of	29.6-30.2	Mb	according	to	
the	human	genome	build	GRCh37/hg19	(Figure1.B).	These	reciprocal	CNVs	contain	29	genes	
and	present	either	a	deletion	or	a	duplication.	They	have	a	prevalence	of	1	over	1000	(1	over	
2000	for	the	deletion	and	1	over	2000	for	the	duplication).	About	60%	percent	of	cases	of	
deletion	occur	de	novo,	the	other	40%	are	inherited,	whereas	we	can	estimate	more	than	60%	
percent	of	duplications	inherited	(D’Angelo	et	al.	2016).	
	
	
	
	
	
1.2.1	Psychiatric	and	medical	features	
The	 deletion	 and	 duplication	 carriers	 present	 a	 high	 frequency	 of	 psychiatric	 and	
developmental	disorders	(.90%	for	deletion	(Hanson	et	al.	2015)).	Both	show	about	10-fold	
Figure	 1:	 The	 16p11.2	 locus,	 A.	 Four	 existing	 rearrangements	 within	 the	 16p11.2	
chromosomal	bands,	described	from	telomere	to	centromere	as	breakpoints	BP1	to	BP5;	
B.	Twenty-nine	genes	encompassing	the	BP4-BP5	genomic	region.	This	 figure	 is	 from	
Zufferey	 et	 al.	 (2012),	 which	 described	 the	 600	 kb	 deletion	 syndrome,	 same	
rearrangements	and	breakpoints	apply	to	the	reciprocal	duplication.	
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enrichment	 to	 develop	 ASD,	 duplication	 shows	 10-fold	 enrichment	 for	 SCZ	 and	 4-fold	
enrichment	 for	 bipolar	 disorder	 and	 recurrent	 depression	 (Sebat	 et	 al.	 2007;	Weiss	 et	 al.	
2008).	 The	 duplication	 is	 associated	 with	 multiple	 psychiatric	 phenotypes,	 whereas	 the	
reciprocal	deletion	is	more	specifically	associated	with	developemental	delay	(McCarthy	et	al.	
2009).	1	in	100	people	diagnosed	with	ASD	has	a	16p11.2	deletion	or	duplication,	which	make	
the	16p11.2	CNVs	ones	of	the	most	common	genetic	risk	factors	for	autism.	Sixteen	percent	
of	 deletion	 probands	 and	 20%	 of	 duplication	 probands	 met	 diagnostic	 criteria	 for	 ASD	
(D’Angelo	et	al.	2016),	comparing	to	only	2.2%	of	the	carrier	relatives	of	duplication	probands.	
Of	note,	probands	are	the	CNV	carriers	in	a	family	first	referred	in	clinics,	so	probably	the	most	
affected	 and	 symptomatic	 carrier,	 compared	 to	 relative	 carriers	 that	 are	 not	 medically	
ascertained	and	diagnosed	 following	 familial	 genetic	 testing.	Even	 the	 individuals	with	 the	
16p11.2	 deletion	 or	 duplication	 not	 meeting	 criteria	 for	 ASD	 have	 a	 significantly	 higher	
prevalence	of	 autism-related	 characteristics	 compared	with	 the	 familial	 noncarrier	 control	
group	(Moreno-De-Luca	et	al.	2015;	Green	Snyder	et	al.	2016).	
Other	psychiatric	diagnoses	are	reported	in	59%	of	deletion	probands	and	50%	of	duplication	
probands,	 including	 significant	 psychiatric	 comorbidity.	 Psychiatric	 conditions	 are	 also	
diagnosed	in	about	44%	of	their	carrier	relatives	without	a	diagnosis	of	ASD.	In	the	deletion	
carriers,	 the	 diagnosed	 conditions	 are	 developmental	 coordination	 disorders,	 phonologic	
processing	disorders,	expressive	and	receptive	language	disorders	(Hanson	et	al.	2015):	the	
uniqueness	of	the	articulation,	the	language,	and	motor	 impairments	are	apparent.	Eighty-
three	percent	of	16p11.2	carriers	have	a	history	of	speech	therapy.	In	the	duplication	carriers,	
the	 phenotype	 presents	 a	wide	 variability	 (from	 asymptomatic	 presentation	 to	 significant	
disability),	wider	than	the	reciprocal	deletion.	The	diagnosed	conditions	are	ID	(inclusive	of	
borderline	 intellectual	 functioning),	developmental	coordination	and	articulation	disorders,	
attention	deficit	hyperactivity	disorders	in	children;	anxiety,	obsessive-compulsive	and	mood	
disorders	in	adults	(Green	Snyder	et	al.	2016).	
We	observe	 a	 broad	 spectrum	of	malformations	 and	medical	 issues	 in	 both	CNVs	 carriers	
(Zufferey	et	al.	2012;	D’Angelo	et	al.	2016).	Twenty	percent	of	carriers	of	the	deletion	have	
vertebral	and	spinal	related	anomalies	and	46%	facial	dysmorphia.	Both	CNVs	carriers	show	a	
variety	of	neurologic	abnormalities,	with	some	shared	and	some	distinct	neurologic	features.	
That	could	reflect	some	opposite	neurobiological	mechanisms	in	the	deletion	and	duplication,	
resulting	in	the	hypo-	vs	hyper-reflexia	and	functional	motor	impairments.	Similar	frequency	
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of	 epilepsy	 is	 observed	 in	 deletion	 and	 duplication	 proband	 carriers,	 24%	 and	 19,4%	
respectively,	 with	 broad	 clinical	 spectrum	 and	 predominance	 of	 generalized	 seizures.	 In	
deletion,	the	mean	age	of	walking,	at	20,5	months	(standard	deviation=8,6),	 is	significantly	
delayed	and	gross	motor	delay	is	observed	in	37,6%	of	the	patients.	The	median	age	at	first	
walking	is	also	delayed	in	duplication	proband	carriers,	with	an	increased	proportion	of	very	
late	 onset	 walking	 (>24	 months)	 compared	 to	 the	 deletion	 proband	 carriers.	 The	 most	
frequent	 findings	 at	 the	 MRI	 level	 are	 the	 cerebral	 white	 matter/corpus	 callosum	
abnormalities,	cerebellar	hypoplasia	and	ventricular	enlargement	for	the	duplication	carriers;	
the	Chiari	I	malformations/cerebellar	tonsillar	ectopia	and	posterior	fossa	abnormalities	for	
the	deletion	carriers	(Steinman	et	al.	2016).	
1.2.2	Anthropometric	measurements	
The	 dosage	 effects	 of	 the	 genes	 regulate	 in	 an	 opposite	 way	 the	 anthropometric	
measurements	(“mirrored”	phenotype):	mean	body	mass	index	(BMI)	is	significantly	higher	in	
the	deletion	carriers	and	lower	in	the	duplication	carriers	than	BMI	in	the	familial	controls,	
+0.7	 Z-score	 and	 -0.6	 Z-score	 respectively	 (Jacquemont	 et	 al.	 2011;	D’Angelo	 et	 al.	 2016).	
Deletion	is	associated	with	a	high	penetrance	of	obesity	(43-fold	increased	risk	of	developing	
morbid	 obesity),	 with	 an	 increase	 of	 BMI	 with	 age:	 birth	 weight	 is	 below	 average	 (Z-
score=−0.61),	 then	 it	 increases	 and	 becomes	 significantly	 higher	 by	 the	 age	 of	 3.5	 (Z-
score=1.01).	 By	 the	 age	of	 7	 years,	 obesity	 (BMI	 ≥30)	 is	 present	 in	more	 than	50%	of	 the	
carriers,	and	the	penetrance	is	up	to	70%	for	the	adult	carriers	(Zufferey	et	al.	2012).	Deletion	
is	also	linked	to	a	lack	of	satiety,	from	early	childhood	and	even	before	the	beginning	of	obesity	
(Maillard	et	al.	2015).	On	the	contrary,	16p11.2	deletion	mice	tend	to	be	smaller	and	leaner	
than	 wild-type	 mice	 (Portmann	 et	 al.	 2014).	 This	 age-related	 effect	 is	 not	 observed	 in	
duplication	carriers,	for	who	the	BMI	remains	relatively	stable	from	0	to	-1	Z-score.		
We	observe	the	same	inverse	and	significant	gene	dosage	effect	for	head	circumference	(HC)	
(Jacquemont	et	al.	2011;	D’Angelo	et	al.	2016):	mean	HC	is	significantly	higher	in	the	deletion	
carriers	 (+0.5	 Z-score)	 and	 lower	 in	 the	 duplication	 carriers	 (-1.1	 Z-score)	 than	 HC	 in	 the	
familial	controls.	17%	of	deletion	carriers	and	22,3%	of	duplication	carriers	are	macrocephalic	
and	microcephalic,	 respectively	 (HC	Z-score>|2|).	HC	Z-scores	decrease	significantly	during	
the	first	2	years	of	life	in	duplication	carriers,	mirroring	the	early	increase	growth	during	the	
same	period	observed	in	deletion	carriers.	The	HC	correlates	positively	with	the	BMI,	the	early	
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increase	in	HC	for	deletion	carriers	precedes	the	onset	of	obesity.	The	animal	models	support	
this	gene	dosage	effect:	brain	volume	size	is	affected	reciprocally	in	deletion	and	duplication	
mice,	in	the	same	direction	than	human	subjects	(Horev	et	al.	2011).	KCTD13,	a	gene	in	the	
16p11.2	 interval,	 seems	 to	 be	 associated	 with	 the	 regulation	 of	 brain	 size	 in	 zebrafish:	
overexpression	of	this	homolog	gene	causes	a	significant	decrease	in	brain	size	in	zebrafish	
embryos	whereas	 inhibition	 leads	to	an	 increase	 in	brain	size	(Golzio	et	al.	2012).	A	recent	
study	on	mice	show	that	underexpression	of	KCTD13	leads	to	increased	levels	of	Ras	homolog	
gene	 family,	member	 A	 (RhoA),	 that	 reduce	 synaptic	 transmission	 (Escamilla	 et	 al.	 2017).	
Although	 KCTD13	 is	 implicated	 in	 the	 regulation	 of	 neuronal	 function	 relevant	 for	
neuropsychiatric	 disorders,	 it	 does	 not	 seem	 to	 alter	 brain	 size	 or	 neural	 progenitor	 cell	
proliferation	in	mammals.	
1.2.3	Neuropsychological	profile	and	developmental	trajectory	
Several	studies,	including	ours,	demonstrated	altered	global	cognition	in	16p11.2	deletion	and	
duplication	carriers	(Zufferey	et	al.	2012;	D’Angelo	et	al.	2016;	Hippolyte	et	al.	2016;	Hanson	
et	al.	2015;	Green	Snyder	et	al.	2016).	Full-scale	intelligence	quotient	(FSIQ)	decreases	by	an	
average	of	22	points	in	the	deletion	and	by	an	average	of	18	points	in	the	duplication	carriers,	
compared	with	the	familial	controls	(significantly	similar	mean	decreases).	In	deletion	carriers,	
FSIQ	variance	is	the	same	than	in	the	general	population,	verbal	IQ	(VIQ)	is	significantly	lower	
than	non-verbal	IQ	(NVIQ),	and	20%	of	the	carriers	meet	criteria	for	ID.	On	the	contrary,	we	
show	 in	 a	 study	 I	 contributed	 at	 the	 beginning	 of	my	 Ph.D.,	 that	 the	 16p11.2	 duplication	
phenotype	 is	characterized	by	wider	variability	 than	 the	 reciprocal	deletion.	We	observe	a	
higher	proportion	of	very	 low	 IQ	 (30,5%	of	duplication	carriers	meet	criteria	 for	 ID),	 lower	
NVIQ	 and	 higher	 rates	 of	 additional	 CNVs,	 likely	 reflecting	 contributions	 of	 additional	 risk	
factors	(D’Angelo	et	al.	2016).	
The	 number	 of	 16p11.2	 genomic	 copies	 may	 also	 modulate	 specific	 cognitive	 skills:	 the	
language	domain	(phonology,	written	language,	vocabulary),	the	memory	processes	(short-	
and	 long-term	memory)	 and	 the	 verbal	 and	motor	 inhibition	 skills	 (Hippolyte	 et	 al.	 2016).	
When	neuropsychological	scores	are	adjusted	for	IQ	levels,	the	deletion	carriers	show	specific	
impairments	in	phonology	and	vocabulary	(-1.3	Z-score	in	a	task	of	non-word	repetition	and	-
0.7	Z-score	in	a	task	of	word	definition);	as	well	as	an	impairment	in	verbal	inhibition	(-0.8	Z-
score	in	a	task	of	Stroop).	Neuroimaging	analyses	reveal	that	the	verbal	inhibition	error	rate	
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may	covary	with	the	gray	matter	(GM)	volume	of	deletion	carriers	in	the	bilateral	insula	and	
transverse	 temporal	 gyri.	 On	 the	 contrary,	 duplication	 carriers	 do	 not	 show	 a	 specific	
impairment	relative	to	their	global	functioning,	but	they	have	preserved	or	even	enhanced	
verbal	long-term	memory	skills	(+1.1	Z-score).	Some	other	domains,	such	as	visuospatial	and	
working	memory,	are	unaffected	by	the	16p11.2	locus,	beyond	the	effect	of	decreased	IQ.		
Both	 CNV	 carriers	 show	 distinct	 cognitive	 profiles,	 highlighting	 their	 heterogeneity.	 The	
cognitive	performances	may	covary	with	molecular	mechanisms,	and	the	mouse	models	have	
enhanced	memory	 skills	 on	 a	 recognition	 task	 in	 duplicated	 mice	 compared	 to	 wild-type	
animals	 (Arbogast	et	al.	2017).	MAPK3	 is	a	good	candidate	gene	mediating	 the	correlation	
between	the	16p11.2	CNV	and	memory	performances	(Golzio	et	al.	2015).	This	is	reminiscent	
of	special	isolated	skills	that	can	be	observed	in	ASD.	
A	longitudinal	study	between	the	ages	of	6	months	and	8	years	highlights	the	developmental	
trajectories	for	young	deletion	and	duplication	carriers:	the	first	ones	show	VIQ	gains	early	in	
development	but	a	decline	 in	motor	and	social	abilities,	 the	 last	ones	 show	VIQ	gains	and	
steady	trajectories	for	the	other	social	and	motor	domains.	They	also	point	out	the	distinct	
trajectories	in	the	sub-group	of	16p11.2	CNV	carriers	who	are	ultimately	diagnosed	with	ID,	
ASD	or	developmental	coordination	disorder,	compared	to	the	carriers	who	will	not	meet	the	
criteria	for	these	psychiatric	conditions	(Bernier	et	al.	2017).	It	is	crucial	to	take	into	account	
and	continue	to	study	this	variability	during	early	development,	to	better	adapt	therapies.	
1.2.4	Variance	in	phenotypes	and	additional	factors	
Most	of	the	disorders	caused	by	CNVs	display	a	significant	clinical	variability.	Other	factors	
may	modulate	this	variable	phenotypic	expression	of	rare	highly	penetrant	variants,	such	as	
genetic	 factors,	 from	 rare	 to	 common	 polygenic	 variation,	 epigenetic	 regulation,	
environmental	sources.		
Regarding	the	16p11.2	CNVs,	even	if	the	average	effects	of	the	duplication	and	the	deletion	
on	cognition	are	 similar,	 they	have	different	profiles.	The	average	effect	of	 the	deletion	 is	
identical	for	proband	and	non-proband	carriers,	suggesting	that	‘asymptomatic’	carriers	are	
uncommon.	The	variance	of	FSIQ	was	also	similar	among	carriers	of	the	deletion	and	control	
population:	the	factors	determining	the	variability	of	FSIQ	may	be	identical	to	those	at	play	in	
the	general	population	and	unrelated	to	the	16p11.2	locus.	However,	Duyzend	et	al.	(2016)	
find	 a	 strong	maternal	 bias	 for	 the	 origin	 of	 the	 de	 novo	 deletions	 and	 they	 identify	 the	
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presence	of	rare,	not	clinically	diagnosed,	additional	CNVs	in	69%	of	the	probands,	suggesting	
that	genetic	background	plays	a	role	in	the	observed	phenotypes.	
We	demonstrate	that	the	duplication	is	associated	with	an	average	decrease	of	26.3	points	in	
FSIQ	between	proband	carriers	and	non-carrier	family	members.	However,	there	is	a	smaller	
decrease	(16.2	to	11.4	points)	between	non-proband	carriers	and	non-carriers	(D’Angelo	et	al.	
2016).	The	distribution	of	FSIQ	in	duplication	carriers	shows	a	very	broad	variance,	with	a	2.0-
fold	 increase	 in	 an	 “above	 average”	 group	 (FSIQ>100)	 and	 a	 19.4-fold	 increase	 in	 low	
functioning	 (FSIQ<40)	 carriers,	 compared	 to	 the	 deletion	 group	 (p<0.001)	 (D’Angelo	 et	 al.	
2016).	Parental	FSIQ	predicts	part	of	this	variation	(~36.0%	in	inherited	probands,	compared	
to	11%	for	deletion	carriers).	FSIQ	is	also	significantly	lower	in	the	duplication	probands	with	
ASD	than	those	without	an	ASD	diagnosis	(mean	FSIQ,	52.8	vs.	75.4).	Additional	deleterious	
CNVs	 were	 2.5-fold	 higher	 in	 duplication	 compared	 with	 deletion	 probands	 (p=0.006).	
Duyzend	et	al.	 (2016)	also	observe	a	modest	negative	 correlation	between	 the	number	of	
additional	 CNVs	 and	 FSIQ	 in	 16p11.2	 CNV	 carriers.	 Other	 traits,	 as	 neurological	 features,	
present	 a	 broader	 phenotypic	 variability	 among	 duplication	 carriers	 than	 deletion	 carriers	
(Steinman	 et	 al.	 2016).	 All	 these	 results	 converge	 towards	 additional	 genetic	 and	 familial	
factors	 contributing	 to	 the	 phenotype	 variability:	 the	 duplication	 may	 require	 additional	
factors	to	reach	the	threshold	for	clinical	evaluation	compared	with	the	deletion.	
The	16p11.2	deletion	is	also	reported	in	apparently	unaffected	control	participants	from	the	
general	population.	However,	although	these	CNV	carriers	do	not	reach	the	current	clinical	
diagnosis	thresholds,	they	exhibit	a	variety	of	cognitive	deficits	(Männik	et	al.	2015).	The	same	
phenomenon	 is	 observed	 in	 the	 carriers	 of	 15q11.2	 BP1-BP2	 deletion	 from	 an	 apparently	
healthy	cohort:	they	have	a	history	of	dyslexia	and	dyscalculia,	even	when	controlling	for	IQ,	
and	 the	brain	 structures	of	 these	CNV	 carriers	 exhibit	 a	pattern	 consistent	with	 structural	
correlates	of	dyslexia	(Stefansson	et	al.	2014).	More	generally,	Männik	et	al.	(2015)	show	that	
recurrent	large	pathogenic	CNVs,	as	well	as	rare	intermediate-size	(non	recurrent)	CNVs	are	
negatively	associated	with	educational	attainment	in	general	population.	
1.3	Contribution	of	neuroimaging	to	neuropsychiatric	and	genetic	disorders	
1.3.1	Neuroimaging	techniques	
During	 the	 last	 decades,	 many	 neuroimaging	 studies	 were	 published	 in	 patients	 with	
psychiatric	disorders,	with	the	hope	that	neuroimaging	would	represent	a	useful	intermediate	
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phenotype	to	understand	psychiatric	conditions	better.	Even	if	this	field	of	research	is	still	in	
its	infancy,	we	have	a	range	of	methods	to	study	the	structure	and	function	of	the	brain,	with	
increasing	 spatial	 resolution	 for	 Magnetic	 Resonance	 Imaging	 (MRI);	 or	 better	 temporal	
resolution	for	the	electro-encephalography	(EEG).	In	this	thesis,	I	focus	on	structural	MRI,	with	
T1-weighted	images,	to	characterize	the	brain	anatomy	of	the	individuals	carrying	a	16p11.2	
CNV.	
The	MR	signal	comes	from	the	application	of	external	magnetic	fields	on	the	subject.	It	aligns	
hydrogen	 nuclei	 along	 the	 direction	 of	 the	 applied	 field.	 Then,	 applying	 a	 pulse	 of	
electromagnetic	energy	at	a	specific	radiofrequency,	the	nuclei	rotate	away	from	the	axes	of	
the	magnetic	field.	It	takes	time	for	the	nuclei	to	return,	in	an	exponential	way,	to	their	original	
position,	pointing	along	the	magnetic	field.	T1	represents	the	time	to	“relax”	back,	it	depends	
on	the	local	structural	patterns.	These	local	differences	in	relaxation	times	are	reflected	in	the	
contrast	 of	 structural	 MRI	 (Paus	 et	 al.	 2001).	 Based	 on	 these	 image	 contrasts,	 different	
measurements	have	been	developed	over	time,	 from	volumetric	 features	to	surface-based	
measurements.	 They	 are	 more	 and	 more	 specific	 regarding	 the	 underlying	 mechanisms:	
Figure	2	represents	the	evolution	of	structural	MRI	measurements	as	applied	to	research	on	
ASD	 (Ecker	 et	 al.	 2015).	Multiple	 other	 types	 of	 images	 can	 be	 acquired	 through	 the	MRI	
techniques,	from	which	measurements	as	the	white	matter	(WM)	integrity	or	connectivity,	
can	be	quantified.	
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1.3.2	Neuroanatomical	alterations	in	psychiatric	disorders	
Early	brain	overgrowth	is	probably	the	most	replicated	finding	in	people	diagnosed	with	ASD	
(Anagnostou	 &	 Taylor	 2011):	 this	 accelerated	 brain	 volume	 growth	 in	 early	 childhood	
corresponds	about	at	a	10%	increase	in	brain	volume.	Some	region-specific	differences,	such	
as	 volumetric	 alterations	 of	 parieto-temporal	 and	 frontal	 lobes,	 the	 cerebellar	 cortex,	 the	
hypothalamus,	 and	 the	 striatum	are	described	 (Stanfield	 et	 al.	 2008;	 Kurth	 et	 al.	 2011).	A	
decreased	volume	of	the	cingulate	is	associated	with	reduced	metabolic	activity	(Haznedar	et	
al.	2006),	and	an	increased	volume	of	the	caudate	is	correlated	with	the	severity	of	repetitive	
behaviors	 (Langen	 et	 al.	 2007;	 Hollander	 et	 al.	 2005).	 A	 decreased	 volume	 of	 the	 corpus	
callosum	is	also	reported,	suggesting	a	reduced	interhemispheric	connectivity	(Hardan	et	al.	
2009;	 Stanfield	 et	 al.	 2008).	 The	 spread	 of	 these	 findings	 indicates	 that	 ASD	 is	 a	 widely	
distributed	disorder	affecting	both	GM	and	WM.	However,	there	is	little	consistency	between	
Figure	2,	from	Ecker	et	al.	(2015):	Evolution	of	structural	MRI	measurements	over	time	in	ASD	research.	
Panel	 A	 reproduced	 from	 Courchesne	 (2002);	 Panel	 B	 reproduced	 from	 Herbert	 et	 al.	 (2003);	 Panel	 C	
reproduced	from	Schumann	et	al.	(2004);	Panel	D	reproduced	from	Waiter	et	al.	(2005);	Panel	E	reproduced	
from	Nordahl	et	al.	(2007);	Panel	F	reproduced	from	Pugliese	et	al.	(2009);	Panel	G	reproduced	from	Hyde	et	
al.	(2010);	Panel	H	reproduced	from	Ecker	et	al.	(2013);	Panel	I	reproduced	from	Wallace	et	al.	(2013);	Panel	
J	reproduced	from	Ecker	et	al.	(2013).	
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studies.	Distinct	brain	patterns	can	be	observed	in	two	groups	of	children	diagnosed	with	ASD.	
For	example,	Hazlett	et	al.	 (2009)	 find	a	robust	enlargement	of	the	caudate	nucleus	 in	the	
brains	 of	 the	 fragile	 X	 children	 with	 ASD	 compared	 to	 controls,	 whereas	 children	 with	
idiopathic	autism	have	an	enlargement	of	 the	amygdala	and	a	modest	enlargement	of	 the	
caudate.	Lefebvre	et	al.	(2015)	do	not	observe	a	significant	decreased	volume	of	the	corpus	
callosum	 in	a	 large	cohort	of	patients	diagnosed	with	autism.	Adopting	another	approach,	
Ellegood	et	al.	(2014)	cluster	anatomical	regions	of	26	different	mouse	models	of	autism.	The	
clustering	reveals	three	neuroanatomical	patterns,	including	the	key	main	regions	associated	
with	autism	in	human:	group	1	 is	a	cortex	to	basal	ganglia	 loop	(associated	with	repetitive	
behaviors,	executive	function,	and	communication),	group	2	represents	more	dispersed	brain	
regions	 involved	 in	social	 recognition	and	autonomic	regulation,	group	3	 is	 localized	 in	the	
cerebellum.	These	clusters	also	distinguish	the	directionality	of	the	anatomical	changes:	for	
example,	the	cerebellar	cortex	is	oppositely	affected	in	Group	1	compared	to	Group	3	and	not	
altered	 in	Group	2.	Group	1	 is	associated	with	an	 increase	and	Group	2	with	a	decrease	 in	
similar	WM	structures.	
The	 volume	 abnormalities	 are	 also	 associated	 with	 atypical	 functional	 and	 structural	
connectivity	 in	 the	 brain.	 Many	 studies	 provide	 evidence	 for	 decreased	 cortical-cortical	
connectivity,	with	possibly	increased	connectivity	between	subcortical	regions	and	cortex,	and	
within	primary	sensory	areas	such	as	the	visual	cortex.	That	supports	the	idea	of	poor	long-
distance	 connectivity	 in	 ASD.	 Intrinsic	 functional	 connectivity	 studies	 suggest	 abnormal	
patterns	of	network	activation	in	the	default	mode	network	(DMN)	at	rest	in	ASD	(Pua	et	al.	
2017).	
Age	 is	 an	 important	 factor,	 but	 fewer	 studies	 examine	 changes	 in	 the	 developmental	
trajectory	 associated	 with	 autism	 (Dennis	 &	 Thompson	 2013).	 At	 birth,	 the	 brain	 of	 ASD	
individuals	seems	to	be	either	at	the	same	size	or	smaller	than	typically	developing	controls.	
During	the	first	2	years	of	life,	individuals	with	autism	demonstrate	a	precocious	brain	growth	
which	exceeds	that	of	the	controls	(Anagnostou	&	Taylor	2011).	But	this	peak	around	2-4	years	
of	age	is	probably	followed	by	a	plateau.	The	controls	catch	up	and,	at	adolescence,	there	is	
no	statistical	difference	in	brain	size	between	individuals	with	ASD	and	age-matched	controls.	
Moreover,	a	 recent	developmental	 study	on	siblings	at	 risk	 for	ASD	shows	 that	very	early,	
post-natal	hyper-expansion	of	cortical	surface	areas	would	precede	brain	volume	overgrowth,	
which	is	temporally	linked	to	the	emergence	and	severity	of	autistic	social	deficits.	Early	brain	
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changes	would	occur	during	the	period	in	which	autistic	behaviors	are	first	emerging	(Hazlett	
et	al.	2017).	The	altered	neurodevelopmental	trajectory	seems	to	vary	across	the	lifespan	and	
different	 brain	 regions	 (Pua	 et	 al.	 2017).	 For	 example,	 Hardan	 et	 al.	 (2009)	 examine	
longitudinal	changes	in	cortical	thickness	in	autistic	boys	and	find	a	higher	decrease	with	age	
in	cortical	thickness	in	the	autistic	boys	than	in	the	controls.	
Regarding	SCZ,	a	decrease	of	global	GM	volume	and	ventricular	enlargement	are	ones	of	the	
most	 consistent	 findings	 (Brugger	&	Howes	2017).	 Studies	 show	also	decreased	volume	 in	
frontal,	temporal	(Hulshoff	Pol	&	Kahn	2007;	Honea	et	al.	2005;	Shepherd	et	al.	2012;	Fornito	
et	al.	2009),	medial	temporal	regions,	including	insula	and	anterior	cingulate	cortex	(Ellison-
Wright	et	al.	2008;	Glahn	et	al.	2008;	Shepherd	et	al.	2012).	These	volume	differences	are	
mainly	driven	by	reduction	in	cortical	thickness,	and	some	reduction	of	surface	area	(Rimol	et	
al.	2012).	A	recent	meta-analysis	exhibits	subcortical	brain	differences	in	one	of	the	largest	
sample	size	to	date	(2028	individuals	with	SCZ	and	2540	controls).	It	ranks	them	according	to	
their	effect	size	(van	Erp	et	al.	2015):	hippocampus	(Cohen’s	d=-0.46),	amygdala	(Cohen’s	d=-
0.31),	 thalamus	 (Cohen’s	 d=-0.31),	 accumbens	 (Cohen’s	 d=-0.25)	 and	 intracranial	 volumes	
(Cohen’s	 d=-0.12)	 are	 reduced	 in	 SCZ	 compared	 to	 controls.	 On	 the	 contrary,	 volumes	 of	
pallidum	 (Cohen’s	 d=0.21)	 and	 lateral	 ventricle	 (Cohen’s	 d=0.37)	 are	 increased.	 The	 GM	
volume	 of	 the	 total	 cerebellum	 is	 robustly	 reduced	 (Cohen’s	 d=-0.35),	 this	 structure	 is	
probably	a	key	node	of	 the	network	underlying	the	SCZ	(Moberget	et	al.	2017).	Brugger	&	
Howes	(2017)	show	that	there	is	a	 lower	variability	of	the	results	 in	the	anterior	cingulate,	
compared	 to	 the	 variability	 found	 in	 other	 regions	 implicated	 in	 SCZ	 (temporal	 cortex,	
thalamus,	 putamen	 and	 third	 ventricle	 volumes).	 Given	 this	 greater	 homogeneity,	 they	
suggest	that	anterior	cingulate	cortex	volume	is	a	core	region	in	SCZ,	shared	across	subtypes	
of	 the	 disorder.	 Morphometric	 abnormalities	 in	 this	 region	 are	 also	 seen	 across	 several	
psychiatric	disorders	(Crossley	et	al.	2014;	Cauda	et	al.	2017).	Of	note,	widespread	reductions	
in	WM,	especially	fractional	anisotropy,	is	observed	in	SCZ,	with	the	largest	effect	sizes	around	
d=0.4	(Kelly	et	al.	2017).	
More	generally,	Goodkind	et	al.	(2015)	identify	GM	loss	in	the	anterior	insula	and	the	dorsal	
anterior	cingulate	as	a	common	neural	signature	across	6	diverse	psychiatric	diagnoses	(SCZ,	
bipolar	disorder,	depression,	addiction,	obsessive-compulsive	disorder,	and	anxiety,	with	the	
largest	effect	size	 in	SCZ).	These	shared	neural	substrates	may	relate	to	executive	function	
deficits	observed	across	these	psychiatric	diagnoses.	The	authors	show	few	diagnosis-specific	
 	 25	
effects.	(figure	3).	This	transdiagnostic	perspective	is	coherent	with	the	National	Institute	of	
Mental	Health’s	 Research	Domain	Criteria	 Project,	 a	 dimensional	 and	organizing	model	 of	
psychiatric	 disorders,	 that	 highlight	 the	 importance	 of	 shared	 intermediate	 phenotypes	
(Cuthbert	&	Insel	2013).	
	
	
In	another	meta-analysis	of	25	voxel-based	studies	comprising	308	ASD	and	352	first-episode	
SCZ	participants,	as	well	as	801	controls,	Cheung	et	al.	 (2010)	show	that	a	decrease	of	GM	
volume	overlaps	in	ASD	and	SCZ	within	limbic-striato-thalamic	circuitry,	suggesting	a	neuro-
anatomical	proof	of	shared	etiological	mechanisms.	Some	other	regions	are	specific	to	each	
disorder	(Figure	4).	
Figure	3,	from	Goodkind	et	al.	(2015):	Shared	patterns	of	decreased	gray	matter	volumes	from	voxel-based	
morphometry	meta-analysis	of	193	studies	comprising	15892	individuals	(estimation	of	gray	matter	loss	in	z-
scores).	A,	 comparison	between	patients	and	controls	 from	studies	pooled	across	all	diagnoses.	The	 results	
show	a	 loss	of	GM	volume	 in	anterior	 insula,	dorsal	 anterior	 cingulate	 cortex,	prefrontal	 cortex,	 thalamus,	
amygdala,	hippocampus,	superior	temporal	gyrus;	B,	comparison	between	patients	and	controls	separately	by	
psychotic	 or	 nonpsychotic	 diagnosis	 studies;	 C,	 results	 from	 a	 conjunction	 across	 the	 psychotic	 and	 non	
psychotic	groups	maps	in	panel	B.	
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Some	 international	 consortia	 aim	 to	 target	 the	 issue	 of	 heterogeneity	 in	 psychiatric	
neuroimaging	 results,	with	powerful	enough	datasets	 to	avoid	 type	 I	and	 type	 II	 statistical	
errors	and	precise	estimates	of	effect	sizes	(Carter	et	al.	2017).	For	example,	the	Autism	Brain	
Imaging	Data	Exchange	–	ABIDE	(http://fcon_1000.projects.nitrc.org/indi/abide/),	aggregates	
and	openly	shares	more	than	1000	resting-state	functional	MRI	and	phenotypic	information	
from	539	individuals	with	ASD	and	573	age-matched	typical	controls,	from	7	to	64	years.	The	
Enhancing	 NeuroImaging	 Genetics	 through	 Meta-Analysis	 (ENIGMA)	 consortium	
(http://enigma.ini.usc.edu)	merges	data	collected	by	independent	studies	to	determine	how	
genetic	variants	influence	the	brain,	and	how	major	psychiatric	or	neurodegenerative	diseases	
affect	the	brain	worldwide	(Thompson	et	al.	2016).	By	pooling	genomic	data	and	brain	imaging	
of	over	30	000	individuals,	the	datasets	are	the	largest	in	the	World.	The	analyses	are	going	to	
make	 possible	 replication	 and	 reproducible	 results,	 generalizable	 estimates	 of	 even	 small	
effect	sizes	(Adhikari	2017),	and	a	distinction	of	common	and	unique	effects	of	brain	disorders	
on	brain	structures	(Bearden	&	Thompson	2017).	The	goal	 is	also	to	 improve	the	power	to	
detect	genetic	variants	 influencing	the	brain.	Even	 if	many	brain	measures	are	significantly	
highly	heritable	(about	80%),	we	still	don’t	know	most	of	the	specific	variants	that	contribute	
to	the	variability	of	these	measurements.	First	results	identify	common	variants	influencing	
human	hippocampal	structures	and	intracranial	volumes	(Stein	et	al.	2012;	Thompson	et	al.	
2016).	
Figure	4,	from	Cheung	C.	et	al.	(2010):	Distinct	and	overlapping	regions	of	decreased	
gray	matter	volumes	in	ASD	and	SCZ.	
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1.3.3	Previous	MRI	studies	on	carriers	of	a	16p11.2	copy	number	variant	
Neuroimaging	 studies	 of	 a	 large	 number	 of	 individuals	 carrying	 a	 CNV	 associated	 with	
psychiatric	disorders	help	to	understand	underlying	mechanisms	better.	Two	previous	studies	
explore	the	brain	structures	of	individuals	with	a	16p11.2	CNV.	Qureshi	et	al.	(2014)	analyzed	
structural	MRI	data	of	the	Simons	variation	in	individuals	project	foundation	(Simons	VIP),	on	
25	 children	 carrying	 a	 deletion	 and	 17	 adults	 carrying	 a	 duplication,	 compared	 with	 age-
matched	controls.	On	the	European	side,	Maillard	et	al.	(2014)	analyze	data	on	14	deletion	
carriers,	23	controls,	and	17	duplication	carriers.	Both	studies	show	an	inverse	gene	dosage	
effect	on	global	brain	measurements:	total	intracranial	volume	(TIV),	GM	and	WM	volumes	
correlate	negatively	with	the	number	of	genomic	copies.	Qureshi	et	al.	(2014)	also	identify	an	
increased	and	reduced	size	in	deletion	and	duplication	carriers	respectively,	for	the	subcortical	
structures	and	the	cerebellum,	with	 the	 largest	effect	on	 the	 thalamus.	They	 interpret	 the	
results	as	a	pervasive	effect	of	the	CNV	on	the	brain.	This	is	reinforced	by	the	gene	dosage	
effect	on	the	global	cortical	surface	area,	but	not	the	cortical	thickness:	this	suggests	that	the	
differences	associated	with	the	CNV	appear	early	in	the	development.	Beyond	the	differences	
on	the	global	brain	metrics,	Maillard	et	al.	(2014)	show	some	specific	regional	gene-dosage	
effects	 of	 GM	 and	WM	 in	 key	 areas	 of	 the	 reward	 system,	 language	 circuitry,	 and	 social	
cognition.	The	observed	brain	anatomy	changes	spatially	overlap	with	brain	changes	in	ASD	
and	SCZ,	 and	 they	are	explained	by	mRNA	 levels	of	 all	 assessed	genes	within	 the	16p11.2	
interval.	 Mouse	 models	 also	 demonstrate	 the	 reciprocal	 effect	 of	 regional	 brain	 volume	
changes	(Horev	et	al.	2011).	In	deletion	mice,	Portmann	et	al.	(2014)	find	a	relative	increase	
in	the	size	of	various	regions,	especially	the	basal	ganglia	circuitry,	the	hypothalamus,	as	well	
as	a	decrease	of	the	corpus	callosum.	The	neuroanatomical	differences	may	be	present	from	
the	young	age	(mice	at	p7).	
Moreover,	 there	 is	 evidence	 of	 a	 specific	 widespread	 pattern	 of	 WM	 microstructure	
alterations,	not	usually	reported	in	NDDs.	Owen	et	al.	 (2014)	show,	 in	deletion	carriers,	an	
increase	 in	 axial	 diffusivity	 in	 some	 major	 central	 WM	 tracts	 (anterior	 corpus	 callosum,	
internal	and	external	capsules),	associated	with	an	increase	in	fractional	anisotropy	and	mean	
diffusivity	in	some	of	the	same	tracts.	Fiber	orientation	dispersion	seems	to	be	decreased	in	
some	of	the	central	tracts.	Chang	et	al.	(2016)	show	the	reciprocal	pattern	for	the	duplication	
carriers,	especially	a	decrease	of	 fractional	anisotropy	and	 the	association	of	WM	changes	
with	general	cognitive	impairments.	
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1.4	Goal	of	the	thesis	
The	 genetic-first	 approach	 is	 a	 powerful	 approach	 to	 gain	 insight	 the	 etiologies	 and	
mechanisms	 of	 psychiatric	 and	 developmental	 disorders,	 in	 the	 context	 of	 a	 biologically	
homogenous	 sample	 of	 individuals	 (The	 Simons	 VIP	 Consortium	 2012).	 Whole	 genome	
chromosomal	microarray	(CMA)	is	now	well	established	as	a	first-tier	clinical	diagnostic	test	in	
the	 developmental	 pediatric	 clinic,	 and	 CNVs	 contributing	 to	 NDDs	 and	 other	 psychiatric	
disorders	are	reported	back	to	patients.	However,	little	is	known	about	their	effect	on	brain	
development	and	structure.	Neuroimaging	studies	have	been	conducted	in	only	a	handful	of	
CNVs	including	22q11.2,	15q11.2,	and	Williams	syndrome.	
My	 Ph.D.	 is	 focused	 on	 patients	 carrying	 a	 proximal	 600	 kb	 16p11.2	 CNV,	 their	 family	
members,	 and	 unrelated	 controls.	 The	main	 goal	 is	 to	 understand	 the	 effects	 of	 16p11.2	
deletion	and	duplication	on	neuroanatomical	traits.	
Our	two	specific	goals	are:	
1-	To	investigate	the	effect	of	the	16p11.2	deletion	and	duplication	on	brain	structures.		
The	two	previous	neuroimaging	studies	reported	gene-dosage	effects	on	global	brain	metrics,	
but	 the	 large	brain	size	and	 the	sample	size	 limited	 the	analyses	and	 the	 interpretation	of	
some	regional	analyses.	Here,	we	merge	multiple	datasets	to	 increase	the	sample	size.	We	
aim	at	quantifying	 the	effect	of	 the	global	and	 regional	gene	dosage	effect,	as	well	as	 the	
specific	contribution	of	 the	deletion	and	the	duplication	to	these	16p11.2-associated	brain	
differences.	We	examine	the	generalizability	of	our	results	across	cohorts,	scanning	sites,	sex	
and	a	broad	age	 range.	Given	 the	different	 types	of	 clinical	 ascertainment	 across	 the	 two	
cohorts,	we	also	aim	at	understanding	the	influence	of	the	ascertainment	and	the	relationship	
between	the	brain	findings	and	the	clinical	phenotypes.	Specifically,	we	ask	whether	language,	
social	responsiveness,	IQ,	the	presence	of	psychiatric	disorders	may	impact	any	of	the	brain	
findings;	 and	 we	 overlap	 our	 results	 with	 the	 ones	 from	 a	 meta-analysis	 on	 psychiatric	
conditions.	We	also	investigate	if	the	non-carrier	familial	controls	show	some	brain	structural	
differences,	 compared	 to	 the	 general	 population,	 that	 would	 contribute	 to	 the	 patterns	
observed	in	the	16p11.2	carriers.	
To	 this	end,	we	perform	voxel-	and	surface-based	analyses	 in	parallel	on	361	participants,	
including	 307	 individuals	 not	 previously	 analyzed	 at	 the	 regional	 level	 using	 whole-brain	
statistical	methods.	We	use	two	complementary	computational	methods,	to	assess	the	GM	
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volume,	the	cortical	thickness,	and	the	surface	area	differences.	This	first	goal	is	developed	in	
the	first	paper,	“Quantifying	the	effects	of	16p11.2	copy	number	variants	on	brain	structure:	
A	multi-site	‘genetic-first’	study”.	
2-	To	characterize	the	developmental	trajectory	of	16p11.2-associated	brain	differences.		
Following	the	description	of	the	alterations	from	the	first	study,	the	next	question	is	“when”	
these	differences	appear	during	brain	development.	In	the	second	study,	we	aim	at	comparing	
the	 developmental	 trajectories	 of	 the	 global	 and	 regional	 volumes	 of	 the	 16p11.2	 CNVs	
carriers	to	the	typical	growth	trajectories	of	children	and	adolescents	controls.	
To	this	end,	we	use	a	large	normative	dataset	from	National	Instituted	of	Health	MRI	study	of	
healthy	brain	development	(NIHPD)	with	339	typically	developing	individuals	aged	from	4.5	to	
23	years	old	(https://pediatricmri.nih.gov/)(Evans	2006).	These	data	are	used	to	obtain	age-	
and	sex-normative	brain	growth	trajectories.	We	compute	Z-scores	for	our	16p11.2	dataset,	
using	previously	published	longitudinal	pipeline	and	normalizing	method	(Aubert-Broche	et	
al.	2013).	Trajectories	of	global	and	‘per	voxel’	brain	measurements	of	the	16p11.2	carriers	
are	 compared	 to	 the	 norm,	 from	 4.5	 years	 to	 23	 years	 old,	 to	 evaluate	 when	 the	 brain	
differences	appear	and	their	effect	size	through	our	age	range.	The	2nd	goal	is	developed	in	
the	second	chapter	of	the	results:	“Developmental	trajectories	of	neuroanatomical	alterations	
associated	with	the	16p11.2	Copy	Number	Variations”.	
To	establish	a	well-characterized	cohort	of	families,	we	acquired	and	pooled	data	from	the	
European	 16p11.2	 consortium	 with	 the	 ones	 from	 the	 Simons	 VIP	
(http://www.simonsvipconnect.org/)	 in	North	America.	 Individuals	were	 recruited	 through	
different	ascertainments	 in	both	studies:	 they	were	 referred	by	a	geneticist	 in	Europe	and	
were	more	broadly	recruited	in	the	USA,	including	referral	by	clinical	genetic	centers,	web-
based	networks	or	active	online	registration	of	families.	They	were	ascertained	regardless	of	
clinical	diagnoses	or	age.	CNV	carriers	are	either	probands	referred	to	the	genetic	clinic	for	
the	investigation	of	neurodevelopmental	and	psychiatric	disorders	or	their	relatives.	Familial	
controls	 are	 relatives	 who	 do	 not	 carry	 the	 CNV.	 Unrelated	 controls	 are	 selected	 among	
volunteers	from	the	general	population	who	have	neither	any	major	DSM-5	diagnosis	nor	a	
relative	with	a	NDD.	Focusing	on	structural	brain	intermediate	phenotypes,	we	collected	T1-
weighted	anatomical	 images	 from	7	scanning	sites	 (5	sites	 in	North	America	and	2	sites	 in	
Europe),	 with	 multi-echo	 or	 single-echo	MPRAGE	 (magnetization	 prepared	 rapid	 gradient	
echo)	sequences.	 	
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ABSTRACT	
BACKGROUND	
16p11.2	 BP4-BP5	 copy	 number	 variants	 (CNVs)	 increase	 the	 risk	 for	 developing	 autism	
spectrum	disorder,	schizophrenia,	language	and	cognitive	impairment.	In	this	multi-site	study,	
we	aimed	to	quantify	the	effect	of	16p11.2	CNVs	on	brain	structure.	
METHODS	
Using	 voxel-	 and	 surface-based	 brain	 morphometric	 methods,	 we	 analyzed	 structural	
magnetic	resonance	imaging	collected	at	seven	sites	from	78	individuals	with	a	deletion,	71	
individuals	with	a	duplication,	and	212	individuals	without	a	CNV.	
RESULTS	
Beyond	the	16p11.2-related	mirror	effect	on	global	brain	morphometry,	we	observe	regional	
mirror	 differences	 in	 the	 insula	 (deletion>control>duplication).	 Other	 regions	 are	
preferentially	 affected	 by	 either	 the	 deletion	 or	 the	 duplication:	 the	 calcarine	 cortex	 and	
 	 31	
transverse	temporal	gyrus	(deletion>control;	Cohen’s	d	>	1),	the	superior	and	middle	temporal	
gyri	 (deletion<control;	 Cohen’s	 d	 <	 -1),	 as	 well	 as	 the	 caudate	 and	 hippocampus	
(control>duplication;	 -0.5	 >	 Cohen’s	 d	 >	 -1).	 Measures	 of	 cognition,	 language,	 and	 social	
responsiveness	and	the	presence	of	psychiatric	diagnoses	do	not	influence	these	results.	
CONCLUSIONS	
The	global	and	regional	effects	on	brain	morphometry	due	to	16p11.2	CNVs	generalize	across	
site,	computational	method,	age,	and	sex.	Effect	sizes	on	neuroimaging	and	cognitive	traits	
are	 comparable.	 Findings	partially	overlap	with	 results	of	meta-analyses	performed	across	
psychiatric	disorders.	However,	 the	 lack	of	 correlation	between	morphometric	 and	 clinical	
measures	suggests	 that	CNV-associated	brain	changes	contribute	 to	clinical	manifestations	
but	require	additional	factors	for	the	development	of	the	disorder.	These	findings	highlight	
the	power	of	genetic	risk	factors	as	a	complement	to	studying	groups	defined	by	behavioral	
criteria.	
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2.2	Developmental	trajectories	of	neuroanatomical	alterations	associated	with	the	
16p11.2	Copy	Number	Variations	
2.2.1	Introduction	
2.2.1.1	16p11.2	Copy	Number	Variants	(CNVs)	
Genetic	variants	associated	with	psychiatric	disorders	represent	unique	opportunities	to	study	
the	 same	biological	mechanism	across	neurodevelopment,	adolescence,	and	adulthood.	 In	
the	absence	of	longitudinal	data,	the	cross-sectional	study	of	a	genetic	variant	can	provide	a	
reasonable	 approximation	 of	 age-related	 effects	 because	 the	mutation	 can	 be	 studied	 in	
individuals	with	different	ages,	genetic	backgrounds,	as	well	as	carriers	with	or	without	clinical	
manifestations.	The	~600kb	16p11.2	BP4-BP5	CNVs	(breakpoints	4–5,	29.6-30.2	Mb-Hg19)	are	
strongly	 associated	 with	 neurodevelopmental	 disorders	 (Weiss	 et	 al.	 2008).	 Deletion	 and	
duplication	 carriers	have	a	10-fold	 increased	 risk	of	developing	autism	spectrum	disorders	
(ASD),	and	duplication	carriers	(but	not	deletion),	a	10-fold	increased	risk	for	schizophrenia	
(McCarthy	et	al.	2009).	
Deletion	and	duplication	carriers	are	also	associated	with	differences	in	brain	size	and	shape.	
Total	gray	and	white	matter	volumes	correlate	negatively	with	the	number	of	genomic	copies	
(Qureshi	et	al.	2014;	Maillard	et	al.	2014),	with	more	volume	in	deletion	and	less	volume	in	
duplication	carriers	than	controls.	Robust	regional	structural	alterations	have	been	observed	
in	 the	 insula,	 calcarine	 cortex,	 and	 superior,	 middle,	 transverse	 temporal	 gyri	 in	 deletion	
carriers.	 Alterations	 in	 the	 insula,	 caudate	 and	 hippocampus	 occur	 in	 duplication	 carriers	
(Martin-Brevet	et	al.	2018).	These	findings	are	thought	to	reflect	the	true	effect	of	the	CNVs	
since	they	are	independent	of	neuroimaging	computational	methods,	sex,	ascertainment	as	
well	as	presence	or	absence	of	a	psychiatric	diagnosis.	Alterations	are	present	in	older	adults	
as	well	as	adolescents	but	in	the	lack	of	proper	normative	data,	we	have	been	unable	to	study	
younger	 individuals,	 and	 it	 is	 unknown	 when	 these	 alterations	 appear	 during	 brain	
development.	
Longitudinal	 studies	point	out	distinct	phenotypic	 trajectories	and	early	 cognitive	or	 social	
communication	 abilities	 for	 16p11.2	 CNVs	 carriers	 who	 are	 ultimately	 diagnosed	 with	
intellectual	disability	(ID)	or	ASD	(Bernier	et	al.	2017),	compared	to	the	16p11.2	CNVs	carriers	
who	will	not	meet	 the	criteria	 for	 these	psychiatric	 conditions.	Given	 that	 some	studies	 in	
16p11.2	mice	show	structural	alterations	 in	cortex	and	striatum	at	7	days	(Portmann	et	al.	
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2014),	we	hypothesize	that	the	aforementioned	brain	differences	appear	during	childhood	in	
humans.	
2.2.1.2	Z-scoring	and	developmental	trajectory	
Because	none	of	the	brain	measures	show	linear	changes	across	childhood	and	adolescence	
(Giedd	et	al.	1999),	it	is	impossible	to	properly	correct	for	age	based	on	small	control	samples.	
Instead,	 large	 normative	 developmental	 datasets	 are	 required	 to	 infer	 these	 trajectories.	
Aubert-Broche	et	al.	(2013)	previously	developed	a	longitudinal	image	processing	pipeline	and	
z-scoring	method	to	define	age-	and	sex-normative	brain	growth	trajectories	 from	the	NIH	
MRI	 study	 of	 normal	 brain	 development	 (NIHPD)	 derived	 from	 339	 typically	 developing	
individuals	aged	4.5	to	23	years	old	(https://pediatricmri.nih.gov/)	(Evans	2006).	This	method	
has	 successfully	been	applied	 to	determine	 the	 impact	on	brain	 growth	of	pediatric-onset	
Multiple	Sclerosis	(Aubert-Broche	et	al.	2014).	
To	 investigate	 brain	 alterations	 beyond	 a	 priori	 specified	 anatomical	 regions	 of	 interest,	
Tensor-Based	Morphometry	 (TBM)	enables	a	whole	brain	voxel-by-voxel	statistical	analysis	
while	accounting	for	brain	size.	This	is	of	particular	interest	for	a	population	as	the	16p11.2	
deletion	and	duplication	carriers,	which	are	known	to	have	significantly	bigger	and	lower	head	
circumferences	 respectively,	 than	 control	 individuals.	 TBM	 uses	 the	 deformation	 fields	
resulting	from	a	non-linear	registration	to	an	appropriate	template.	It	can	be	used	to	quantify	
changes	in	morphology	across	time	(Frackowiak	2004;	Lau	et	al.	2008).	It	enables	estimation	
of	voxel-wise	trajectories	of	normal	development	when	applied	to	data	such	as	the	NIHPD	
study	(Frackowiak	2004;	Aubert-Broche	et	al.	2011).	
2.2.1.3	Goal	
We	aimed	to	characterize	the	developmental	trajectory	of	global	and	regional	differences	in	
16p11.2	 CNVs	 carriers.	 To	 this	 end,	 we	 z-scored	 our	 cross-sectional	 16p11.2	 dataset	 (56	
deletion	 carriers,	 19	 duplication	 carriers,	 105	 control	 individuals)	 using	 our	 previously	
published	 longitudinal	 pipeline	 and	 normalizing	 methods	 (Aubert-Broche	 et	 al.	 2013).	
Jacobian	determinants	of	the	deformation	field	were	used	as	a	surrogate	metric	of	relative	
local	tissue	volume	for	the	voxel-based	analyses.	
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2.2.2	Methods	
2.2.2.1	Participants	
16p11.2	CNVs	cohort	
Cross-sectional	 data	 were	 acquired	 in	 2	 different	 cohorts	 (the	 European	 -EU	 16p11.2	
consortium	and	the	Simons	VIP	-SVIP	study	in	North	America)	of	180	individuals	(The	Simons	
VIP	Consortium	2012;	Maillard	et	al.	2014).	We	included	data	only	from	participants	between	
4	to	23	years	of	age	as	they	could	be	normalized	with	the	NIHPD	data.	This	included	56	16p11.2	
BP4-5	 deletion	 carriers	 (DEL,	 42	 American	 and	 14	 European	 individuals),	 19	 duplication	
carriers	(DUP,	15	American	and	4	European	individuals),	and	105	controls	(CTRL,	75	American	
and	30	European	individuals,	34	familial	and	71	unrelated	controls).	CNV	carriers	were	either	
probands	 referred	 for	 genetic	 testing	 or	 relatives	 of	 probands.	 The	 familial	 controls	were	
recruited	among	the	non-carriers	of	the	same	CNV-related	families.	The	unrelated	controls	
were	selected	among	volunteers	from	the	general	population	who	did	not	have	a	relative	with	
a	neurodevelopmental	disorder.	The	study	was	approved	by	the	institutional	review	boards	
of	each	consortium	and	 signed	 informed	consents	were	obtained	 from	 the	participants	or	
their	legal	representatives.	A	full	description	of	demographics	is	available	in	Table	2.	
	 DEL	 CTRL	 DUP	
N	 56	 105	 19	
Age	(years)	
Mean	(SD)	
range	(min-max)	
11.26	(3.62)	*	
6.33-22.33	
14.15	(4.24)	*	
4.67-22.92	
12.29	(4.87)	
5-20.33	
Sex	(M/F)	 29/27	 67/38	 13/6	
Scan	parameter	
(Multi/Single	echo	
acquisition)	
38/18	 76/29	 12/7	
	
	
	
General	population	–	NIHPD	cohort	
As	 normative	 data	 for	 growth	 reference,	 we	 used	 the	 multi-site	 longitudinal	 data	 from	
Objective	 1	 of	 the	 publicly	 available	 NIHPD	 project	 (Evans	 2006).	 The	 normative	 model	
(Aubert-Broche	et	al.	2011)	used	data	from	339	children	(179	females	and	160	males),	scanned	
serially	at	2	or	3-time	points,	with	approximately	24	months	between	scans,	for	a	total	of	874	
Table	2.	Population	characteristics	of	the	16p11.2	dataset	
*	Deletion	carriers	significantly	younger	than	control	individuals	(t	=	-4.5272,	p=	1.347e-05)	
DEL,	deletion	carriers;	CTRL,	control	individuals;	DUP,	duplication	carriers;	N,	sample	size;	
SD,	standard	deviation;	M,	male;	F,	female	
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scans.	The	age	range	was	from	4.5	to	18	years	(initial	time-point	for	enrollment),	mean	age	at	
first	scan	was	11.0	years.	
2.2.2.2	MRI	protocol	
The	MRI	data	on	16p11.2	individuals	included	T1-weighted	(T1w)	anatomical	images	acquired	
at	7	sites	using	different	3T	scanners:	Philips	Achieva,	Siemens	Prisma	Syngo,	and	Siemens	Tim	
Trio.	The	MRI	protocol	included	a	whole	brain,	3D	T1w	magnetization	prepared	rapid	Gradient	
echo	 sequence	 (MPRAGE)	 with	 1-mm-thick	 sagittal	 slices.	 Three	 sites	 used	 multi-echo	
sequences	 for	126	participants	 (38	DEL,	12	DUP,	76	CTRL	with	5	 familial	and	71	unrelated	
CTRL),	 and	 4	 sites	 used	 single-echo	 sequences	 for	 54	participants	 (18	DEL,	 7	DUP,	 and	29	
familial	CTRL).	Details	of	the	scanners	and	image	acquisition	sequences	can	be	found	in	Table	
3.	 Extensive	 analyses	 on	 the	 potential	 effect	 of	 these	 scanning	 sites	 and	 protocols	 were	
performed	in	a	previous	study	showing	that	none	of	the	regions	associated	with	the	16p11.2	
deletion	or	duplication	could	be	attributed	to	artifacts	introduced	by	the	multisite	analyses	
(Martin-Brevet	et	al.	2018).	
Scans	of	the	NIHPD	controls	were	obtained	at	6	study	centers	with	1.5	MRI	scanners	 from	
General	Electric	or	Siemens	Medical	Systems.	The	MRI	protocol	 included	a	whole	brain,	3D	
T1w	RF-spoiled	gradient	echo	sequence	(1-mm-thick	sagittal	partitions,	TR	22–25	msec,	TE	
10–11	msec,	excitation	pulse	angle	30°,	Field	Of	View	160–180	mm).	Details	on	acquisition	
and	participants	were	previously	published	(Evans	2006).	
Cohort	 Scanner	 Echo	sequences	 TR	 TE	
Flip	
angle	
Field	Of	
View	
EU	 Magnetom	TIM	Trio	(1	site)	 ME-MPRAGE	 2530	ms	
TE1:	1.64	ms	
TE2:	3.5	ms		
TE3:	5.36	ms	
TE4	:	7.22	ms	
7°	 256	
EU	 Magnetom	Prisma	Syngo	(1	site)	 MPRAGE	 2000	ms	 2.39	ms	 9°	 256	
SVIP	 Magnetom	TIM	Trio	(2	sites)	 ME-MPRAGE	 2530	ms	 1.64	ms	 7°	 256	
SVIP	 Philips	Achieva	(2	sites)	 MPRAGE	 2300	ms	 3	ms	 9°	 256	
SVIP	 Magnetom	TIM	Trio	(1	site)	 MPRAGE	 2300	ms	 2.98	ms	 9°	 256	
	
	
Table	3.	Image	acquisition	parameters	for	the	16p11.2	dataset	
EU	European	cohort,	SVIP	Simons	VIP	cohort,	ME-MPRAGE	Multi-Echo	Magnetization	
Prepared	RApid	Gradient	Echo,	MPRAGE	Magnetization	Prepared	RApid	Gradient	Echo,	TR	
Repetition	Time,	TE	Echo	Time.	
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2.2.2.3	Image	processing	
The	longitudinal	automatic	image	processing	pipeline,	developed	for	NIHPD	analysis	(Aubert-
Broche	et	al.	2013),	was	adapted	to	the	scans	from	the	16p11.2	dataset	as	described	below.	
The	preprocessing	steps	applied	to	the	native	T1w	images	were	(1)	denoising,	 (2)	 intensity	
inhomogeneity	 correction	 using	 the	 N3	 algorithm	 (Sled	 et	 al.	 1998),	 and	 (3)	 intensity	
normalization	by	histogram	matching	to	the	ICBM152	template	(Fonov	et	al.	2011;	Fonov	et	
al.	2009).	A	hierarchical	9-parameter	linear	registration	based	on	an	intensity	cross-correlation	
similarity	measure	was	performed	between	the	T1w	 images	and	the	 ICBM152	template	to	
align	the	images	with	the	stereotaxic	population	template	(Collins	et	al.	1994).	Subsequently,	
images	 were	 non-linearly	 registered	 using	 the	 Automated	 Nonlinear	 Image	Matching	 and	
Anatomical	 Labelling	 (ANIMAL)	 algorithm	 (Collins	 et	 al.	 1995),	 a	 hierarchical,	 multi-scale	
registration	algorithm.	Brain	extraction	was	achieved	using	the	BEaST	algorithm	(Eskildsen	et	
al.	2012),	a	multi-resolution,	nonlocal	patch-based	segmentation	technique.	To	obtain	optimal	
brain	extraction,	BEaST	was	applied	 iteratively	three	times,	with	each	subsequent	 iteration	
including	the	best	segmented	images	from	the	previous	iteration	as	additional	priors.	Whole	
brain	volumes	were	segmented,	and	the	right	and	left	volumes	were	combined	for	analysis.	
The	non-linear	deformation	grids	for	each	scan’s	registration	to	the	ICBM152	template	were	
inverted,	effectively	yielding	a	voxel-by-voxel	nonlinear	mapping	from	the	ICBM152	template	
reference	space	to	the	space	of	each	linearly	registered	scan.	A	3D	Gaussian	filter	with	FWHM	
of	10	mm	was	applied	to	the	resulting	inverted	deformation	grids.	The	Jacobian	determinant	
of	 the	 deformation	 field	 was	 computed	 for	 every	 voxel,	 log-transformed	 and	 used	 as	 a	
surrogate	of	the	local	volume	difference	between	each	subject	and	the	ICBM152	template.	In	
general,	a	log-transformed	Jacobian	determinant	value	less	than	0	represents	shrinking	from	
the	template	to	the	native	space,	a	value	of	0	indicates	that	there	is	no	volume	change	in	the	
voxel	and	a	value	of	more	than	0	indicates	enlargement	with	respect	to	the	template.	
2.2.2.4	Data	analyses	
Z-scoring	for	the	main	effect	of	age	and	gender	for	global	and	voxel-based	volumes	
To	compute	z	scores	that	normalize	for	the	effect	of	growth	and	sex	in	a	pediatric	population,	
we	modeled	 the	effect	of	 those	2	 variables	 in	 the	NIHPD	normative	dataset.	Mixed-effect	
models	were	used	since	it	is	appropriate	to	estimate	growth	in	longitudinal	studies	that	take	
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repeated	measures	from	the	same	individuals	over	time.	It	accounts	for	the	within-participant	
correlation	and	varying	numbers	of	measurements	for	each	participant.	
As	we	previously	described	(Aubert-Broche	et	al.	2013),	individual	profiles	suggest	modeling	
brain	growth	as	a	quadratic	function	over	time:	we	included	both	linear	and	quadratic	effects	
of	age	in	the	fixed	effects	structure.	Age	was	not	divided	into	age	bins,	but	it	was	considered	
as	a	continuous	variable	and	was	centered	at	13	years	old,	the	mean	age	of	NIHPD	cohort.	The	
linear	effect	of	sex	was	also	included	in	the	fixed	terms	(Aubert-Broche	et	al.	2013).	
The	proposed	mixed-effects	model	is:	
Voli	=	β0	+	g0	+	(β1	+	g1)	(Agei-13)	+	β2	(Agei-13)2	+	β3	Sexi	+	ei	
where	
•	Voli	is	the	value	of	the	response	variable	(global	brain	volume	or	voxel)	for	subject	i,	
•	Agei,	Age2i,	Sexi	are	the	ﬁxed	and	random	effect	explanatory	variables	for	subject	i,	
•	β0,	g0	are	the	intercept	for	the	fixed	and	random	terms,	
•	β1,	β2,	β3	are	the	fixed	effects	coefficients	and	are	identical	for	all	subjects,	
•	g1	is	a	random	effect	coefficient,	
•	ei	is	the	error	in	subject	i.	The	errors	for	subject	i	are	assumed	to	have	mean	zero	and	
constant	independent	variance.	
To	estimate	the	standard	deviation	of	the	model,	we	extracted	the	variance-covariance	matrix	
of	the	fixed	effects	along	with	the	residual	variance	of	the	random	effects.	Using	the	mean	
and	the	estimated	standard	deviation	of	the	model	we	were	able	to	compute	Z-scores	for	the	
global	 volumes	 of	 the	 brain	 as	 well	 as	 for	 each	 voxel	 independently,	 for	 the	 16p11.2	
participants.	
Analyses	of	Z-scored	global	brain	volumes	and	voxels	in	CNV	carriers	and	controls	
To	 identify	 local	acquisition	biases,	as	well	 as	differences	 in	 scan	parameters	between	 the	
NIHPD	and	16p11.2	cohorts	(e.g.,	1.5T	vs.	3T	scans),	we	first	compared	the	Z-scores	from	the	
global	 volumes	and	 the	 voxel-wise	 log-transformed	 Jacobian	determinants	of	CTRL,	 to	 the	
controls	from	the	NIHPD	cohort.	Any	residual	effects	were	corrected	for	in	the	linear	model	
used	to	compare	the	DEL	and	DUP	subjects	with	the	CTRL	from	the	16p11.2	dataset.	As	we	
consider	this	control	group	as	our	reference	and	to	have	a	better	visualization	of	the	effect	
sizes,	we	re-centered	at	0	the	predicted	Z-score	mean	and	corrected	for	any	age	related	effect	
of	the	control	group	from	all	groups	for	the	developmental	trajectories.	
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We	extracted	the	p-values	from	the	linear	models:	results	with	a	Bonferroni	correction	for	2	
simultaneous	comparisons	are	presented	for	the	global	volumes	and	with	a	False	Discovery	
Rate	FDR	correction	(q<0.05)	for	the	voxel-wise	analysis.	Regions	with	significant	differences	
were	 anatomically	 labeled	 using	 the	 neuromorphometric	 atlas	
(http://www.neuromorphometrics.com).	
All	 analyses	 were	 conducted	 using	 R	 3.4.0	 (The	 R	 Project	 for	 Statistical	 Computing;	
http://www.R-project.org/).	The	mixed-effect	models	were	built	using	the	nlme	package.	
2.2.3	Results	
Data	were	analyzed	for	56	DEL,	19	DUP,	105	familial	and	unrelated	CTRL	(Table	2).	Age	ranges	
from	4.5	 to	 23	 years,	 and	 the	 range	differs	 significantly	 between	 genetic	 groups:	 deletion	
carriers	are	younger	than	control	individuals	from	the	16p11.2	dataset.	
2.2.3.1	Differences	between	16p11.2	controls	and	NIHPD	controls	
The	NIHPD	and	16p11.2	datasets	are	acquired	at	different	fields	of	strength	(respectively	1.5	
and	3	Tesla).	To	understand	the	effects	due	to	these	differences	in	magnet	and	protocol,	we	
first	study	and	Z-score	our	intrafamilial	controls.	There	is	a	linear	effect	of	age	on	Z-scores	in	
our	control	group.	The	intercepts	and	the	slopes	are,	respectively	-0.68	/	-0.04	for	the	total	
brain	volume;	-0.11	/	-0.1	for	the	gray	matter	volume	(GM);	0.42	/	0.05	for	the	white	matter	
volume	(WM)	and	-0.32	/	-0.02	for	the	lateral	ventricle	(LV).	The	exact	same	linear	effect	of	
age	is	observed	in	the	deletion	and	duplication	groups.		
Regarding	 voxel-based	mean	 Z-scores,	 16p11.2	 CTRL	 show	 also	 some	 deviations	 from	 the	
baseline	of	NIHPD	controls,	in	particular	in	the	left	putamen	and	the	medial	frontal	cortex	(Z-
scores	between	-0.88	and	1.09)	(Figure	5).		
After	adjusting	for	these	monotonous	and	linear	effects	due	to	scanning	protocol,	the	control	
sample	shows	a	normal	distribution	with	a	mean	of	zero	at	all	ages	 (Figures	6	and	8).	We	
further	 investigate	 our	 control	 group	which	 is	 a	 combination	 of	 familial	 controls	 (34	 first	
degree	relatives	who	do	not	carry	a	16p11.2	CNV)	and	71	unrelated	controls.	The	two	control	
groups	show	no	significant	differences	at	the	global	or	voxel	level	with	an	adjusted	mean	of	0	
Z-score.	 For	 all	 future	 analyses,	 the	 same	 adjustment	 for	 magnet	 and	 scanning	 protocol	
controls	are	performed	for	controls	and	CNV	carriers.	
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2.2.3.2	Developmental	trajectory	of	the	global	volumes	of	each	genetic	group		
Deletion	 carriers	 have	 higher	 volume	 than	 controls	 for	 total	 brain	 volume	 (mean	 Z-
score=1.165,	p-value<0.0001),	grey	matter	(mean	Z-score=0.414,	p-value=0.00433)	and	white	
matter	volume	(mean	Z-score=0.693,	p-value<0.0001)	 (Figure	6).	Duplication	carriers	show	
the	opposite	effect,	with	lower	total	brain	volume	(mean	Z-score=-1.17,	p-value=0.0001),	grey	
matter	volume	(mean	Z-score=-0.631,	p-value=0.00272)	and	white	matter	volume	(mean	Z-
score=-0.53,	 p-value=0.0018)	 compared	 to	 controls.	 However,	 duplication	 carriers	 have	 a	
higher	 volume	 than	 CTRL	 for	 the	 lateral	 ventricle,	 with	 mean	 Z-score	 of	 1.629	 (p-
value<0.0001).	
We	do	not	observe	any	age	effects	on	the	age-	and	sex-normalized	z-score	global	volumes	
that	are	specific	to	one	of	the	three	genetic	groups	(Figure	6).	As	age	was	centered	at	13	years	
old	(mean	age	for	the	reference	NIHPD	cohort)	for	all	analyses,	we	tested	other	centering,	at	
Figure	5.	Mean	z-scores	
voxel-based	per	genetic	
group	
Results	of	the	mean	z-scores	
per	 genetic	 groups,	 on	 the	
Jacobian	 determinants	
voxel-by-voxel.		
A.	 Mean	 z-scores	 for	 the	
CTRL;	 B.	 Mean	 z-scores	 for	
the	DEL;	C.	Mean	z-scores	for	
the	DUP.		
16p11.2	 CTRL	 show	 similar	
profile	 than	 the	 baseline	 of	
NIHPD	 controls,	 with	 only	
some	 deviations	 in	 the	 left	
putamen	 and	 the	 medial	
frontal	 cortex,	 whereas	 DEL	
and	 DUP	 show	 extensive	
clusters	 different	 from	
NIHPD	controls.	
DEL,	 deletion	 carriers;	 CTRL,	
control	 individuals;	 DUP,	
duplication	carriers	
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6,	8,	10,	16,	18	years	old,	and	they	don’t	reveal	any	interaction	between	genetic	groups	and	
age	either.	
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2.2.3.3	Developmental	trajectory	for	regional	alterations	
The	 TBM	 analysis	 identifies	 several	 brain	 regions	 associated	with	 an	 inverse	 gene	 dosage	
effect.	Deletion	carriers	have	significantly	higher	Jacobian	determinants	values	than	controls,	
and	duplication	have	significantly	lower	values	(i.e.,	DEL>CTRL>DUP)	in	the	following	regions:	
bilateral	 calcarine	 cortex,	 insula,	 left	 transverse	 temporal	 gyrus,	 planum	 temporale,	 and	
parietal	operculum.	Reciprocal	inverse	gene	dosage	effects	are	also	present	in	the	frontal	and	
occipital	white	matter	(Figure	7,	Table	4).	
Differences	 predominantly	 or	 specifically	 associated	 with	 the	 deletion	 include	 increased	
Jacobian	determinants	values	in	the	cuneus,	anterior	cingulate,	posterior	orbital	and	inferior	
frontal	 gyri.	 Regions	 predominantly	 decreased	 in	 deletion	 carriers	 compared	 to	 controls	
include	the	bilateral	cerebellum,	middle	cingulate	gyrus,	pallidum,	putamen,	precentral	and	
post-central	 gyri,	 fusiform	 gyrus,	middle	 and	 inferior	 temporal	 gyri,	 supplementary	motor	
cortex,	gyrus	rectus,	left	accumbens	area	and	angular	gyrus.	
The	only	region	predominantly	or	specifically	associated	with	the	duplication	is	the	occipital	
fusiform	gyrus	with	a	decrease	in	volume	compared	to	controls	as	well	as	the	lateral	ventricles	
with	an	increase	in	volume.	Additional	regions	with	smaller	significant	clusters	are	described	
in	Table	4.	
We	do	not	identify	any	effect	of	age	for	any	of	the	clusters	described	above.	Figure	8	shows	
this	complete	 lack	of	age-related	effects	for	the	top	8	regional	differences	with	the	 largest	
effect	sizes.	Whatever	the	age,	the	DEL	have	Z-scores	of	0.7	and	1	for	the	anterior	insula	and	
the	calcarine	cortex	 respectively,	and	 the	DUP	have	Z-scores	of	 -0.9	and	 -1,2	on	 the	same	
structures.	DEL	have	Z-scores	of	0.9	and	0.7	for	the	posterior	orbital	and	anterior	cingulate	
gyri	 respectively;	 they	 have	 the	most	 negative	 Z-scores,	 -1.6	 and	 -1.1,	 for	 the	 cerebellum	
exterior	 and	 the	 fusiform	 gyrus.	 DUP	 have	 also	 high	 Z-scores	 for	 the	 lateral	 ventricle	 and	
inferior	 temporal	gyrus,	1.6	and	0.9	 respectively.	We	observe	 the	same	 lack	of	 interaction	
between	the	genetic	groups	and	age	when,	in	the	linear	model,	we	center	the	age	at	different	
values	(6,	8,	10,	16	or	18	years).	
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Figure	7.	Effect	of	genetic	status	on	brain	structures	for	voxel-based	analyses	
Significant	differences	on	Jacobian	determinants	highlight	 the	 inverse	gene	dosage	effect	at	the	regional	
level	on	volumes	between	DEL>CTRL>DUP,	as	well	as	some	specific	volume	differences	between	DEL>CTRL,	
CTRL>DUP	and	DEL<CTRL.	
A.	DEL	versus	CTRL,	B.	DUP	versus	CTRL.	Only	regions	with	a	False	Discovery	Rate	FDR	correction	(q<0.05)	
are	presented.	Negative	t-values	represent,	respectively,	the	contrasts	DEL<CTRL	and	DUP<CTRL,	positive	t-
values	represent	the	contrasts	DEL>CTRL	and	DUP>CTRL.	
DEL:	deletion	carriers;	CTRL:	control	individuals;	DUP:	duplication	carriers.	
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Table	 4.	 Coordinates	 of	 brain	 regions	 with	 significant	 differences	 between	 genetic	 groups	 in	 Jacobian	
determinant	analyses	
“Overlap”	refers	to	the	percentage	of	significant	voxels	within	each	brain	region.	When	some	brain	regions	have	
more	than	one	cluster	that	overlaps	with	them,	we	reported	the	bigger	one.	Only	regions	with	a	False	Discovery	
Rate	FDR	correction	(q<0.05)	and	with	size	>30	voxels	are	presented.	
(1)	The	developmental	trajectory	of	a	typical	voxel	for	each	of	these	regions	is	shown	in	Figure	8.	
A.						Deletion	>	Control	 Side	 Size	 Overlap(%)	 Z	 Y	 X	 t-score	
CLUSTER	1	
Posterior	orbital	gyrus	(1)	
	
Right	
Left	
200	
190	
62	
61	
-14	
-17	
21	
23	
40	
-31	
5.58	
4.52	
Inferior	frontal	gyrus	orbital	
part	
Left	
Right	
73	
64	
49	
42	
-8	
-9	
25	
23	
-45	
41	
4.39	
5.04	
Frontal	operculum	 Left	 95	 41	 -1	 27	 -43	 5.35	
Inferior	frontal	gyrus	
triangular	part	
Left	 150	 35	 1	 29	 -53	 4.90	
Anterior	cingulate	gyrus	(1)	
	
Right	
Left	
212	
142	
33	
21	
-4	
-1	
37	
41	
5	
-10	
4.44	
3.57	
Anterior	insula	(1)	
	
Left	
Right	
156	
148	
28	
27	
3	
-5	
25	
28	
-33	
29	
3.88	
4.47	
Temporal	pole	
	
Left	
Right	
93	
61	
8	
5	
-26	
-22	
9	
9	
-37	
39	
4.80	
3.72	
CLUSTER	2	
Transverse	temporal	gyrus	 Right	
	
87	 60	 14	 -29	 43	 7.77	
Parietal	operculum	 174	 59	 16	 -33	 41	 8.27	
Posterior	insula	 87	 31	 15	 -25	 33	 5.92	
Planum	temporale	 44	 23	 13	 -33	 41	 8.17	
Posterior	cingulate	gyrus	 134	 22	 5	 -53	 21	 6.76	
Middle	occipital	gyrus	 133	 21	 6	 -81	 36	 4.76	
Calcarine	cortex	(1)	 96	 17	 7	 -68	 25	 8.75	
Lingual	gyrus	 164	 14	 3	 -58	 25	 7.94	
Ventral	DC	 92	 14	 -14	 -15	 15	 3.40	
Cuneus	 69	 11	 13	 -98	 11	 5.04	
Occipital	pole	 31	 9	 11	 -103	 14	 2.82	
Central	operculum	 33	 7	 14	 -19	 43	 3.88	
Precuneus	 116	 6	 7	 -60	 25	 8.16	
Lateral	ventricle	 75	 6	 6	 -54	 29	 7.58	
Inferior	occipital	gyrus	 47	 6	 4	 -83	 33	 4.07	
Thalamus	proper	 41	 3	 1	 -35	 13	 4.03	
CLUSTER	3	
Calcarine	cortex	 Left	 260	 45	 5	 -67	 -25	 7.44	
Superior	occipital	gyrus	 194	 43	 30	 -88	 -12	 4.15	
Cuneus	 241	 35	 13	 -63	 -15	 4.48	
Lingual	gyrus	 183	 15	 3	 -57	 -19	 7.04	
Posterior	cingulate	gyrus	 95	 15	 5	 -51	 -17	 6.13	
Lateral	ventricle	 115	 9	 8	 -53	 -28	 6.25	
Inferior	occipital	gyrus	 68	 9	 3	 -83	 -33	 4.36	
Precuneus	 140	 8	 7	 -58	 -20	 6.97	
Middle	occipital	gyrus	 30	 5	 6	 -84	 -31	 3.71	
Thalamus	proper	 35	 3	 4	 -33	 -11	 3.80	
CLUSTER	4	
Transverse	temporal	gyrus	 Left	 130	 94	 7	 -21	 -41	 9.82	
Planum	temporale	 128	 59	 14	 -33	 -38	 8.11	
Parietal	operculum	 162	 59	 18	 -31	 -38	 8.35	
Posterior	insula	 99	 35	 8	 -21	 -35	 7.74	
Superior	temporal	gyrus	 124	 13	 9	 -27	 -71	 4.19	
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B.						Deletion	<	Control	 Side	 Size	 Overlap(%)	 Z	 Y	 X	 t-score	
CLUSTER	1	
Pallidum	 Right	
Left	
190	
182	
95	
89	
4	
5	
-1	
-3	
23	
-24	
-7.12	
-8.07	
Middle	cingulate	gyrus	 Right	
Left	
543	
426	
81	
61	
42	
39	
9	
12	
1	
-3	
-5.12	
-5.30	
Putamen	 Right	
Left	
480	
454	
77	
73	
5	
7	
-1	
-3	
23	
-25	
-7.20	
-8.60	
Accumbens	area	 Left	 34	 77	 -7	 11	 -11	 -6.04	
Cerebellum	exterior	(1)	 Right	
Left	
6247	
6113	
70	
69	
-53	
-54	
-61	
-59	
35	
-33	
-8.37	
-6.89	
Precentral	gyrus	 Left	
Right	
924	
556	
56	
33	
61	
27	
-13	
-1	
-30	
55	
-5.06	
-4.36	
Fusiform	gyrus	(1)	 Right	
Left	
589	
224	
54	
20	
-26	
-21	
-45	
-50	
44	
-47	
-6.34	
-4.43	
Middle	temporal	gyrus	 Left	
Right	
1139	
243	
51	
12	
5	
-5	
-45	
-29	
-49	
50	
-6.05	
-3.72	
Angular	gyrus	 Left	 801	 51	 47	 -65	 -50	 -5.20	
Inferior	temporal	gyrus	 Left	
Right	
715	
465	
40	
25	
-17	
-19	
-51	
-43	
-51	
47	
-5.41	
-5.41	
Supplementary	motor	cortex	 Left	
Right	
258	
208	
36	
28	
45	
45	
11	
9	
-3	
5	
-4.50	
-4.20	
Postcentral	gyrus	 Left	
Right	
434	
167	
32	
12	
31	
21	
-7	
-4	
-57	
57	
-4.03	
-3.70	
Caudate	 Right	
Left	
116	
77	
31	
21	
13	
-5	
10	
13	
17	
-11	
-5.36	
-5.52	
Parahippocampal	gyrus	 Left	
Right	
90	
75	
30	
27	
-29	
-30	
-21	
-20	
-23	
27	
-4.82	
-3.66	
Thalamus	proper	 Right	 325	 27	 9	 -15	 9	 -4.56	
Hippocampus	 Left	
Right	
121	
62	
25	
12	
-2	
-7	
-37	
-33	
-27	
33	
-4.20	
-3.41	
Central	operculum	 Left	
Right	
121	
106	
24	
23	
3	
5	
7	
-1	
-43	
47	
-4.90	
-3.69	
Anterior	insula	 Left	
Right	
134	
37	
24	
7	
4	
1	
5	
1	
-41	
45	
-4.90	
-3.65	
Inferior	frontal	gyrus	
opercular	part	 Right	 98	 22	 29	 17	 51	 -4.61	
Superior	temporal	gyrus	 Left	
Right	
186	
176	
20	
20	
10	
-5	
-43	
-25	
-51	
49	
-5.18	
-3.92	
Lingual	gyrus	 Right	
Left	
237	
208	
20	
17	
-17	
-15	
-90	
-90	
7	
-3	
-4.99	
-4.35	
Precentral	gyrus	medial	
segment	 Right	 64	 18	 49	 -21	 3	 -3.58	
Brain	stem	 		 387	 14	 -47	 -41	 -11	 -5.78	
Temporal	pole	 Right	 136	 11	 -34	 15	 23	 -3.62	
Supramarginal	gyrus	 Left	 146	 11	 50	 -51	 -47	 -3.27	
Middle	frontal	gyrus	 Right	
Left	
240	
227	
8	
8	
31	
31	
20	
7	
49	
-35	
-5.23	
-4.36	
Ventral	DC	 Left	 31	 5	 -9	 -25	 -25	 -3.77	
Superior	frontal	gyrus	 Left	 84	 4	 59	 -11	 -27	 -4.47	
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CLUSTER	2	
Gyrus	rectus	 Left	
Right	
182	
149	
55	
47	
-25	
-25	
45	
43	
-5	
1	
-4.68	
-4.25	
Medial	orbital	gyrus	 Left	 102	 17	 -26	 43	 -9	 -4.36	
CLUSTER	3	
Temporal	pole	 Left	 232	 19	 -37	 19	 -25	 -4.34	
CLUSTER	4	
Supramarginal	gyrus	 Right	 137	 12	 27	 -32	 70	 -3.97	
CLUSTER	5	
Superior	parietal	lobule	 Left	 153	 10	 66	 -63	 -13	 -3.71	
CLUSTER	6	
Superior	parietal	lobule	 Right	 69	 5	 60	 -68	 15	 -3.22	
CLUSTER	7	
Superior	frontal	gyrus	medial	
segment	 Right	 41	 4	 39	 49	 2	 -2.99	
	
C.			Duplication	>	Control	 Side	 Size	 Overlap(%)	 Z	 Y	 X	 t-score	
CLUSTER	1	
Lateral	ventricule	(1)	 Left	
Right	
1038	
875	
77	
67	
14	
19	
-37	
-33	
-23	
23	
5.29	
5.36	
Caudate	 Right	
Left	
66	
66	
18	
18	
24	
9	
-13	
19	
17	
-13	
4.92	
3.98	
Thalamus	Proper	 Left	
Right	
100	
70	
8	
6	
17	
19	
-23	
-17	
-14	
15	
4.43	
4.56	
CLUSTER	2	
Inferior	temporal	gyrus	(1)	 Right	 91	 5	 -24	 -53	 53	 3.56	
CLUSTER	3	
Posterior	cingulate	gyrus	 Left	 70	 11	 35	 -35	 -5	 3.76	
CLUSTER	4	
fusiform	gyrus	 Left	 41	 4	 -29	 -27	 -39	 3.67	
	
D.			Duplication	<	Control	 Side	 Size	 Overlap(%)	 Z	 Y	 X	 t-score	
CLUSTER	1	
Occipital	fusiform	gyrus	 Left	
Right	
267	
46	
60	
12	
-13	
-7	
-91	
-78	
-25	
31	
-4.45	
-4.05	
Calcarine	cortex	(1)	 Left	
Right	
260	
171	
45	
30	
5	
9	
-67	
-73	
-17	
17	
-3.93	
-3.94	
Inferior	occipital	gyrus	 Left	 300	 38	 2	 -85	 -29	 -4.79	
Occipital	pole	 Left	 45	 13	 3	 -101	 -11	 -3.45	
Superior	occipital	gyrus	 Right	 58	 12	 27	 -78	 28	 -3.66	
Middle	occipital	gyurs	 Left	 62	 10	 5	 -85	 -29	 -4.72	
Cuneus	 Right	 52	 8	 19	 -71	 20	 -3.73	
Lingual	gyrus	 Right	
Left	
65	
43	
5	
3	
-7	
-2	
-90	
-65	
15	
-17	
-3.48	
-3.77	
Cerebellum	exterior	 Left	 219	 2	 -21	 -81	 -37	 -3.84	
CLUSTER	2	
Anterior	insula	(1)	 Right	
	
187	 34	 6	 15	 32	 -4.4	
Putamen	 123	 20	 3	 9	 29	 -4.34	
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CLUSTER	3	
Parietal	operculum	 Left	
		
		
		
		
147	 53	 25	 -33	 -45	 -4.69	
Posterior	insula	 139	 49	 8	 -19	 -35	 -5.63	
Transverse	temporal	gyrus	 67	 49	 9	 -23	 -37	 -5.36	
Planum	temporale	 49	 23	 23	 -35	 -49	 -4.21	
Central	operculum	 37	 7	 21	 -15	 -37	 -4.1	
CLUSTER	4	
Anterior	insula	 Left	
	
96	 17	 3	 27	 -29	 -4.08	
Putamen	 105	 17	 1	 9	 -29	 -4.65	
CLUSTER	5	
Thalamus	Proper	 Right	 88	 7	 3	 -30	 15	 -4.05	
Posterior	cingulate	gyrus	 Left	 43	 7	 15	 -43	 0	 -4.37	
CLUSTER	6	
Medial	orbital	gyrus	 Left	 54	 9	 -19	 11	 -19	 -4.62	
	
2.2.4	Discussion	
Our	 study	 provides	 a	 thorough	 investigation	 of	 the	 effects	 of	 the	 16p11.2	 deletion	 and	
duplication	 on	 neuroanatomy	 between	 the	 age	 of	 4.5	 and	 23	 years	 of	 age.	 This	 is	 to	 our	
knowledge,	one	of	the	first	attempt	of	tracking	changes	related	to	 large	effect-size	genetic	
variants	across	a	broad	period	of	brain	development	using	a	powerful	normative	sample.	We	
do	not	observe	any	age-related	effects	on	global	metrics	and	regional	volumes	in	deletion	or	
duplication	carriers.	These	results	are	in	favor	of	early	brain	changes	that	remain	stable	across	
childhood,	adolescence	and	early	adulthood.	16p11.2	CNV	carriers	brain	related-differences	
are	already	present	at	4.5	years	of	age.	
2.2.4.1	Effect	size	and	brain	alterations	in	DEL	and	DUP	
DEL	and	DUP	present	similar	effect	sizes,	with	a	range	in	absolute	values	from	about	1	to	1.5	
Z-scores,	for	the	total	brain	volumes	and	the	regional	brain	differences:	the	highest	Z-scores	
are	in	the	calcarine	cortex	and	the	cerebellum;	and	in	the	lateral	ventricles	and	the	insula	for	
the	duplication.	These	effect	size	values	are	5	to	10	times	higher	than	the	ones	observed	in	a	
recent	study	on	about	1500	ASD	individuals	(van	Rooij	et	al.	2017),	and	much	closer	to	the	
severity	of	the	symptoms.	This	highlights	the	important	heterogeneity	in	ASD	cohorts	and	the	
utility	of	the	genetic-first	approach	to	study	biologically	homogeneous	groups.		
Our	results	also	corroborate	some	global	and	regional	findings	from	our	previous	publication:	
insula	is	affected	in	both	CNVs	in	a	mirror	way,	while	calcarine	cortex,	temporal	and	precentral	
gyri	are	altered	in	DEL.	This	current	paper	highlights	the	importance	of	the	alteration	of	the	
cerebellum	 in	 the	 deletion	 carriers	 and	 the	 alteration	 of	 the	 ventricles	 in	 the	 duplication	
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carriers.	We	don’t	replicate	specific	alterations	of	the	caudate	and	the	hippocampus	in	DUP:	
in	our	current	analyses,	the	anterior	and	medial	portions	of	the	caudate	have	higher	values	in	
DUP,	while	the	posterior	and	lateral	portions	show	lower	values	in	DEL.	However,	the	results	
in	the	duplication	carriers	need	to	be	interpreted	carefully:	the	small	sample	size	of	this	group	
(N=19)	can	bias	the	brain	regions	involved	and	over/under-estimate	some	of	the	effect	sizes	
for	the	significant	regions	(Carter	et	al.	2017).	Moreover,	given	the	large	effect	in	the	ventricle,	
it	 may	 cause	 registration	 errors	 which	 in	 turn	 can	 propagate	 to	 the	 brain	 segmentation,	
depending	 on	 the	 different	 computational	 methods	 used	 in	 the	 previous	 and	 current	
publications.	
Familial	 and	unrelated	controls	 show	homogeneous	global	and	 regional	 values,	 and	 so	we	
merged	all	the	control	individuals.	We	don’t	find	the	subtle	differences	between	the	unrelated	
controls	and	the	 familial	controls	with	a	relative	carrying	the	deletion,	as	suggested	 in	our	
previous	paper,	which	 is	probably	associated	with	 the	very	 low	sample	sizes	of	 these	sub-
groups	of	controls.	
2.2.4.2	Continuous	model	of	normative	developmental	trajectory	
One	of	the	major	contributions	of	our	paper	is	the	use	of	a	model	to	normalize	the	non-linear	
effect	of	age	during	typical	brain	development	(Giedd	et	al.	1999;	Aubert-Broche	et	al.	2013).	
This	allows	us	to	reliably	study	a	sample	of	mutation	carriers	and	controls	spanning	a	broad	
age	range.	Papers	analyzing	developmental	trajectories	of	brain	structures	have	mostly	used	
narrow	 age	 bins	 because	 the	 study-specific	 control	 groups	were	 too	 small	 (less	 than	 100	
individuals)	to	model	the	effect	of	age	reliably.	Here,	despite	the	fact	that	the	NIHPD	data	have	
been	 collected	 with	 a	 1.5T	 magnet,	 the	 model	 for	 the	 effect	 of	 age	 during	 typical	 brain	
development	 is	 robust	 and	 applies	 to	 data	 acquired	 on	 a	 3T	 after	 a	 straightforward	
adjustment.	It	is	known	that	images	acquired	at	3T	and	1.5T	can	differ	due	to	the	presence	of	
different	artifacts	as	well	as	different	inhomogeneity	field	characteristics	(Dietrich	et	al.	2008).	
Other	 studies	 have	 shown	 that	 some	 differences	 in	 signal-to-noise	 and	 contrast-to-noise	
ratios	can	be	found	between	3T	and	1.5T	fields,	and	are	to	a	certain	degree	dependent	on	the	
specific	imaging	protocol	used	(Fushimi	et	al.	2007;	Stanisz	et	al.	2005).	
Integrating	 large	 normative	 datasets	 to	 correct	 for	 complex	 covariates	 such	 as	 age	 still	
requires	an	additional	control	group	scanned	with	the	same	protocol	as	the	cases.	It	may	be	
possible	to	include	in	control	groups,	future	normative	dataset	acquired	with	3T	scanners.	
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2.2.4.3	Comparison	with	developmental	trajectories	in	neurodevelopmental	disorders	and	
genetic	risk	factors	
Our	results	are	in	line	with	previous	findings	in	ASD.	Early	brain	differences	may	be	already	
present	during	the	first	2	years	of	life	on	high-risk	children	who	were	finally	diagnosed	with	
autism	at	2	years	of	age,	compared	to	low-risk	children:	the	significant	hyper-expansion	in	the	
cortical	 surface	 area	 between	 6	 and	 12	 months	 precedes	 the	 brain	 volume	 overgrowth	
between	12	and	24	months	(Hazlett	et	al.	2017),	across	multiple	brain	regions.	A	longitudinal	
study	did	not	show	an	increased	rate	of	cortical	growth	between	2	and	4-5	years	old,	except	
an	 enlargement	 in	WM	 temporal	 lobe	 (Hazlett	 et	 al.	 2011).	 Similar	 parallel	 trajectories	 of	
global	 brain	 volume	between	 2	 and	 5	 years	 of	 age	were	 observed	 between	 children	with	
fragile	X	syndrome	and	controls,	even	if	they	show	some	specific	increase	in	WM	temporal	
lobe,	 GM	 cerebellum,	 caudate	 nucleus,	 and	 smaller	 amygdala.	 Recently,	 the	 largest	 ASD	
neuroimaging	study	(van	Rooij	et	al.	2017)	analyzed	individuals	between	2	and	64	years	old:	
the	authors	found	differences	in	subcortical	volumes	and	cortical	thickness	from	the	earliest	
age.	 Without	 interaction	 between	 age	 and	 ASD	 diagnosis	 for	 subcortical	 volumes,	 they	
concluded	that	ASD	and	healthy	controls	follow	similar	developmental	trajectories	for	these	
volumes.	However,	they	highlighted	an	interaction	for	the	cortical	thickness	with	a	peak	of	
differences	 around	 adolescence.	 The	 cortical	 thickness	 developmental	 trajectories	 of	 the	
carriers	of	a	22q11.2	deletion	syndrome	are	also	different	than	control	trajectories	for	each	
age	bin,	with	 significantly	 thicker	 cortex	 in	 preadolescents	with	 22q11DS,	 and	 subsequent	
disappearance	of	the	changes	by	the	end	of	adolescence	(Schaer	et	al.	2009).	This	underscores	
the	need	to	go	beyond	the	effect	in	volumes	and	to	study	other	brain	measurements.	
Our	results	are	in	also	line	with	brain	alterations	in	16p11.2	mice,	that	are	already	present	at	
7	days	(equivalent	to	neonate	period	in	humans).	The	increase	of	head	circumference	for	DEL	
and	the	decrease	for	DUP	is	also	before	one	year	of	age	(D’Angelo	et	al.	2016).	Finally,	early	
brain	differences	may	occur	before	the	clinical	phenotypes	related	to	the	16p11.2	CNV.	
2.2.5	Conclusion	
Neurodevelopmental	 disorders	 and	 genetic-first	 approach	 are	 a	 unique	 situation	 to	 study	
alteration	 of	 brain	 growth	 trajectories.	 Thanks	 to	 a	 continuous	 model	 of	 normative	
developmental	 trajectory	 per	 voxel,	 we	 show	 that	 the	 16p11.2	 CNV	 carriers	 have	 brain	
alterations	already	present	at	4.5	years	old,	with	an	effect	size	similar	from	4.5	to	23	years	old.	
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The	brain	differences	found	in	the	insula	and	the	calcarine	cortex	for	both	CNVs,	cerebellum	
and	temporal	gyri	for	the	deletion	carriers	and	lateral	ventricles	for	the	duplication	carriers,	
replicate	 the	 brain	 differences	 already	 known	 in	 adults	 carrying	 a	 16p11.2	 CNV.	 The	
computational	method	developed	in	this	paper	needs	to	be	applied	to	normative	datasets	at	
younger	and	older	age,	to	understand	when	the	brain	alterations	appear	during	development	
and	whether	this	CNV	has	a	differential	impact	on	brain	structures	later	in	age.	Finally,	a	larger	
dataset	 would	 allow	 studying	 how	 the	 ultimate	 cognitive	 level	 of	 the	 16p11.2	 carriers	 is	
associated	with	the	age	of	onset	of	the	alterations.	
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3.	DISCUSSION	OF	THE	THESIS	
3.1	Global	and	regional	differences	on	the	16p11.2	reciprocal	CNVs	
The	first	study	replicates	the	gene	dosage	effects	of	the	16p11.2	CNVs	on	total	brain	metrics	
as	well	as	the	regional	effects	for	volumetric,	surface	area	and	cortical	thickness	parameters.	
Beyond	the	replication,	the	sample	size	of	this	new	study	allows	to	decipher	the	reciprocal	
and	 non-reciprocal	 anatomical	 effects	 of	 the	 deletion	 and	 duplication.	We	 demonstrate	 a	
robust	 reciprocal	 alteration	 for	 the	 volume	 and	 surface	 of	 the	 insula	
(deletion>control>duplication,	Cohen’s	d	>	1)	and	non-reciprocal	alterations	in	the	calcarine	
cortex	 and	 transverse	 temporal	 gyrus	 (Cohen’s	 d	 for	 deletion	 >	 1),	 superior	 and	 middle	
temporal	 gyri	 (Cohen’s	 d	 for	 deletion	 <	 -1),	 caudate	 and	 hippocampus	 (Cohen’s	 d	 for	
duplication	between	-0.5	and	-1).	These	alterations	are	stable	in	adults,	adolescents	and	old	
children,	males	and	females.	We	do	not	observe	any	correlation	between	these	brain	regions	
and	measures	of	 general	 cognition,	 language	 scores,	 or	 social	 behavior.	However,	we	 find	
partial	 overlap	with	 regions	 altered	 in	 a	 psychiatric	 cross-disorder	meta-analysis.	We	 also	
highlight	 some	 brain	 differences	 comparing	 familial	 and	 unrelated	 controls:	 controls	 from	
deletion	families	show	changes	in	volume	and	cortical	thickness	of	the	left	posterior	 insula	
and	 right	 lingual	 gyrus,	 compared	 to	 unrelated	 controls.	 We	 hypothetize	 that	 additional	
factors,	 potentially	 visible	 first	 degree	 relative,	 are	 required	 for	 CNV	 carriers	 to	 develop	
significant	psychiatric	symptoms.	
3.1.1	Regional	volumetric	and	surface	differences	beyond	the	effect	of	the	global	brain	
metrics	
The	two	previous	papers	analyzing	the	brain	structures	of	the	16p11.2	carriers	differed	in	their	
analyses	and	interpretations.	Qureshi	et	al.	(2014)	found	differences	between	deletion	and	
duplication	 carriers,	 compared	 to	 controls,	 on	global	brain	measurements.	At	 the	 regional	
level,	only	differences	in	the	thalamus	survived	correction	for	intracranial	volume.	The	authors	
concluded	on	a	pervasive	effect	of	the	16p11.2	CNVs	on	the	brain	without	clear	regional	brain	
differences.	In	particular,	the	latter	could	not	be	interpreted	due	to	the	general	effects	of	brain	
volume	and	the	surface	area.	Maillard	et	al.	(2014)	showed	the	same	differences	for	global	
metrics,	as	well	 as	voxel-wise	differences	between	 the	deletion	and	 the	duplication	 in	 the	
reward	system,	language,	and	social	cognition	circuitry.	
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The	first	study	was	run	in	parallel	in	2	labs	pooling	all	available	data	and	reconciles	findings	
from	the	two	previous	papers.	It	demonstrates	that	regional	differences	are	associated	with	
deletions	and	duplications,	regardless	of	the	TIV.	Moreover,	we	share	some	conclusions	with	
Qureshi	et	al.	(2014)	as	the	surface	area	is	mainly	impacted	in	the	results,	and	not	the	cortical	
thickness,	which	is	in	favor	of	some	early	and	pervasive	effects.	
We	 show	 consistent	 results	 across	 both	 cohorts	 wich	 were	 ascertained	 through	 different	
methods.	Individuals	in	Europe	were	directly	referred	by	geneticist,	whereas	participants	were	
more	broadly	recruited	in	the	USA,	including	referral	by	clinical	genetic	centers,	social	media	
requiring	online	registration	on	the	part	of	the	families.	D’Angelo	et	al.	(2016)	showed	that	
the	 IQ	was	higher	 in	 the	American	 compared	 to	 the	European	cohorts	 across	 carriers	 and	
controls,	and	we	have	the	same	trend	on	IQ	for	the	sub-sample	that	has	passed	the	MRI.	The	
head	circumference	of	CNV	carriers	and	the	age	range	was	also	different	between	cohorts.	All	
these	differences	have	challenged	the	replication	of	the	results.		
Replication	is	one	of	the	major	issues	in	neuroscience.	Carter	et	al.	(2017)	point	out	the	issue	
of	false-positive	results:	“only	21%	of	studies	met	a	previously	specified	minimum	criterion	
(for	an	imaging	study)	of	20	subjects	per	cell,	 .90%	had	flaws	in	the	clinical/genetic	design,	
correction	 for	 multiple	 comparisons	 was	 rare,	 and	 few	 true	 replications	 were	 reported	
(Gurung	&	Prata	2015)”.	A	reasonable	sample	size	is	between	50	and	100	in	numbers,	to	detect	
effect	sizes	of	0.5	or	greater	(as	the	effect	size	observed	in	our	dataset).	This	is	exactly	what	
we	reach	with	about	70	carriers	 in	each	CNV	group	and	more	than	200	control	 individuals	
(Carter	et	al.	2017).	Underpowered	studies	are	associated	not	only	with	low	reproducibility	
but	 also	 with	 over-estimation	 of	 the	 effect	 sizes	 (Button	 et	 al.	 2013).	 Moreover,	 the	
differences	 in	 scanners	 and	 acquisition	 protocols	 could	 lead	 to	 site-to-site	 differences	 in	
resolution,	quality,	and	temporal	signal-to-noise	ratio	(Adhikari	2017).	Our	powerful	sample	
size,	using	T1	MPRAGE	images	(one	of	the	most	standardized	images	in	the	World),	also	allows	
overcoming	 the	 effect	 of	 the	 scanners.	 Of	 note,	 it’s	 essential	 to	 continue	 to	 support	 the	
harmonization	of	scanners	and	acquisition	protocols,	as	well	as	shared	optimized	pipelines,	
through	different	types	of	MRI	images.	
We	also	take	advantage	of	several	major	software	programs	to	analyze	the	data	and	combine	
the	results	of	their	main	outcomes.	Even	if	a	critical	debate	exists	between	the	use	of	these	
various	software	programs,	for	example	about	the	linear	and	non-linear	registration	process	
used	by	the	software	programs,	we	still	arrive	at	the	same	main	statistical	differences	between	
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the	genetic	groups.	In	a	large	cohort	worldwide,	Stein	et	al.	(2012)	also	find	consistent	results	
using	 two	widely-used	 software	 programs,	 analyzing	 human	 hippocampal	 and	 intracranial	
volumes:	 they	 conclude	 that	 no	 single	 algorithm	 performs	 better	 for	 measuring	 these	
volumes.	
Finally,	 it’s	 important	to	use	different	metrics	to	understand	the	different	process.	Cortical	
GM	 volume	 is	 decomposed	 into	 its	 orthogonal	 components:	 surface	 area	 and	 cortical	
thickness.	We	 show	 that	most	 of	 the	 volumetric	 differences	 between	 the	 genetic	 groups	
overlap	with	the	surface	area	differences.	The	cortical	thickness	differences	are	lighter.	In	a	
biological	point	of	view,	cortical	thickness	and	surface	area	represent	different	features	of	the	
cortical	 architecture	 (Ecker	et	al.	 2015).	 They	are	believed	 to	arise	 from	different	 types	of	
progenitor	 cells.	 Cortical	 surface	 area	 is	 associated	 with	 the	 production	 of	 radial	 unit	
progenitor	cells	and	reflects	the	number	of	cortical	columns	(Pontious	et	al.	2008;	Rakic	1988;	
Rakic	 &	 Lombroso	 1998):	 increase	 in	 the	 division	 of	 progenitor	 cells	 in	 the	 embryological	
periventricular	 area	 is	 associated	 with	 an	 increased	 cortical	 surface	 area.	 It	 seems	 to	 be	
associated	with	very	early	brain	development.	Cortical	 thickness	 is	 related	to	 intermediate	
progenitor	cells	(Pontious	et	al.	2008):	 it	depends	on	the	neuronal	output	from	each	radial	
unit	(Rakic	1995)	and	represents	the	number	of	neurons	in	the	column	(Rakic	1988;	Rakic	&	
Lombroso	1998).	It	reflects	the	variations	in	the	dendritic	development	in	GM	or	myelination	
at	the	interface	of	GM	and	WM	(Huttenlocher	1990;	Huttenlocher	&	de	Courten	1987;	Sowell	
et	 al.	 2004).	 Regional	 cortical	 thickness	 varies	 during	 childhood	 and	 provides	 important	
information	on	cortical	maturation.	As	the	cortical	surface	is	more	affected	in	16p11.2	CNV	
carriers	than	cortical	thickness,	this	is	a	sign	of	an	early	alteration	in	brain	development.	
3.1.2	Relationship	between	the	16p11.2	pattern	of	brain	structures	differences	and	the	
behavior	
Regions	impacted	by	the	CNVs	are	known	to	affect	different	cognitive	domains.	We	submitted	
the	 results	 to	 the	 Neurosynth	 platform,	 to	 decode	 the	 psychological	 terms	 most	 closely	
associated	 with	 the	 main	 structural	 clusters	 of	 the	 findings	 on	 the	 16p11.2	 dataset.	 As	
expected,	we	show	that	temporal	gyri	are	associated	with	language,	phonology,	and	auditory	
terms.	These	regions	are	the	ones	mainly	altered	in	the	deletion	carriers,	and	the	results	are	
in	 coherence	 with	 the	 language	 impairment	 observed	 in	 these	 patients.	 In	 their	 paper,	
Blackmon	 et	 al.	 (2017)	 demonstrate,	with	 a	 different	methodology,	 that	 the	 focal	 cortical	
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anomalies	 in	 the	 left	 temporal	 and	 frontal	 areas	 (Broca’s	 area)	 are	 associated	with	 lower	
performance	 on	 comprehensive	 language	 on	 16p11.2	 deletion	 carriers.	 Regarding	 the	 top	
associations	 of	 the	 anterior	 insula	 and	 caudate	 in	 the	 Neurosynth	 platform,	 they	 are	
associated	 with	 terms	 such	 as	 reward,	 pain	 and	 executive	 function.	 Reward	 system	 and	
executive	functions	are	two	critical	domains	in	psychopathology,	in	particular	in	ASD.	
Maillard	 et	 al.	 (2014)	 already	 reported,	 qualitatively,	 the	 overlap	 between	 the	 structures	
altered	in	the	16p11.2	CNV	patients,	with	areas	known	to	be	affected	in	ASD	and	SCZ.	In	our	
paper,	 we	 can	 quantify	 this	 overlap	 with	 a	 Dice	 index,	 using	 a	 large	 cross-disorder	
neuroimaging	meta-analysis	(http://anima.fz-juelich.de	(Goodkind	et	al.	2015)).	We	observe	
a	partial	overlap:	33%	of	overlap	in	mean	for	the	right	and	left	insula.	Insula	is	an	important	
and	 «	 underestimated	 »	 brain	 area	 in	 psychopathology	 (Namkung	 et	 al.	 2017).	 At	 the	
intersection	of	 three	 lobes,	 it	 has	 a	main	 role	 in	 interoception,	 in	 the	 integration	 and	 the	
homeostasis	of	the	body	states.	It	has	a	role	in	the	subjective	feelings	(a	basis	for	the	«	self	»)	
and	 in	 the	 motivation,	 to	 encode	 incentive	 values	 of	 a	 stimulus.	 The	 dysfunction	 of	 the	
dynamic	 interactions	 between	 feelings,	 motivation,	 and	 cognition	 is	 crucial	 in	 a	 lot	 of	
psychiatric	disorders.	This	region	appears	to	be	categorized	as	“high	cost	/	high	values”	hubs	
in	 human	 brain	 networks	 and	 more	 likely	 affected	 in	 many	 neurological	 and	 psychiatric	
disorders	(Crossley	et	al.	2014).	
In	our	analyses,	the	cognitive	and	behavioral	scores	(on	global	cognition,	social	behavior,	and	
language)	do	not	correlate	with	the	16p11.2	brain	patterns.	The	limited	power	may	lead	to	
this	lack	of	correlation	between	the	brain	measurements	and	the	cognitive	data.	Other	metrics	
than	 the	 typical	 structural	MRI	 metrics,	 may	 be	more	 associated	 with	 the	 phenotype,	 as	
diffusion	metrics	(Alexander	et	al.	2007;	Travers	et	al.	2012).	Looking	at	a	simple	correlation	
and	between-group	differences	in	average	can	also	lead	to	some	missing	results,	and	probably	
other	statistical	methods	and	measurements	should	be	explored	(Brugger	&	Howes	2017b).	
However,	 in	 coherence	with	 our	 results,	 the	 intermediate	 phenotypes	 are	 assumed	 to	 be	
closer	to	the	gene	effects	than	the	clinical	symptoms	and	psychiatric	disorders,	that	may	be	
influenced	by	a	lot	of	factors	(Hashimoto	et	al.	2015).	
Of	note,	in	the	European	cohort,	few	patients	carrying	the	CNV	are	diagnosed	with	ASD.	But	
even	 if	 they	don’t	have	a	 formal	diagnosis,	 they	have	differences	 in	scores	on	some	social	
traits,	compared	to	controls.	The	CNV	is	a	model	to	study	brain	structures,	that	could	overlap	
with	 sub-groups	 of	 ASD-like	 patients.	 We	 also	 observe	 an	 important	 co-morbidity	 in	 the	
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diagnoses	 for	 the	 patients.	 Even	 if	 we	 focus	 our	 discussion	 on	 the	 literature	 on	 ASD,	 the	
16p11.2	CNV	is	not	only	a	model	for	ASD,	but	more	generally	for	some	categories	of	symptoms	
that	can	overlap	between	different	disorders.	
3.1.3	Additional	factors	to	the	rare	CNVs	in	psychiatric	disorders	
We	also	hypothetize	an	additive	model	underlying	psychiatric	disorders	(Weiner	et	al.	2017):	
CNVs	contribute	to	the	psychiatric	condition,	but	additional	brain	alterations	and	other	factors	
are	required	for	the	onset	of	the	disorder.	Combination	of	common	and	rare	variants	also	act	
additively	to	lead	to	a	diagnostic	as	ASD	or	other	conditions	as	bipolar	disorders	(Weiner	et	al.	
2017;	Mellerup	 et	 al.	 2017).	 That	 highlights	 the	 importance	 of	 familial	 background	 when	
accounting	for	phenotype	variability.	 It’s	what	we	point	out	when	we	compare	the	familial	
and	unrelated	controls,	and	we	show	that,	even	at	the	neuroimaging	level,	we	can	see	some	
brain	differences	between	the	two	types	of	controls,	reinforcing	the	idea	of	a	familial	loading.	
The	 discovery	 of	 some	 of	 these	 additional	 risk	 factors	 would	 be	 decisive	 for	 an	 accurate	
projection	of	 the	 various	 outcomes	 associated	with	 these	pathogenic	 CNVs.	 In	 one	of	 our	
studies	 (D’Angelo	 et	 al.	 2016),	 we	 show	 an	 enrichment	 in	 additional	 deleterious	 genetic	
variants	in	duplication	carriers,	some	of	which	are	inherited.	The	duplication	carriers	can	be	
subdivided	 into	different	 levels	of	global	cognition,	with	a	specific	“low-functioning”	group	
also	enriched	in	ASD	diagnosis.	This	group	may	be	associated	with	some	specific	additional	
deleterious	 variants.	 Green	 Snyder	 et	 al.	 (2016)	 argue	 that	 the	 phenotypic	 variability	 in	
16p11.2	 duplication	 carriers	 could	 depend	 on	 “double	 hits”	 with	 large	 effect,	 heritable	
common	variants	with	small	effect,	and	non-genetic	factors.		
In	a	study	in	progress,	we	explore	the	differences	between	the	16p11.2	carriers	who	develop	
ASD	 and	 the	 ones	who	 don’t	 (Maillard	 et	 al.,	May	 2017).	We	 identify	 distinct	 clinical	 and	
neuroanatomical	 profiles	 in	 deletion	 and	 duplication	 carriers	 that	 reach	 the	 threshold	 for	
clinical	evaluation.	For	example,	deletion	carriers	meeting	criteria	for	ASD	present	larger	head	
size	and	higher	nonverbal	skills	than	carriers	without	ASD:	these	effects	are	already	present	in	
their	parents	(not	diagnosed	with	ASD).	In	contrast,	the	duplication	carriers	with	ASD	show	an	
additional	decrease	in	IQ	compared	to	the	duplication	carriers	without	ASD.	Of	note,	it’s	not	
because	a	proband	doesn’t	reach	the	arbitrary	threshold	for	a	categorical	diagnostic	that	he’s	
not	 affected	 (Moreno-De-Luca	 et	 al.	 2015).	 Another	 approach	 to	 characterizing	 additive	
effects	is	to	compare	individuals	carrying	the	CNV	and	ascertained	for	a	neurodevelopmental	
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disorder	to	the	ones	identified	in	the	general	population	(Männik	et	al.	2015;	Stefansson	et	al.	
2014).	
Finally,	our	results	are	a	proof	that	the	haplo-insufficiency	and	over-expression	of	the	same	
reciprocal	CNV	may	have	a	different	impact	on	the	phenotype	observed,	and	so	on	the	neural	
mechanisms.	The	deletion	is	known	to	be	more	deleterious	than	the	duplication.	However,	
we	have	to	take	into	account	that	to	be	included	in	the	study,	the	participants	have	to	be	able	
to	 pass	 a	MRI,	 without	 too	many	movements,	 and	 this	 limitation	may	 exclude	 the	 “low-
functioning”	group	of	duplication	carriers.	
3.1.4	The	broad	age	range	of	the	dataset	on	rare	CNVs	
Another	crucial	aspect	of	the	paper	is	the	broad	age	range	of	the	dataset,	from	6	to	63	years	
old.	As	we	work	on	rare	patients,	with	less	than	1	for	2000	per	CNV,	we	have	to	aggregate	
data	from	spread	age	to	have	sufficient	sample	size.	Qureshi	et	al.	(2014)	tackle	this	issue	by	
selected	 only	 deletion	 children	 compared	 to	 age-matched	 controls	 (most	 of	 the	 deletion	
carriers	are	children),	and	only	duplication	adults	compared	to	age-matched	controls	(most	of	
the	duplication	carriers	are	adults).	We	choose	another	strategy	by	using	the	whole	dataset	
and	including	the	linear	and	quadratic	expansion	of	age	as	a	covariate	in	the	model	(the	cubic	
expansion	do	not	show	any	significant	effects	and	so	is	not	included	in	the	design	matrix).	We	
also	 perform	 a	 division	 of	 the	 dataset	 in	 3	 age	 groups	 (children,	 adolescents,	 adults)	 to	
consider	if	the	brain	differences	are	already	present	in	children.	However,	to	go	further	in	the	
analyses	and	to	know	the	real	developmental	trajectories	of	the	brain	structures,	we	tackle	
this	issue	in	the	next	section,	with	the	second	paper.	
3.2	Normative	data	and	developmental	trajectory	of	brain	structures	across	the	
development	of	the	16p11.2	carriers	
Carriers	of	the	16p11.2	CNV	present	structural	brain	differences	when	compared	to	control	
individuals.	However,	it	remains	unknown	when	during	development	these	brain	alterations	
appear.	The	2nd	objective	of	my	Ph.D.	is	to	characterize	the	developmental	emergence	of	the	
structural	 alterations	and	 to	 reveal	how	 these	genetic	 risk	 factors	become	expressed	over	
time.	Z-scores	and	typical	growth	curves	are	computed	from	a	normative	dataset	of	the	NIH	
MRI	study	of	normal	brain	development	(https://pediatricmri.nih.gov/nihpd/info/index.html)	
(Evans	2006):	it	consists	of	339	typically	developing	children	from	4.5	to	23	years	old.	We	find	
 	 58	
that	the	global	and	regional	brain	alterations	are	present	at	4.5	years,	and	the	curves	for	the	
deletion	and	duplication	brain	structures	are	parallel	to	the	ones	of	the	controls	until	23	years.	
To	our	knowledge,	this	is	the	first	time	this	methodology	is	used	in	the	field	of	NDDs.	This	kind	
of	 proof	 of	 concept,	 to	 adapt	 this	methodology	 to	 our	 dataset,	 is	 a	 first	 step	 toward	 the	
acquisition	 and	 the	 analysis	 of	 a	 broader	 age	 range	 of	 normative	 dataset	 and	 a	 16p11.2	
dataset	on	younger	children.	
3.2.1	Effect	size	in	neuro-imaging	genetic	
Few	studies	 in	neuro-imaging	directly	report	the	effect	sizes.	 In	our	results,	we	find	similar	
effect	 sizes	 than	 the	 ones	 we	 previously	 published	 on	 cognition	 (D’Angelo	 et	 al.	 2016),	
between	1	and	1.5	Z-scores	in	absolute	value.	We	observe	that	the	effect	sizes	in	the	16p11.2	
brain	patterns	are	5	to	10	times	larger	than	the	ones	observed	in	a	paper	on	ASD	with	a	huge	
sample	size	(1571	patients	diagnosed	with	ASD	and	1651	healthy	control	subjects)	(van	Rooij	
et	al.	2017).	This	Enigma	paper	highlights	some	effect	sizes	between	0.1	and	0.2,	which	seems	
low	in	comparison	to	the	strong	alterations	in	ASD.	Enigma	consortium	analyzes	the	volume	
and	the	cortical	thickness	per	regions	of	interest,	while	we	analyze	the	data	per	voxel:	this	can	
be	part	of	the	variability	between	the	studies.	In	our	results,	they	are	often	only	parts	of	the	
brain	structures	that	are	altered.	It’s	possible	that	an	approach	per	region	of	interest	under-
estimates	 the	effect	 size	of	 the	 results,	or	 the	voxel	analyses	could	also	over-estimate	 the	
results.	However,	the	differences	could	be	due	to	the	heterogeneity	in	an	ASD	cohort:	there	
may	be	only	a	small	common	denominator	between	individuals	with	ASD,	reflected	by	low	
effect	sizes;	whereas	the	large	effect	sizes	for	a	CNV	directly	reflect	the	large	impact	of	the	
genetic	variant.	The	same	phenomenon	is	observed	in	other	psychiatric	conditions,	such	as	
SCZ:	the	effect	sizes	on	the	volumes	of	subcortical	structures	are	below	0.5,	in	absolute	value,	
and	most	of	 them	are	around	0.3	 (van	Erp	et	al.	2015).	The	heterogeneity	of	 the	patients	
diagnosed	with	SCZ	could	cancel	part	or	the	totality	of	some	effects.	On	the	other	side,	large	
effect	sizes	are	observed	in	a	risk	factor	as	the	22q11.2	deletion	syndrome	carriers	(Lin	et	al.	
2017),	 between	 -1	 and	 -2	 Z-scores	 for	 the	 most	 important	 findings.	 Mechanistically	
homogenous	groups	are	closer	to	the	effect	of	the	diseases,	with	Z-scores	closer	to	the	ones	
observed	 on	 cognition.	 Interestingly,	 the	 effect	 sizes	 are	 more	 important	 in	 the	 22q11.2	
deletion	than	the	duplication	 (between	0.5	and	1	Z-scores	 for	 the	most	significant).	This	 is	
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coherent	 with	 the	 idea	 that	 the	 duplication	 CNVs	 have	 less	 deleterious	 effects	 than	 the	
deletion	(Männik	et	al.	2015).	
3.2.2	Normalization	
Most	of	the	studies	are	not	able	to	have	large-enough	control	groups.	A	real	norm	and	some	
proper	comparisons	between	healthy	 individuals	and	patients	cannot	be	done.	This	 lack	of	
control	individuals	also	contributes	to	diminishing	the	power	of	these	studies.	We	overcome	
this	issue	thanks	to	the	NIH	MRI	normative	dataset.		
A	limitation	of	our	work	is	the	difference	between	the	strength	of	the	magnetic	field	used	in	
the	normative	dataset	(1.5	Teslas)	and	the	16p11.2	dataset	(3	Teslas).	It’s	known	that	artifacts	
can	happen	in	the	3	Teslas	acquisition	(Dietrich	et	al.	2008).	This	effect	can	be	confused	with	
the	real	effect	of	age	on	the	data.	Hopefully,	we	manage	to	add	a	correction	to	our	 linear	
model	to	have	similar	curves	for	the	NIH	MRI	controls,	from	the	ones	for	the	16p11.2	controls.	
Thus	the	NIH	MRI	controls	are	a	reliable	norm	to	model	our	comparison	between	the	genetic	
groups.	 For	 sure,	 other	 normative	 data	 with	 3T	 and	 the	 comparison	 of	 normative	 data	
between	1.5	and	3	teslas	would	be	beneficial	to	confirm	the	results.		
Moreover,	 the	model	 to	obtain	the	norms	has	been	tuned	for	 this	particular	data	and	age	
range.	NIH	MRI	study	already	acquired	in	their	objective	2,	neuroimaging	and	clinical	data	on	
newborns	to	preschooler’s	children,	from	3	months	for	the	youngest	participants	to	4.5	years	
old.	The	preprocessing	pipeline	of	the	data	has	to	be	adapted	to	the	specific	GM	and	WM	
maturation	at	these	crucial	early	ages,	and	the	trajectory	of	the	data	needs	to	be	modeled	
according	to	the	specific	growth	curves	at	this	age	range.	The	information	on	the	younger	age	
is	still	limited	in	NDDs,	in	particular	in	the	CNV	carriers.	The	same	question	can	be	asked	for	
the	adult	ranges:	what	happens	to	individuals	with	autism	as	they	age?	
The	Enigma	consortium	just	initiates	a	Lifespan	working	group,	to	compile	charts	of	regional	
brain	volumes,	through	life	from	3	to	90	years	old	(Bearden	&	Thompson	2017).	Once	again,	
this	type	of	dataset	will	be	beneficial	to	draw	reference	growth	curves	per	regional	structures,	
with	the	standard	variation	in	the	healthy	population,	to	ultimately	compare	them	to	patients	
and	better	understand	the	evolution	of	the	brain	diseases.	
3.2.3	Developmental	trajectories	in	neuro-imaging	of	psychiatric	disorders	
In	research	on	ASD,	the	developmental	studies	target	children	at	high	risk	for	ASD	(i.e.,	having	
a	sibling	with	a	diagnosis	of	ASD):	they	show	that	at-risk	children	could	be	distinguished	from	
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low-risk	 controls	 before	 overt	 behavioral	 symptoms	 appear	 (Elsabbagh	 &	 Johnson	 2016).	
Changes	in	brain	volume	and	cortical	surface	may	become	significant	in	the	second	year	of	life	
(Courchesne	et	al.	2011;	Ecker	et	al.	2015;	Hazlett	et	al.	2011;	Schumann	et	al.	2010),	with	an	
increase	in	total	brain	volume	and	surface	area	during	development,	not	observed	anymore	
in	adolescents	and	adults	(Hazlett	et	al.	2011;	Schumann	et	al.	2010).	A	recent	mega-analysis,	
including	participants	from	2	to	64	years	old,	shows,	in	mean,	smaller	subcortical	volumes	in	
the	cognitive	and	affective	parts	of	the	striatum	and	the	amygdala,	reduced	thickness	in	the	
temporal	cortex,	increased	thickness	in	the	frontal	cortex,	compared	to	controls	(van	Rooij	et	
al.	 2017):	 the	 subcortical	 volumes	 don’t	 show	 any	 age	 by	 diagnosis	 interaction,	 but	 the	
development	 of	 the	 cortical	 thickness	 would	 differ	 according	 to	 the	 age	 of	 the	 patients,	
showing	a	peak	around	adolescence	(greater	thickness	in	the	ASD	group	in	the	frontal	cortex,	
and	lesser	thickness	in	the	temporal	areas).	
However,	given	the	heterogeneity	of	the	development	of	this	disorder,	it’s	important	again	to	
study	 developmental	 changes	 in	 a	 mechanistically	 homogeneous	 group,	 as	 in	 a	 16p11.2	
cohort,	with	clear	knowledge	of	the	adolescent/adult	clinical	and	neuroanatomical	outcomes	
(unlikely	to	ASD	patients).	Right	now,	only	one	paper	exists	on	the	developmental	trajectories	
of	behavioral	phenotypes	in	young	children	carrying	a	16p11.2	CNV.	Some	papers	exist	on	the	
brain	developmental	trajectories	in	the	22q11.2	deletion	syndrome:	the	carriers	of	this	CNV	
would	have	distinct	patterns	of	cortical	thickness	alterations,	especially	around	adolescence	
(Schaer	et	al.	2009).	
Age	effects	appear	to	be	nonlinear	across	a	wide	age	range,	which	may	 limit	 the	ability	 to	
detect	interactions	across	the	lifespan.	Daan	van	Rooij	et	al.	(2017)	use	a	fractional	polynomial	
approach	to	face	this	issue.	Each	paper	develops	its	own	model	or	its	metrics	to	characterize	
the	developmental	 trajectories.	On	 the	 contrary,	 our	 study	 is	 based	on	a	modeling	with	a	
normative	dataset,	and	could	be	easily	transferred	to	another	genetic	risk	factor	for	NDDs	or	
any	types	of	disorders.	Tensor-Based	Morphometry	is	a	great	measure	to	go	over	the	global	
metric	 issue,	 without	 GM-WM	 classification	 issue,	 but	 other	 measurements	 should	 be	
interested	in	 looking	at,	as	the	trajectory	of	cortical	thickness	and	surface	area.	 In	the	first	
study	 of	 my	 thesis,	 we	 show	 some	 potential	 interaction	 between	 older	 age	 and	 cortical	
thickness.	 We	 model	 the	 mean	 cortical	 thickness	 to	 evaluate	 the	 group	 differences	 in	
developmental	trajectories.	When	the	age	variable	is	centered	one	standard	deviation	above	
the	mean	age	(39	years),	the	duplication	group	shows	a	significantly	thinner	cerebral	cortex	
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than	 the	 control	 participants.	No	 differences	 are	 found	 for	 the	 deletion	 group.	 In	 brief,	 it	
would	be	good	to	develop	our	method	on	other	metrics,	tackling	differential	developmental	
process.	
Finally,	we	still	lack	information	about	individual	trajectories,	and	prediction	of	some	potential	
different	 outcomes	 for	 the	 carriers	 of	 a	 16p11.2	 CNV,	 to	 better	 adapt	 the	 prevention	
strategies.	In	the	analyses,	we	never	take	into	account	the	form	of	treatment	followed	by	the	
participants,	as	the	medication,	the	behavioral	and	physical	therapies,	the	particular	school-
based	supports,	etc	(Bernier	et	al.	2017).	
3.3	The	study	of	intermediate	phenotypes	in	16p11.2	cohorts	
Further	 steps	 including	 some	multi-modal	 approaches,	 network	 analyses	 and	 some	 other	
intermediate	 phenotypes,	 may	 improve	 our	 understanding	 of	 the	 16p11.2-associated	
differences.	
3.3.1	Tissue	properties	underlying	the	16p11.2	associated-volumetric	alterations	
The	study	of	the	histological	tissue	properties,	through	a	multi-modal	approach,	could	help	to	
understand	the	pathological	processes	underlying	the	GM	volume	changes	(Draganski	et	al.	
2011;	Lutti	et	al.	2014;	Weiskopf	2013).	Multi-Parameter	Mapping	–MPM	sequences	provide	
a	set	of	quantitative	measures	to	highlight	intrinsic	characteristics	of	brain	tissue	indicative	of	
myelin,	iron	and	tissue	water	content.	The	4	maps	are	so	called	proton	density	map,	associated	
with	water	content;	magnetization	 transfer	map	and	R1	map,	which	correlate	with	myelin	
content;	and	R2*	map	sensitive	to	iron	concentration.	I	already	acquired	data	on	18	deletion	
carriers,	31	control	individuals	and	8	duplication	carriers	with	MPM	data.	First	validation	has	
been	done	for	an	increase	of	the	standard	isotropic	voxel	dimension	of	the	usual	MPM,	from	
1	mm3	to	1.5	mm3,	to	reduce	time	acquisition.	Then,	our	preliminary	analyses	on	the	genetic	
groups	focused	on	the	comparison	between	deletion	carriers	and	control	individuals.	Different	
types	 of	 tissue	 alterations	 could	 explain	 the	 volumetric	 differences:	 anterior	 insula	 in	 the	
deletion	carriers	seems	to	be	altered	on	the	proton	density	maps,	calcarine	cortex	on	the	R1	
maps	and	some	frontal	parts	and	postcentral	gyrus	on	the	R2*	maps.	Additional	MPM	data	
and	analyses	are	necessary	to	replicate	and	interpret	these	results.	
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3.3.2	White	matter	microstructure	and	brain	connectivity	
Heritability	of	diffusion-weighted	measurements	are	important	(Jahanshad	et	al.	2013).	Owen	
et	al.	(2014)	reported	widespread	alterations	of	WM	microstructures	in	children	carriers	of	
the	deletion.	In	some	current	analyses,	Moreau	et	al.	(June	2017)	emphasize	these	first	results	
by	analyzing	subcortical	diffusivity	in	16p11.2	CNV	carriers.	Despite	the	reciprocal	effect	of	the	
deletion	and	the	duplication	on	the	overall	brain	volume,	both	variants	seem	to	be	associated	
with	increased	mean	diffusivity	compared	to	controls,	on	all	subcortical	structures	examined,	
except	the	putamen.	More	precisely,	the	caudate,	amygdala,	thalamus	have	increased	mean	
diffusivity	in	the	deletion	and	duplication	carriers;	the	mean	diffusivity	in	nucleus	accumbens	
only	 increases	 in	deletion	carriers;	 in	hippocampus	and	globus	pallidus,	 it	only	 increases	 in	
duplication	carriers.	 These	alterations	are	 supported	by	 the	 results	of	behavioral	analyses,	
which	show	differential	relationships	between	mean	diffusivity	and	social	responsiveness,	as	
well	as	FSIQ,	in	several	subcortical	structures.	Interestingly,	caudate	and	hippocampus	are	also	
the	 regions	 we	 highlight	 in	 our	 first	 study	 with	 specifically	 lower	 volumes	 in	 duplication	
carriers	compared	to	controls.	The	opposite	direction	for	diffusion	measurement	(increase)	in	
sub-cortical	 structures	 and	 brain	 volume	 and	 surface	 (decrease)	 worth	 studying	 more	
precisely.	
Some	other	analyses	are	focusing	on	measures	of	the	gray-white	intensity	contrast	(Lewis	et	
al.,	June	2017),	a	ratio	of	the	intensity	of	the	T1	sampled	1mm	inside	and	1mm	outside	the	
white	surface.	In	the	deletion	carriers,	the	contrast	is	reduced	in	broad	regions	of	the	bilateral	
insula,	temporal	lobe	and	part	of	the	inferior	frontal	cortex	(Broca’s	area	and	right	hemisphere	
homolog).	 In	 duplication	 carriers,	 the	 contrast	 is	 increased	 in	 the	 bilateral	 central	 sulcus,	
medial	 visual	 areas	and	 the	 left	primary	auditory	 cortex:	 this	pattern	 is	 aligned	 to	 localize	
abnormalities	 in	 regions	 associated	 with	 low-level	 sensory	 processing.	 These	 additional	
findings	related	to	WM	corroborate	our	results	on	reciprocal	and	non-reciprocal	effects	on	
volumes	 in	 the	 deletion	 and	 the	 duplication.	 They	 could	 be	 integrated	 with	 our	 cortical	
thickness	analyses.	
Finally,	recent	results	on	resting-state	functional	MRI	are	showing	striato-striatal	and	striato-
cortical	over-connectivity	in	the	deletion	carriers	compared	to	the	individual	controls	and	the	
duplication	 carriers	 (Moreau	 et	 al.,	 October	 2017).	 The	 highest	 proportion	 of	 altered	
connectivity	 are	 among	 the	 caudate,	 putamen	 and	 lateral	 occipito-temporal	 gyrus.	 The	
duplication	carriers	do	not	show	specific	differences	in	functional	connectivity	compared	to	
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the	control	groups,	probably	due	to	the	 low	sample	size.	These	results	are	consistent	with	
previous	 reports	 of	 aberrant	 functional	 connectivity	 in	ASD.	Given	 the	 role	 of	 the	 cortico-
striato-thalamo-cortical	circuitry	in	sensory-motor	processes	and	learning,	these	mechanisms	
are	 interesting	 targets	 for	 future	 analyses	 in	 our	 16p11.2	 dataset.	 The	 16p11.2	 functional	
network	could	be	part	of	an	“autism	cluster”,	contributing	to	parse	the	heterogeneity	of	ASD.	
It	would	also	be	interesting	to	examine	whether	and	how	structural	variations	are	related	to	
functional	variations	during	some	well-known	experimental	tasks,	as	the	monetary	incentive	
delay	task	that	tackles	the	reward	system	or	other	social	tasks	already	used	in	the	field	of	ASD.	
Further	investigations	of	biochemical	markers	of	the	integrity	of	GM	and	WM,	as	the	magnetic	
resonance	 spectroscopy,	 may	 help	 to	 identify	 some	 chemical	 substrate	 of	 aberrant	
connectivity	(Anagnostou	&	Taylor	2011).	
3.3.3	Study	of	microbiotia	in	the	16p11.2	CNV	carriers	
The	 mechanisms	 underlying	 the	 variability	 of	 the	 16p11.2	 cognitive	 and	 behavioral	
phenotypes	 could	 also	 implicate	 peripheral	 mechanisms	 including	 alterations	 of	 the	 gut	
microbiota.	 Amounting	 evidence	 suggests	 a	 microbiota-gut-brain	 axis,	 with	 bidirectional	
communication	between	the	central	nervous	system	and	the	intestinal	organs	(Foster	et	al.	
2016).	 That	 has	 led	 researchers	 to	 hypothesize	 that	 gut	microbiota	 could	modulate	 brain	
function	via	immune,	neural,	and	metabolic	mechanisms	(Stilling	et	al.	2013).	
Obesity	 is	 among	 the	 most	 common	 comorbidity	 of	 neurodevelopmental	 and	 psychiatric	
disorders	 (Chen	et	 al.	 2010),	 and	 it’s	 especially	 true	 for	 the	16p11.2	CNVs.	Obesity	 is	 also	
associated	with	‘low	gene	count’	reflecting	low	bacterial	richness	(Le	Chatelier	et	al.	2013)	and	
only	a	few	bacterial	species	are	needed	to	differentiate	obese	from	lean	people.	Contrastingly,	
energy	restriction	can	increase	gut	microbiota	richness	(Cotillard	et	al.	2013).	Genetic	factors	
are	important	determinants	of	the	microbiota	profile	in	individuals	(Stilling	et	al.	2013).	The	
gut	 microbiota	 profile	 may	 mediate	 some	 of	 the	 associations	 underlying	 the	 complex	
relationship	between	genes,	cognition,	and	BMI.	Dysbiosis	of	 the	gastrointestinal	 tract	has	
been	associated	with	 cognitive	deficits,	 in	 conditions	 such	as	neurodegenerative	disorders	
(Scheperjans	et	al.	2015)	and	psychiatric	diseases	(Jiang	et	al.	2015;	Son	et	al.	2015).	Animal	
models	studies	corroborate	and	extend	these	human	findings	(Clarke	et	al.	2012;	Neufeld	et	
al.	 2011;	 Bercik	 et	 al.	 2011).	 Gene	 dosage	 at	 the	 16p11.2	 locus	 may	 modulate	 the	 gut	
microbiota,	 which	 could	 have	 an	 impact	 on	 the	 severity	 and	 the	 nature	 of	 the	 observed	
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phenotype.	In	16p11.2	deletion	carriers,	75%	of	adults	develop	obesity	and	among	adult	obese	
patients,	 45%	 are	 morbidly	 obese	 (Zufferey	 et	 al.	 2012).	 The	 investigation	 of	 the	 gut	
microbiota	 in	 these	 CNVs	 could	 give	 considerable	 insight	 into	 changes	 due	 to	 the	
dysregulation	of	satiety	and	could	allow	identifying	gut	microbiota	changes	in	individuals	at	
high	risk	but	who	do	not	present	an	increase	in	BMI	yet.	
A	study	in	progress	aims	at	determining	the	dysregulation	of	the	microbiome	in	the	carriers	
of	the	16p11.2	CNVs,	using	16S	high-throughput	sequencing	of	stool	samples.	Specific	bacteria	
seem	to	be	increased	in	these	individuals,	especially	a	few	species	within	the	bacterial	genus	
Lactobacillus,	 previously	 implicated	 in	 social	 behavior.	 Some	 of	 the	 same	 species	 are	 also	
dysregulated	in	the	16p11.2	mouse	models:	this	highlights	the	role	of	genetics	in	establishing	
the	 microbiome.	 It	 would	 be	 interesting	 to	 go	 even	 further	 in	 the	 analyses	 of	 the	 gut	
microbiota	diversity,	to	characterize	gene	presence	and	abundance.	Comparing	CNV	carriers	
with	an	obese	reference	group	could	also	help	to	understand	the	gut	microbiota	differences	
related	to	the	host’s	genetic	variation,	independent	of	obesity.	If	proven	correct,	modifying	
the	gut	microbiota	composition	could	provide	new	therapeutic	 leads,	such	as	specific	diet,	
probiotic	 medication	 or	 gut	 microbiota	 transplantation	 for	 16p11.2	 CNV	 carriers.	 Indeed,	
previous	 animal	 studies	 have	 shown	 that	 improvement	 in	 behavior	 may	 be	 achieved	 by	
changing	gut	microbiota	 composition	 (Savignac	et	al.	 2015;	Hsiao	et	al.	 2013;	Bercik	et	al.	
2011),	but	these	observations	still	need	to	be	replicated	in	human	studies.	
3.4	Neuroanatomy	and	CNVs	in	psychiatric	disorders	
3.4.1.	Neuroanatomy	across	CNVs	associated	with	neurodevelopmental	disorders	
We	 observe	 recurrent	 overlapping	 brain	 regions	 across	 different	 genetic	 risks	 factors	
associated	 with	 SCZ	 and	 ASD.	 A	 recent	 work	 on	 the	 distal	 interval	 of	 the	 16p11.2	 locus,	
containing	the	SH2B1	gene,	find	a	negative	gene	dosage	effect	on	intracranial	volume	and	sub-
cortical	 structures	 (pallidum,	 accumbens,	 and	 caudate,	 putamen),	 independently	 of	 the	
neurodevelopmental	 conditions	 and	 ancestry,	 with	 effect	 size	 around	 -1	 (Sønderby	 et	 al.,	
October	 2017).	As	 the	proximal	 16p11.2	CNVs,	 the	distal	 16p11.2	CNVs	would	have	 some	
common	neuropathological	patterns	underlying	 the	various	clinical	 symptoms.	They	would	
play	a	role	in	the	development	of	the	basal	ganglia	structures,	essential	for	core	phenotypes	
of	major	NDDs.	 Both	 distal	 and	 proximal	 16p11.2	 CNVs	 also	 are	 associated	with	 the	 BMI,	
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highlighting	the	role	of	these	brain	structures	in	the	predisposition	to	obesity	(Bochukova	et	
al.	2009;	Willer	et	al.	2009).	
The	22q11.2	deletion	syndrome	(22q11.2	DS)	is	another	strong	risk	factor	for	SCZ.	Most	of	the	
protein-coding	genes	within	this	deletion	are	highly	expressed	in	the	brain	(Guna	et	al.	2015).	
Some	prior	studies	report	widespread	structural	cortical	changes	(Jalbrzikowski	et	al.	2013;	
Eisenberg	et	al.	2010):	a	reduced	cortical	volume	and	surface	area	in	occipito-parietal	cortex	
(Bearden	et	al.	2006;	Gothelf	et	al.	2007;	Kates	et	al.	2001),	temporal	cortex	(Chow	et	al.	2011;	
van	Amelsvoort	et	al.	2004)	and	anterior	cingulate	cortex	(Dufour	et	al.	2008;	Shashi	et	al.	
2010).	Right	precentral	and	middle	 frontal	 cortices	would	also	be	affected.	Debbané	et	al.	
(Debbané	et	al.	2006)	observe	a	significantly	reduced	volume	in	the	hippocampus,	driven	by	
a	decrease	of	the	body	of	the	hippocampus.	On	the	contrary,	an	increased	volume	is	observed	
in	bilateral	insula	and	some	frontal	regions,	driven	by	increased	cortical	thickness	(Campbell	
2006;	 Simon	et	 al.	 2005).	 Significant	 age	by	 genetic	 group	 interaction	 is	 found	 for	 cortical	
thickness	in	occipital	and	parietal	regions:	the	typical	pattern	of	decreased	thickness	with	age	
observed	in	controls	(Tamnes	et	al.	2009)	is	not	observed	in	22q11	DS	participants.	The	cortical	
maturation	of	adolescents	with	22q11.2	DS	would	be	disrupted,	 in	particular	 in	 regions	as	
fusiform	gyrus	and	precuneus.	These	regions	are	known	to	be	important	for	socially	relevant	
processes	(Cavanna	&	Trimble	2006;	Schultz	et	al.	2003).	Some	of	these	alterations	would	be	
related	to	the	psychotic	symptoms	(Kates	et	al.	2011;	Dufour	et	al.	2008).		
The	7q11.23	deletion	(Williams	syndrome),	another	genetic	risk	factor	associated	with	NDDs,	
is	 associated	with	 reduced	 total	brain	volume	as	well	 as	 regional	differences	 compared	 to	
controls.	Some	gyrification	abnormalities	in	the	orbital	frontal	cortex	would	be	linked	to	their	
social	profile	and	the	same	abnormalities	in	superior	parietal	regions	would	be	associated	to	
their	visuospatial	deficits	(Eisenberg	et	al.	2010).	Sylvian	fissures	(located	at	the	insula	level)	
and	basal	ganglia	seem	also	affected,	with	variance	depending	on	the	size	of	the	deletion.	The	
alterations	are	consistent	in	both	adults	and	children	cohorts	(Fan	et	al.	2017).	
Some	of	 these	brain	 regions	affected	 in	 the	22q11.2	and/or	 the	7q11.23	deletions,	 as	 the	
insula,	the	temporal	giry,	the	cingulate	cortex	and	sone	occipital	regions,	are	similar	to	the	
ones	altered	 in	 the	16p11.2	CNVs	carriers.	A	 formal	and	quantitative	comparison	between	
CNVs	 associated	 with	 NDDs	 is	 required	 to	 understand	 the	 common	 and	 distinct	 neural	
mechanisms	between	several	genetic	risks	factors,	to	characterize	the	probability	of	overlap	
between	 neuroanatomical	 alterations	 and	 to	 compare	 the	 effect	 size	 of	 the	 global	 and	
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regional	alterations	depending	on	the	size	of	the	mutation.		
3.4.2.	Neuroimaging	analysis	of	psychiatric	diagnoses	
A	 long-term	perspective	 is	 to	perform	a	multivariate	pattern	 classification	of	ASD	and	SCZ	
neuroanatomical	differences	and	to	compare	these	patterns	to	the	ones	related	to	different	
genetic	 loci	 (common	and	 specific	 patterns).	 This	would	 contribute	 to	 identify	ASD	or	 SCZ	
subgroups	 that	 share	 alterations	 in	 the	 same	pathways	 than	 the	 genetic	 loci.	 Advances	 in	
statistical	methods	and	modeling	will	help	to	understand	the	complex	genetic	architecture	of	
these	diseases.	
On	the	animal	model,	Ellegood	and	al.	(2014)	adopted	an	ingenious	approach	by	conducting	
a	 genetic-first	 approach	 with	 several	 genetic	 risks	 factors:	 they	 implemented	 structural	
neuroimaging	in	26	mouse	models	for	genes	associated	with	ASD	and	intellectual	disability.	
Results	 demonstrate	 that	 the	 26	 genetic	 models	 are	 associated	 with	 3	 patterns	 of	
neuroanatomical	alterations,	suggesting	that	different	ASD	genetic	risk	factors	may	converge	
on	 shared	 brain	 structures	 and	 networks	 involved	 in	 ASD.	 These	 results	 are	 in	 favor	 to	
implement	the	same	type	of	design	in	human	studies	and	to	compare	the	results	to	mouse	
models.	Although	mice	and	humans	are	separated	by	80	million	years	of	evolution	and	show	
divergence	in	the	structure	and	function	of	the	brain,	the	general	organization	of	the	brain	is	
conserved	across	mammals.	Genes	differentially	expressed	in	one	brain	region	in	humans	are	
highly	likely	to	be	differentially	expressed	in	mice.	Some	cognitive	impairments	in	mice	may	
be	relevant	to	some	aspects	of	cognitive	phenotypes	in	human	(Yang	et	al.	2015).	However,	
neuroanatomical	measurements	are	more	analogous	between	model	organisms	and	humans	
(Malhotra	&	Sebat	2012),	and	some	neuroanatomical	alterations	seem	well	conserved	across	
humans	and	mice	with	the	same	genetic	variant	(Horev	et	al.	2011;	Portmann	et	al.	2014).	On	
the	 other	 hand,	 neuroimaging	 alterations	 showing	 no	 concordance	 across	 species	 and	
different	 genetic	 risk	 factors	 may	 also	 have	 implications	 for	 translational	 and	 preclinical	
studies.	 Another	 step	 is	 to	 study	 the	 developmental	 aspect	 of	 the	 abnormalities,	 to	
understand	at	what	stages	of	development	multiple-gene	effects	or	genetic	interactions	occur	
(Eisenberg	et	al.	2010).	
3.4.3	Relationship	between	genes	within	CNVs	and	brain	alterations	
The	pathways	from	genes	to	neural	circuits	to	phenotypes	remain	elusive.	In	their	paper	on	
neuro-imaging	16p11.2	patterns,	Maillard	et	al.	(2014)	did	some	complementary	analyses	on	
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peripheral	measures	of	gene	expression	levels.	mRNA	levels	of	most	of	the	genes	within	the	
16p11.2	interval	show	a	negative	correlation	with	global	metrics	of	brain	volume.	However,	
only	 a	 few	 papers	 tried	 to	 isolate	 the	 relative	 contribution	 of	 genes	 responsible	 for	 the	
observed	phenotypes	and	influencing	the	cortical	development.	Lin	et	al.	(2015)	investigated	
the	 changes	 in	 protein	 interactions	 network	 and	 identified	 that	 the	 mid-fetal	 cortical	
development	is	critical	for	the	16p11.2	proteins	to	connect	with	proteins	from	other	genes	
expressed	during	the	human	brain	development.	The	dysregulation	of	the	KCTD13-Cul3-RhoA	
pathway	in	layer	4	of	the	inner	cortical	plate	could	play	a	role	in	the	mirror	phenotype	on	brain	
size	and	connectivity,	although	this	is	still	in	debate	(Golzio	et	al.	2012;	Escamilla	et	al.	2017).	
Right	now,	it	seems	that	none	of	the	genes	in	the	16p11.2	interval	have	a	major	effect.	This	
would	be	the	interaction	between	all	of	them	and	the	addition	of	their	small	effects	that	would	
lead	to	the	large	alterations	(Huguet	et	al.,	2018).	Animal	models	targeting	specific	subsets	of	
genes	in	the	16p11.2	interval	are	still	important	tools	to	associate	intermediate	phenotypes	
variability	 with	 a	 temporal/spatial	 pattern	 of	 genes	 expression	 and	 to	 understand	 the	
genotype-phenotype	relationship	and	the	neurodevelopmental	processes.	
3.4.4	Study	of	CNVs	associated	with	psychiatric	conditions	
A	 last	 point	 is	 about	 our	 focus	 on	 a	 rare	 recurrent	 CNV.	 Since	 the	 implementation	 of	
chromosomal	microarrays	in	clinics	in	2009,	pathogenic	CNVs	are	currently	identified	in	10	to	
15	%	of	patients	referred	for	NDDs	(Battaglia	et	al.	2013;	Miller	et	al.	2010).	However,	clinical	
and	general	population	studies	suggest	that	the	majority	of	CNVs	is	not	recurrent	(Miller	et	al.	
2010;	Itsara	et	al.	2009).	Association	studies	show	that	the	non-recurrent	CNVs	are	enriched	
in	the	population	diagnosed	with	NDDs	(Cooper	et	al.	2011;	Männik	et	al.	2015).	Over	75%	of	
“clinically	significant”	CNVs	are	observed	only	once	or	a	few	times	 in	patients:	there	 is	still	
need	to	characterize	and	quantify	these	“non-recurrent”	CNVs.	To	this	end,	it’s	necessary	to	
move	from	a	case-control	design	to	model	the	effect	of	mutations	on	cognitive	and	neural	
traits,	 by	 developing	 predictive	models,	 depending	 on	 the	 characteristics	 of	 the	 disrupted	
genes.	It	will	also	be	important	to	integrate	the	information	from	de	novo,	inherited,	rare	and	
common	variations	(Malhotra	&	Sebat	2012).	Right	now,	despite	the	high	heritability	of	ASD,	
a	 genetic	 cause	 is	 identified	 in	 only	 25%	 of	 cases	 maximum,	 with	 genes	 implicated	 in	
chromatin	remodeling,	mRNA	translation,	metabolism,	synaptic	function.	Neuroimaging	can	
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be	a	tool	to	help	to	discover	new	genetic	variants,	through	genome-wide	association	studies	
with	brain	measurements.		
Detailed	cataloging	of	rare	and	penetrant	variants	allows	making	models	with	strong	construct	
validity.	However,	common	variants	also	contribute	to	ASD	susceptibility,	with	much	smaller	
effects	for	each	variant	(Huguet	et	al.	2013;	Sullivan	et	al.	2018).	Enigma	consortium	is	initially	
focus	on	the	discovery	of	common	variants	that	influence	normal	brain	variation	(Bearden	&	
Thompson	2017).	Their	current	studies	aim	at	identifying	genetic	overlap	between	multiple	
brain	 imaging	phenotypes	and	risks	 for	psychiatric	disorders	 (Lee	et	al.	2016;	Franke	et	al.	
2016;	Smeland	et	al.	2017).	Finally,	the	penetrance	and	variability	of	the	variants	might	be	
influenced	by	complex	interactions	between	genetic,	epigenetic	and	environmental	factors.	
Trying	 to	 unravel	 some	 of	 these	 factors	 will	 hopefully	 give	 insights	 on	 additional	 events	
necessary	to	push	the	CNV	carriers	beyond	the	threshold	of	diseases	(Pua	et	al.	2017). 	
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4.	GENERAL	CONCLUSIONS	
Neuroimaging	studies	of	psychiatric	disorders	such	as	ASD	have	produced	conflicting	results	
and	do	not	fully	contribute	to	the	understanding	of	the	underlying	mechanisms.	That	is	likely	
due,	 in	 part,	 to	 their	 heterogeneous	 and	 complex	 genetic	 architecture.	 The	 genetic	 first	
approach	 is	 a	 way	 to	 tackle	 this	 heterogeneity	 and	 to	 define	 subtypes	 of	 such	 diseases	
(Stessman	et	al.	2014).		
In	my	Ph.D.,	I	focused	on	large	recurrent	CNVs	associated	with	NDDs,	at	the	16p11.2	locus.	I	
replicate,	in	a	large	dataset,	some	previous	findings	and	demonstrate	the	robustness	of	our	
results.	 The	 reciprocal	 deletion	 and	 duplication	 are	 associated	 with	 robust	 reciprocal	
structural	brain	differences.	The	haploinsufficiency	and	over-expression	of	 the	same	genes	
lead	also	to	some	distinct	neural	mechanisms,	highlighting	by	specific	cerebral	alterations.		
We	observe	that	the	effect-sizes	of	this	genetic	risk	factor	on	neuroanatomy,	are	consistent	
with	 its	effect	 sizes	on	cognitive	and	behavioral	 symptoms.	That	puts	 into	perspective	 the	
much	 smaller	 effect-sizes	 observed	 in	 neuroimaging	 studies	 performed	 in	 groups	 of	 ASD	
patients,	 for	 example.	 This	 may	 be	 the	 consequence	 of	 the	 presence	 of	 multiple	
neuroanatomical	patterns	present	in	such	groups.	
16p11.2	CNVs	seem	to	have	an	early	impact	on	the	brain,	and	further	studies	are	required	to	
test	whether	neuroimaging	patterns	may	appear	before	the	onset	of	behavioral	symptoms.	It	
worths	to	test	if	and	which	additional	factors,	summed	with	those	of	the	16p11.2	CNVs,	are	
required	 to	 meet	 criteria	 for	 a	 psychiatric	 diagnosis.	 Understanding	 the	 developmental	
trajectories	and	the	variable	phenotypes	of	16p11.2	patients	will	 require	further	studies	 in	
very	young	carriers.	
More	generally,	 in	the	context	of	ASD,	significant	progress	has	been	made	to	 improve	and	
systematize	behavioral	therapies	(Amaral	2011),	but	no	biomarkers	are	available	to	guide	the	
clinical	decisions.	Neuroimaging	features	are	potentially	important	tools	to	evaluate	the	effect	
of	treatments,	they	may	improve	the	predictive	value	of	preclinical	studies	and,	first	of	all,	
they	 may	 help	 to	 the	 diagnosis.	 Many	 genetic	 and	 environmental	 factors	 modify	 brain	
development	 in	 ASD.	 Delineate	 some	 specific	 molecular	 mechanisms	 involved	 in	 ASD,	 as	
investigated	 in	 a	 genetic-first	 approach,	 may	 be	 a	 crucial	 step	 on	 the	 path	 to	 precision	
medicine.	 	
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ABSTRACT
BACKGROUND: 16p11.2 breakpoint 4 to 5 copy number variants (CNVs) increase the risk for developing autism
spectrum disorder, schizophrenia, and language and cognitive impairment. In this multisite study, we aimed to
quantify the effect of 16p11.2 CNVs on brain structure.
METHODS: Using voxel- and surface-based brain morphometric methods, we analyzed structural magnetic
resonance imaging collected at seven sites from 78 individuals with a deletion, 71 individuals with a duplication,
and 212 individuals without a CNV.
RESULTS: Beyond the 16p11.2-related mirror effect on global brain morphometry, we observe regional mirror
differences in the insula (deletion . control . duplication). Other regions are preferentially affected by either the
deletion or the duplication: the calcarine cortex and transverse temporal gyrus (deletion . control; Cohen’s
d . 1), the superior and middle temporal gyri (deletion , control; Cohen’s d , 21), and the caudate and
hippocampus (control . duplication; 20.5 . Cohen’s d . 21). Measures of cognition, language, and social
responsiveness and the presence of psychiatric diagnoses do not inﬂuence these results.
CONCLUSIONS: The global and regional effects on brain morphometry due to 16p11.2 CNVs generalize across site,
computational method, age, and sex. Effect sizes on neuroimaging and cognitive traits are comparable. Findings
partially overlap with results of meta-analyses performed across psychiatric disorders. However, the lack of
correlation between morphometric and clinical measures suggests that CNV-associated brain changes contribute
to clinical manifestations but require additional factors for the development of the disorder. These ﬁndings
highlight the power of genetic risk factors as a complement to studying groups deﬁned by behavioral criteria.
Keywords: 16p11.2, Autism spectrum disorder, Copy number variant, Genetics, Imaging, Neurodevelopmental
disorders
https://doi.org/10.1016/j.biopsych.2018.02.1176
Autism spectrum disorder (ASD) and related neurodevelopmental
disorders are deﬁned behaviorally and characterized by a signif-
icant clinical and etiologic heterogeneity. As a consequence,
investigating ASD under the assumption of an underlying homo-
geneous condition has resulted in controversial ﬁndings in the
ﬁeld of neuroimaging (1). Increased brain growth early in devel-
opment (2–4) and alterations of many regional brain volumes (5)
have been implicated in ASD, but results have proven difﬁcult
to replicate (1,6–8).
To mitigate some of these issues, cohorts of individuals with
shared genetic risk factors have been assembled to minimize the
noise introduced by etiologic and biological heterogeneity (9).
Such a “genetic-ﬁrst” study design provides the opportunity to
investigate a given neurodevelopmental risk (and associated
mechanism) shared by individuals who carry the same genetic
etiology irrespective of the psychiatric diagnosis.
Copy number variants (CNVs) at the 16p11.2 (breakpoints
4–5, 29.6–30.2 Mb-hg19) (10) are among the most frequent risk
factors for neurodevelopmental and psychiatric conditions.
There is a similar 10-fold enrichment of deletions and dupli-
cations in ASD cohorts (11,12), and both CNVs have large
effects on IQ (Z scores of 1.5 and 0.8, respectively) and Social
Responsiveness Scale (SRS) (Z scores of 1 and 2, respectively)
(10,13–15). However, there are phenotypic differences be-
tween both CNVs: the 10-fold enrichment in schizophrenia
cohorts (16,17) is only observed for duplications, and only
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deletions affect measures of language by 1.5 Z scores (18).
Previous studies demonstrated “mirror” effects of both CNVs
on head circumference and body mass index (13,19). Neuro-
imaging studies reported gene-dosage effects on global brain
metrics (20,21). However, large global effects and sample size
limited the interpretation of the regional analyses, any estimate
of effect size, and the generalizability of study results across
different ascertainments.
In the current study, we aimed at quantifying the effects of
16p11.2 deletions and duplications on brain structure. We also
examined the generalizability of our results across cohorts,
scanning sites, sex, and a broad age range. Finally, we aimed
at understanding the inﬂuence of clinical ascertainment. In
particular, we asked whether language, social responsiveness,
IQ, or the presence of psychiatric disorders may impact any of
the ﬁndings. To this end, we analyzed structural magnetic
resonance imaging (MRI) performed at seven sites from two
international cohorts of 16p11.2 CNV carriers, familial control
subjects, and unrelated control subjects. Voxel- and surface-
based methods were performed in parallel on 361 partici-
pants, including 307 individuals not previously analyzed at the
regional level, using whole-brain statistical methods.
METHODS AND MATERIALS
Participants
Data were acquired in two different cohorts in North America
and Europe. Enrollment in the Simons Variation in Individuals
Project (22) included referral by clinical genetic centers or web-
based networks, or active online registration of families, while
in the European 16p11.2 consortium the families were directly
recruited by the referring physician.
Carriers were ascertained regardless of clinical diagnoses or
age. The CNV carriers were either probands (n = 76) referred to
the genetic clinic for the investigation of neurodevelopmental
and psychiatric disorders, or their relatives (parents [n = 49],
siblings [n = 14], and other relatives [n = 10]). Familial control
subjects were relatives who do not carry a 16p11.2 CNV.
All families participated in a larger phenotyping project, as
previously reported (10,13,20–22). Trained neuropsychologists
performed all cognitive and behavioral assessments, including
tests of overall cognitive functioning (nonverbal IQ [NVIQ])
(23–27) and phonological skills (standard score of the nonword
repetition) (28,29). Participants also completed a broad
screening measure of social impairment, the SRS (30). Expe-
rienced, licensed clinicians provided clinical DSM-5 diagnoses
(31), using all information obtained during the research evalu-
ation. NVIQ scores and psychiatric diagnoses were available
for all participants. SRS total score was available for 77% of
the participants (72 of 78 deletion carriers, 57 of 71 duplication
carriers, and 149 of 212 control subjects), and phonological
measures for 43% of the participants (56 of 78 deletion car-
riers, 19 of 71 duplication carriers, and 81 of 212 control
subjects). Full description of cognitive and psychiatric
assessment is available in the Supplemental Methods and
Materials.
We analyzed data from 78 16p11.2 (breakpoints 4–5) dele-
tion carriers, 71 duplication carriers, 72 familial control sub-
jects, and 140 unrelated control subjects, including data not
previously analyzed at the regional level on 64 deletion carriers,
54 duplication carriers, 51 familial control subjects, and 138
unrelated control subjects. The latter were selected among
volunteers from the general population who had neither a
major DSM-5 diagnosis nor a relative with a neuro-
developmental disorder.
The study was approved by the institutional review boards
of each consortium. Signed informed consent was obtained
from the participants or legal representatives. Full description
of participants is available in Table 1, Supplemental Table S1,
and the Supplemental Methods and Materials.
MRI Data Acquisition and Processing
The MRI data included T1-weighted (T1w) anatomical images
acquired at seven sites using different 3T whole-body scan-
ners: Philips Achieva (Philips Healthcare, Andover, MA) and
Siemens Prisma Syngo and TIM Trio (Siemens Corp., Erlangen,
Germany). Four sites used multiecho sequences for 264 par-
ticipants (52 deletion carriers, 51 duplication carriers, 21 fa-
milial control subjects, and 140 unrelated control subjects),
and three sites used single-echo sequences for 97 participants
(26 deletion carriers, 20 duplication carriers, and 51 familial
control subjects). Thirty-four scans were excluded from the
analysis based on standardized visual inspection, which
identiﬁed signiﬁcant artifacts potentially compromising the
accurate tissue classiﬁcation and boundary detection (details
in Supplemental Methods and Materials).
Surface-Based Morphometry. In FreeSurfer 4.5.0 (http://
surfer.nmr.mgh.harvard.edu), each participant’s T1w image
was registered to a custom hybrid template consisting of 48
subjects (12 deletion children, 12 noncarrier children, 12 dupli-
cation adults, and 12 noncarrier adults) (21). Then, we used
FreeSurfer’s volumetric (32) and surface-based (33) algorithms
with default settings. We estimated the total intracranial volume
(eTIV) (34), global brain measures, cortical thickness, and sur-
face area. The cortical thickness and surface area maps were
resampled in fsaverage5 space and spatially smoothed with a
Gaussian kernel of 8-mm full width at half maximum.
Voxel-Based Morphometry. In parallel we processed
subjects’ T1w data within the computational anatomy frame-
work of SPM12 (http://www.ﬁl.ion.ac.uk/spm). T1w images
were classiﬁed in different brain tissue classes using the
“uniﬁed segmentation” (35) and an enhanced set of brain tis-
sue priors (36). Aiming at optimal spatial registration, we
applied the diffeomorphic registration algorithm DARTEL (37)
followed by a Gaussian spatial smoothing with 8-mm full
width at half maximum. Of note, total intracranial volume
computed by SPM is referred to as TIV.
Regions of interest were extracted using maximum proba-
bility tissue labels (http://www.neuromorphometrics.com)
within SPM12 using data from the OASIS project (http://www.
oasis-brains.org).
All MRI scanning parameters and processing are detailed in
the Supplemental Methods and Materials.
Data Analysis
Our whole-brain voxel-based morphometry (VBM) (38) analysis
used a factorial design to test for gene dosage–related local
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gray matter (GM) volume differences within the general linear
model framework of SPM12 (39). SPM t maps were generated
with a voxel-level threshold of p , .05 after familywise error
correction for multiple comparisons over the whole GM volume
using Gaussian random ﬁeld theory (40). We generated
Cohen’s d maps from familywise error–corrected t scores to
show the unbiased magnitude of the effects (Supplemental
Methods and Materials).
Surface-based analyses tested regional differences in
cortical thickness and surface area using linear models. For
each vertex in the cerebral cortex surface mesh, we ran a
multiple regression analysis. The vertexwise results were cor-
rected for multiple comparisons at a false discovery rate of q ,
.05 (41,42) (Supplemental Methods and Materials).
The main effects of linear and quadratic expansions of age,
sex, MRI site, and NVIQ were included as additional variables.
The cubic expansion of age did not show any signiﬁcant effect
and was subsequently removed from all analyses. In an
attempt to increase the power of our analyses we controlled for
the effect of the seven scanning sites by introducing them as a
random factor in a linear mixed model. This approach did not
change the obtained results.
Z scores for global brain metrics were obtained in CNV car-
riers and familial control subjects using the adjusted measures
from unrelated control subjects as the reference population.
Regional analyses were also corrected for the SPM estimate
of TIV, the mean cortical thickness, or the total cortical surface
area. In addition to the linear effect of gene dosage, we
investigated the quadratic term to identify nonreciprocal ef-
fects of both CNVs. Post hoc analyses comparing deletion
carriers and control subjects as well as duplication carriers and
control subjects identiﬁed regions predominantly altered by
each CNV.
We analyzed the interaction of the genetic groups with the
regressors (age, sex, MRI site, NVIQ) as well as the MRI pa-
rameters (single-echo vs. multiecho) and three other clinical
variables: SRS, phonological processing (nonword repetition),
and psychiatric diagnoses. NVIQ did not show any signiﬁcant
effect and was removed from the analyses on the whole
dataset. Dice index was computed to estimate the overlap
between 16p11.2-related alterations and statistical maps ob-
tained from a large cross-disorder neuroimaging meta-analysis
(http://anima.fz-juelich.de) (43). We computed the rate of
overlap between both maps. Finally, to motivate future hy-
potheses we relied on the Neurosynth database (http://
neurosynth.org) to meta-analytically decode the functional
association of the structural alterations observed in the gene
dosage analyses of the 16p11.2 CNV carriers. All these ana-
lyses are detailed in the Supplemental Methods and Materials.
Linear models on global metrics and regions of interest were
performed in R, version 3.2.5 (http://www.r-project.org; R
Project for Statistical Computing, Vienna, Austria), and voxel-
and surface-based analyses in MATLAB 2016b (The Math-
Works, Inc., Natick, MA).
RESULTS
Demographics
We analyzed 78 deletion carriers, 71 duplication carriers, and
212 familial and unrelated control subjects (Table 1,T
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Supplemental Table S1), including new data on 138 individuals
and data on 307 individuals not previously analyzed with
whole-brain statistical methods. Age ranges from 6 to 63
years. Deletion carriers and control subjects from the Simons
Variation in Individuals Project cohort are younger than the
same groups in the European cohort, and deletion carriers
overall are younger than the other groups. There is no sig-
niﬁcant difference in sex ratio across genetic groups and
cohorts. Mean NVIQ is 81 and 89 in deletion carriers, and 78
and 89 in duplication carriers for the European and Simons
Variation in Individuals Project cohorts, respectively. Ninety
percent of the deletion carriers, 69% of the duplication
carriers, and 25% of familial control subjects meet criteria for
at least one psychiatric diagnosis. Twelve categories of di-
agnoses are recorded across the CNV carrier groups,
including ASD in 13% of deletion carriers and 11% of
duplication carriers (Table 2).
Global Brain Metrics
Head circumference Z scores (Table 1) and eTIV (Figure 1A)
correlate negatively with the number of genomic copies of the
16p11.2 locus in both cohorts. Both GM and white matter total
volumes contribute to this effect on eTIV (Figure 1B, C). The
effect sizes on global brain metrics are up to 1 Z score for the
deletion and approximately 20.4 Z score for the duplication
(Supplemental Table S2). FreeSurfer and SPM estimates of
TIV, GM, and white matter are comparable across groups,
cohorts, and MRI parameters (Supplemental Figure S1). Gene
dosage preferentially affects cortical surface area and not
thickness (Figure 1E, F). Of note, age-related thinning of
cortical thickness is not signiﬁcantly different between genetic
groups (Supplemental Figure S2).
Regional Brain Differences Related to the 16p11.2
CNVs
In both cohorts, the whole-brain VBM analysis shows a
negative relationship between the number of genomic
copies at the 16p11.2 locus and the volume of several brain
regions. Alterations with an effect size .1 Cohen’s
d (detected with a conservative power of 74.4% for family-
wise error–corrected p , .05) include the bilateral anterior
and posterior insula, transverse temporal gyrus, and cal-
carine cortex (Figure 2A, Supplemental Table S3). Regions
with smaller volumes in deletion carriers compared with
control subjects and duplication carriers include the bilateral
precentral gyrus and middle and superior temporal gyri.
Altered regions with smaller effect sizes are detailed in
Supplemental Table S3.
There is a high degree of overlap between VBM ﬁndings
with large effects and regional cortical surface area alterations,
namely the insula, transverse temporal gyrus, and calcarine
cortex (negative gene dosage), as well as the precentral gyrus
Table 2. DSM-5 Diagnoses
Deletion Familial Control Subjects Duplication
EU (n = 25) SVIP (n = 53) EU (n = 45) SVIP (n = 27) EU (n = 23) SVIP (n = 48)
Neurodevelopmental Disorders 3 5 – – 4 6
Intellectual Disability
Communication disorder 16 53 – 2 – 3
Autism spectrum disorder – 10 – 1 2 6
Attention-deﬁcit/hyperactivity disorder 2 12 2 4 1 7
Speciﬁc learning disorder 1 14 1 – 4 4
Motor disorder, tic disorder – 26 – 1 1 9
Schizophrenia Spectrum and Other Psychotic Disorders – – – – 1 –
Bipolar and Related Disorders – – – – 1 –
Depressive Disorders 2 3 7 1 5 9
Anxiety Disorders 2 7 – 3 9 13
Obsessive-Compulsive and Related Disorders 1 1 – – 1 2
Trauma and Stressor-Related Disorders 1 – – – – 2
Elimination Disorders 5 14 – 2 1 2
Disruptive, Impulse-Control, and Conduct Disorders 1 5 – – – –
Substance-Related and Addictive Disorders 3 – – – 1 –
Feeding and Eating Disorders – – 2 – – –
Other Conditions That May Be a Focus of Clinical Attention – 9 – – – 9
From the DSM-5 (31).
A total of 20 of 25 European (EU) cohort deletion carriers (80%) had at least one psychiatric diagnosis: 11 had one diagnosis and 9 had several
diagnoses (between two and ﬁve); 17 of 23 EU cohort duplication carriers (74%) had at least one psychiatric diagnosis: 7 had one diagnosis and 10
had several diagnoses (two or three); 9 of 45 familial control subjects (20%) had at least one psychiatric diagnosis: 6 had one diagnosis and 3 had
two diagnoses. In the Simons Variation in Individuals Project (SVIP) dataset, 50 of 53 deletion carriers (94.3%) had at least one psychiatric diagnosis:
6 had one diagnosis and 44 had several diagnoses (between two and eight); 32 of 48 SVIP duplication carriers (66.6%) had at least one psychiatric
diagnosis: 10 had one diagnosis and 22 had several diagnoses (between two and ﬁve); 9 of 27 familial control subjects (33%) had at least one
psychiatric diagnosis: 4 had one diagnosis and 5 had two diagnoses. In both cohorts, unrelated control subjects without psychiatric diagnosis
were recruited.
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and superior and middle temporal gyri (positive gene dosage).
Regions with smaller effect size and no overlap are shown in
Figure 3; Supplemental Figure S3A, C; and Supplemental
Table S4. Cortical thickness, on the other hand, shows little
overlap with the VBM results (Figure 3; Supplemental
Figure S3B, D; and Supplemental Table S5).
Figure 1. Effects of gene dosage on global brain measures in the European (EU) and Simons Variation in Individuals Project (SVIP) cohorts. Boxplots of (A)
estimated total intracranial volume (eTIV), (B) gray matter (GM) volume, (C) white matter (WM) volume, (D) ventricular volume, (E) cortical surface area, and (F)
mean cortical thickness in each genetic group separately for the EU and SVIP cohorts. Gene dosage effect is estimated with a linear model using the number of
16p11.2 genomic copies (1, 2, or 3), and including linear and quadratic expansions of age, sex, nonverbal IQ, and magnetic resonance imaging site as ﬁxed
covariates. In each box, the bold line corresponds to the median. The bottom and top of the box show the 25th (quartile 1 [Q1]) and 75th (quartile 3 [Q3])
percentiles, respectively. The upper whisker ends at the largest observed data value within the span from Q3 to Q3 1 1.5 3 the interquartile range (Q3 2 Q1),
and lower whisker ends at the smallest observed data value within the span for Q1 to Q12 (1.53 interquartile range). Circles that exceed whiskers are outliers.
Post hoc comparisons show Bonferroni-corrected p values.
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These regional results are not inﬂuenced by subjects’ age,
sex, cohort, MRI site, or MRI protocol (multiecho vs. single-
echo): None of the variables shows an interaction with genetic
groups (Figure 2B, Supplemental Figures S4 and S5A). In
particular, a subgroup of participants who underwent both
multi- and single-echo protocols presents the same alterations
(Supplemental Figure S5B). NVIQ does not show any main
effect on regional brain structure and was removed as a co-
variate for the subsequent analyses. Given the above obser-
vations, we pooled all data.
Relationship Between Total Brain Volume and
Regional Differences
We examined the contribution of global differences to regional
alterations. There was no relationship between global metrics
and any of the aforementioned large effect regional ﬁndings,
even after adding GM volume as a covariate in the VBM ana-
lyses. We then tested for correlations between eTIV and the
raw or adjusted volumes of some signiﬁcant regions
(Supplemental Figure S6). This demonstrates that small,
average, or large brains contribute equally to the regional ef-
fects of 16p11.2 CNVs.
Mirror Effects Versus Differential Contribution of
CNVs to Regional Differences
To differentiate reciprocal from nonreciprocal effects driven by
either the deletion or the duplication carriers, we compared the
linear and quadratic effects of gene dosage. The nonreciprocal
effects of the 16p11.2 deletion and duplication identiﬁed by the
quadratic term are detailed in Supplemental Figure S7. Post
hoc analyses show that the deletion preferentially impacts the
volume and surface area of the calcarine cortex and the
Figure 2. Effects of gene dosage on regional gray matter volume in the Europe (EU) and Simons Variation in Individuals Project (SVIP) cohorts. (A) Left
panels (deletion . duplication) show voxel-based whole-brain maps, with the volumes of regions showing a negative relationship with the number of 16p11.2
genomic copies. Right panels (deletion , duplication) present the volumes of regions showing a positive relationship with the number of 16p11.2 genomic
copies. (B) Negative and positive gene dosage effects on gray matter volume following a leave-one-out approach by systematically removing one of the
magnetic resonance imaging sites. All the analyses are controlled for linear and quadratic expansions of age, sex, magnetic resonance imaging site, total
intracranial volume, and nonverbal IQ. Results signiﬁcant at a threshold of p , .05 familywise error corrected for multiple comparisons are displayed in
standard Montreal Neurological Institute space. Color bars represent Cohen’s d. L, left; R, right.
Effects of 16p11.2 Copy Number Variants on Neuroanatomy
258 Biological Psychiatry August 15, 2018; 84:253–264 www.sobp.org/journal
Biological
Psychiatry
transverse temporal gyrus (deletion . control) and the superior
and middle temporal gyri (deletion , control), with absolute
effect size .j1j Cohen’s d. The duplication carriers do not
show any neuroanatomical differences with effect size .j1j
Cohen’s d. We observe GM volume changes in the caudate
and hippocampus with Cohen’s d between j0.5j and j1j
(duplication , control) (Figure 4B, Supplemental Table S6).
Differences with smaller effect sizes or identiﬁed only by one of
the analytical methods such as alterations in the cerebellum,
precentral gyrus, and cingulate are detailed in the
L Lateral
L Medial
R Lateral
R Medial
L Lateral
L Medial
R Lateral
R Medial
VBM Only
Surface Area Only
A B
Figure 3. Overlap between voxel-based and surface-based results for cortical alterations associated with gene dosage. The relationship between gene
dosage and the morphometric features was compared in the pooled sample (n = 361). The voxel-based and surface-based statistical maps are thresholded at
the multiple comparisons–corrected p value and then projected on the cortical surface mesh. Regions with effect size $1 Cohen’s d and overlapping between
voxel-based and surface-based analyses are (A) the bilateral insula, transverse temporal gyrus, calcarine cortex and (B) the precentral, superior and middle
temporal gyri. L, left; R, right; VBM, voxel-based morphometry.
Figure 4. Differential and overlapping contribution of deletion and duplication to the regional gray matter volume differences. (A) Results of voxel-based
whole-brain maps from the conjunction analysis of both negative (deletion . control AND control . duplication) and positive (deletion , control AND con-
trol , duplication) gene dosage. The main mirror pattern is the insula. (B) Results of voxel-based whole-brain maps showing the effect size in regions with
larger volume in deletion carriers compared with control subjects (deletion . control), in control subjects compared with duplication carriers (control .
duplication), in regions with smaller volume in deletion carriers compared with control subjects (deletion , control), and in control subjects compared with
duplication carriers (control , duplication). Results signiﬁcant at a voxel-level threshold of p , .05 familywise error corrected for multiple comparisons are
displayed in standard Montreal Neurological Institute space. Color bars represent t scores for panel (A) and Cohen’s d for panel (B). CTRL, control individuals;
DEL, deletion carriers; DUP, duplication carriers; L, left; R, right.
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Supplemental Table S6 and Supplemental Figures S8A–D and
S9C–F.
The reciprocal mirror effects of the 16p11.2 deletion and
duplication are restricted to the bilateral insula. The post hoc
conjunction analysis shows that the deletion is associated with
an increase of the volume and surface area of the insula, and
the duplication is associated with a decrease of this region
(Figure 4A, Supplemental Table S6). We do not observe
reciprocal effects of gene dosage for cortical thickness mea-
surements (Supplemental Figure S9A, B).
Relationship With Psychiatric Diagnosis and
Cognitive Traits
Because the 16p11.2 locus is associated with more than one
psychiatric diagnosis, we quantiﬁed the overlap of our ﬁndings
with a large, cross-disorder neuroimaging meta-analysis
[http://anima.fz-juelich.de (43)]. We observe that the 16p11.2-
related VBM map overlaps 33% of the meta-analytic map
(Dice index): 46% for the cluster including the left insula, 28%
for the right insula, and none for the dorsal anterior cingulate
cortex.
We used Neurosynth to meta-analytically decode the psy-
chological terms most closely associated with the main
anatomical clusters identiﬁed in the VBM analysis. Supplemental
Table S7 illustrates the domains most associated with each
cluster. The transverse, superior, and middle temporal gyri (re-
gions predominantly affected in deletion carriers) show top as-
sociations with language, phonology, and auditory terms. The
anterior insula and caudate (alterations found in duplication
carriers) are associated with terms such as reward, pain, and
executive function (Supplemental Figure S10). Recognizing such
inverse inferences can provide hypotheses for future studies but
are unable to support strong conclusions.
However, the measures of NVIQ, SRS, and phonological
processing measured in participants do not show main effects
or interact with the gene dosage effects. The presence of low
general intelligence (NVIQ), language impairment (measured by
phonological processing), or poor social skills (SRS), or the
presence and number of comorbid psychiatric diagnoses,
does not change any of the neuroanatomical ﬁndings associ-
ated with the 16p11.2 deletion or duplication.
Ascertainment and Additional Factors Contributing
to Changes in Brain Structure
We tested whether ascertaining carriers for neuro-
developmental symptoms could bias our results. Because
clinical ascertainment may enrich as well for additional neu-
rodevelopmental factors present in CNV carriers and their
families, we investigated potential brain alterations in the family
members who do not carry a 16p11.2 CNV. Comparing control
subjects from deletion families (n = 51) and unrelated control
subjects shows changes in volume and thickness with medium
effect size (.0.5 Cohen’s d) of the left posterior insula and right
lingual gyrus; changes of volume also include the putamen and
hippocampus (Figure 5, Supplemental Figure S14E). No effect
was found for the cortical surface area (Supplemental
Figure S13E).
However, comparing deletion or duplication carriers with fa-
milial or unrelated control subjects does not change any of the
global (Supplemental Table S2 and Supplemental Figure S11) or
regional ﬁndings reported above (Supplemental Figures S12,
S13A–D, and S14A–D).
DISCUSSION
This large, multisite dataset combines new and previously
published data to expand our understanding of the neuroan-
atomical differences associated with 16p11.2 deletions and
Figure 5. Contribution of familial control subjects to the regional gene dosage-dependent gray matter volume differences. Results of voxel-based whole-
brain maps showing (A) regions with larger volume in control subjects from deletion families (n = 51) compared with unrelated control subjects (n = 140); and
(B) regions with smaller volume in control subjects from duplication families (n = 21) compared with unrelated control subjects (n = 140). Results signiﬁcant at a
voxel-level threshold of p, .05 familywise error corrected for multiple comparisons are displayed in standard Montreal Neurological Institute space. Color bars
represent effect size (Cohen’s d). L, left; R, right.
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duplications. The effect of the reciprocal CNVs on brain
structure is generalizable across heterogeneously ascertained
cohorts and remains signiﬁcant beyond differences in MRI
scanners, imaging protocols, analysis with two complementary
computational methods, sex, age, and presence and number
of comorbid psychiatric diagnoses. We extend previous neu-
roimaging studies by characterizing the reciprocal and differ-
ential effect of deletions and duplications on brain structure.
While 16p11.2 deletions and duplications impact reciprocally
bilateral insula [a gateway for sensory interoception, self-
recognition, and emotional awareness (44)], differences in
other brain areas are predominantly associated with either
CNV.
Recent publications have questioned the reliability of neu-
roimaging studies that are prone to both type I and II errors
(45). Our results provide robust estimates for CNV effect sizes
on brain structure. Our sample size is adequate to detect the
large effects associated with both CNVs, greatly reducing the
probability of spurious ﬁndings. In imaging genetics, it has
often been assumed that genetic variants may have larger
effects on imaging phenotypes than on clinical traits or psy-
chiatric risk (45). Our study shows, however, that the effect size
of CNVs on brain structure is similar to their effect previously
published for cognitive and behavioral traits (13,18). The effect
of the deletion is approximately twice that of the duplication for
global and regional brain volumes as well as clinical traits (such
as IQ loss) (13).
The brain regions showing gene dosage effects are
implicated in phonology, language, reward, and executive
function networks. These are diverse functions that are each
complex and heterogeneous. Nonetheless, the associations
raise hypotheses for future studies. Similarly, the spatial
overlap between our ﬁndings and the meta-analytical results
performed across all Axis I psychiatric diagnoses from the
DSM-IV-TR (43) may provide clues to pathological patterns
underlying the risk for psychiatric diagnoses conferred by
16p11.2 CNVs.
The effects of CNVs on brain structure are not changed by
ascertainment for either neurodevelopmental or psychiatric
symptoms. Differences in IQ, language ability, or social
responsiveness or the presence and number of psychiatric
diagnoses do not inﬂuence any of the ﬁndings. We have pre-
viously reported a similar observation for cognition showing
that the 16p11.2 deletion is associated with a decrease in IQ of
25 points regardless of whether carriers have intellectual dis-
abilities or intelligence in the normal range (13).
This observation is consistent with an additive model un-
derlying psychiatric disorders (46). Under this assumption,
brain alterations associated with CNVs contribute to, but do
not necessarily correlate with, a psychiatric diagnosis because
additional brain alterations or other factors are required for the
onset of the disorder. This is in agreement with studies
demonstrating that GM changes in the superior temporal gy-
rus, insula, and cingulate are observed in individuals both
diagnosed with psychosis and at high risk for developing
psychosis (47).
Contrasting familial and unrelated control subjects reveals
regional differences partially overlapping with the 16p11.2
gene dosage alterations. Of note, these alterations involve
cortical thickness as opposed to CNV-related cortical surface
changes. This may suggest the presence of additional factors
in these families ascertained in the neurodevelopmental
clinic. Assortative mating in families (in particular when the
CNV is inherited) may also contribute to an increase of risk
factors (48).
We are not implying that our ﬁndings are speciﬁc to the
16p11.2 locus. Differences in global and local GM volumes
as well as surface and thickness have been observed in
similar regions in 22q11.2 deletion carriers, another large-
effect-size genetic risk factor for psychiatric conditions
(49–51). They are also reminiscent of decreased regional
volumes in brain areas associated with emotion and face
processing demonstrated in individuals with a 7q11.23
deletion (52,53). It is still unclear whether these shared al-
terations in brain structure relate to similar changes in tis-
sue properties and underlying molecular mechanisms, but
they may suggest neuroanatomical convergence across
different genetic risk factors. This is illustrated by a study of
several genetically modiﬁed mouse models of ASD and in-
tellectual disability showing that their regional neuroana-
tomical alterations can be grouped in three different
clusters (6).
Limitations
The broad age range of our dataset (6–63 years of age) is a
potential limitation. However, we did not ﬁnd any interaction
between age and effects of gene dosage. The global and
regional alterations remain unchanged in age-speciﬁc sub-
groups, with the caveat of a signiﬁcant decrease in power
(Supplemental Figures S2 and S4A). The developmental
onset of global and regional differences in 16p11.2 CNV
carriers remains unknown, but the insula, striatum, and thal-
amus are also altered in a 7-day-old 16p11.2 deletion mouse
model (54,55), suggesting an early developmental effect.
However, speciﬁc anatomical effects are difﬁcult to interpret
between humans and mouse models. The multisite data
represents another limitation and can introduce false-positive
ﬁndings. However, investigating the impact of sites using
main as well as random effects did not identify any biases
introduced by the different scanners: this means that the
effect of the CNV may be more important than the noise
introduced by the multiple MRI sites. Finally, the missing
clinical data may limit our power to detect correlations be-
tween the brain morphometric measurements and the
cognitive and clinical data.
The strong results of this multisite genetic-ﬁrst neuro-
imaging study provide a robust characterization of 16p11.2
deletion and duplication effects on neuroanatomy. The
deletion and duplication of the same genetic interval may
affect brain regions in opposing ways, but other structures
are preferentially altered by one of the two CNVs. The
morphometric effect sizes are comparable to those previ-
ously recorded on cognitive traits. Results are generalizable
across sites, computational methods, age, sex, and ascer-
tainment for psychiatric or neurodevelopmental disorders.
This suggests that these brain alterations are related to the
risk conferred by the CNVs rather than the clinical manifes-
tations observed in carriers. This highlights the relevance of
studying genetic risk factors as a complement to groups
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deﬁned on the basis of behavioral criteria. Future longitudinal
studies are required to establish the onset of these
alterations.
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Quantifying the Effects of 16p11.2 Copy Number Variants on Brain 
Structure: A Multi-site ‘Genetic-First’ Study 
 
Supplemental Information 
 
 
Supplemental Methods & Materials 
Participants 
Participants below 6 years old were excluded. Participants with lower intelligence quotient (IQ) 
and severe externalized behavior and anxiety were unable to undergo the scanning procedure. 
Thirty-four scans were excluded from the analysis based on standardized visual inspection which 
detected the following image artefacts: incomplete head coverage, ghosting, inhomogeneities, and 
susceptibility artefacts. We scored each individual image for the abovementioned artefacts using 
a scale from 1 to 4 (1=extensive, 4=non-existent). Images scoring 3 or 4 in the scale were not used 
in the analyses. We applied a second level of inspection after the first step of the pre-processing 
in order to check if the tissue segmentation succeed or failed. If failed, the segmentation was done 
again. 
 
Psychiatric and cognitive assessments 
We pooled IQ assessments using the Wechsler intelligence scales, Wechsler Abbreviated Scale of 
Intelligence or Differential Abilities Scale (1-5). We used nonverbal IQ (NVIQ) standardized to a 
mean (standard deviation) of 100 (15), and four IQ subtests: block design, matrices, vocabulary 
and verbal similarities. Phonological skills were evaluated in the American cohort with the 
comprehensive test of phonological processing – non-word Repetition subtest (6) and in the 
European cohort with the developmental neuropsychological assessment - nonword repetition task 
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(7). Parents completed the social responsiveness scale, SRS (8)– an extensively validated 
quantitative measure of characterizing traits and symptoms of the autistic syndrome– about their 
offspring 4-18 years old. The SRS-Adult version was completed for each parent by a spouse or 
partner. Raw scores were used to provide greater differentiation of scores at the lower and higher 
end of the scales. 
Experienced, licensed clinicians provided clinical DSM-V diagnoses (9), using all information 
obtained during the research evaluation. In Europe, participants underwent a Diagnostic Interview 
for Genetic Studies (DIGS) (10) in case of suspicion of a psychiatric diagnosis, and an Autism 
Diagnostic Interview (ADI-R) (11) in case of suspicion of autism. In North America, the Autism 
Diagnostic Observation Schedule (ADOS) (12), ADI-R, Vineland-II (13) and Social 
Communication Questionnaire (14) were systematically performed. Unrelated controls with any 
major DSM-V diagnosis or with a family member diagnosed with neurodevelopmental disorders 
or genetic abnormalities were excluded. Data have been collected on the entire dataset for NVIQ 
and the number of psychiatric diagnosis. Numbers for the other measures are detailed in Table 1 
and Supplemental Table S1. 
 
MRI data acquisition and processing 
16p11.2 European Consortium. MRI data of the EU participants were acquired on two 3T 
whole-body scanners: 14 carriers of a 16p11.2 deletion and 17 duplication carriers, together with 
59 controls (21 familial and 38 unrelated controls) were examined on a Magnetom TIM Trio 
(Siemens Healthcare, Erlangen, Germany), using a 12-channel RF receive head coil and RF body 
transmit coil. New data from 17 carriers (11 deletions, 6 duplications) and 24 familial controls 
were scanned on a Magnetom Prisma Syngo (Siemens Healthcare, Erlangen, Germany) using a 
Martin-Brevet et al.  Supplement 
3 
64-channel RF receive head coil and RF body transmit coil. T1-weighted (T1w) anatomical 
images acquired with the TIM Trio scanner used a Multi-Echo Magnetization Prepared RApid 
Gradient Echo sequence (ME-MPRAGE: 176 slices; 256×256 matrix; echo time (TE): TE1 = 1.64 
ms, TE2 = 3.5 ms, TE3 = 5.36 ms, TE4 = 7.22 ms; repetition time (TR): 2530 ms; flip angle 7°). 
On the Prisma Syngo scanner, T1w images were acquired using a single-echo MPRAGE sequence 
(176 slices; 256×256 matrix; TE = 2.39 ms; TR = 2000 ms; flip angle 9°).  
Simons VIP study. Data were acquired using multi and single-echo sequences. Overall, 174 
participants (38 deletion carriers, 34 duplication carriers and 102 unrelated controls) underwent 
the research MRI protocol at two imaging core sites on matched 3T Magnetom TIM Trio MRI 
scanners (Siemens Healthcare, Erlangen, Germany), using the vendor-supplied 32-channel 
phased-array radio-frequency head coils. Sixty-eight participants were scanned at University of 
California sites (UC) and 106 at the Children Hospital of Philadelphia (CHOP). Structural MRI 
data included multi-echo T1w ME-MPRAGE using the following parameters: 176 slices, 256×256 
matrix, TR = 2530 ms, TI = 1200 ms, TE = 1.64 ms, and flip angle 7°. Clinical MRI images 
(single-echo) obtained at the phenotyping core sites were also analyzed. A sample of 15 deletion 
and 14 duplication carriers, together with 27 familial controls were scanned at University of 
Washington Medical Center, Baylor University Medical Center and Boston Children’s Hospital 
on two matched 3T Philips Achieva (Philips Healthcare, United States of America) and one 
unmatched Magnetom TIM Trio scanner (Siemens Healthcare, Erlangen, Germany), respectively. 
T1w images were acquired using single-echo MPRAGE sequence and the following parameters: 
160 slices; 256×256 matrix; TE = 2.98 ms; TR = 2300 ms; flip angle 9°. 
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All multi-echo images were averaged following a Root-Mean Square (RMS) averaging method. 
For each voxel, RMS calculates the mean of the intensities between the magnitude images of all 
echo times as follows:  
ܴܯܵ௔௩௘௥௔௚௘ ൌ 	ඥܫሺܶܧ1ሻଶ ൅ ܫሺܶܧ2ሻଶ ൅ ܫሺܶܧ3ሻଶ ൅ ܫሺܶܧ4ሻଶ 
Surface-based processing. The FreeSurfer’s automated volumetric algorithm allowed to estimate 
the global measures of brain structure such as cortical gray and white matter volumes (GM and 
WM respectively) (15) and the ventricular volumes. Cortical GM volume was then decomposed 
by FreeSurfer’s automated surface-based algorithms into its two orthogonal components: cortical 
thickness and surface area (16). This algorithm estimated the white matter/gray matter and gray 
matter/pial matter boundaries and constructed tessellated meshes, representing the cortical 
surfaces. The cortical thickness of all vertices in the cerebral cortex was then calculated from the 
white matter and pial surfaces. The total surface area for each individual was calculated by 
summing the area of the triangles that formed the tessellated mesh of the cortex. The local cortical 
surface area measurements were calculated by summing the area of the triangles immediately 
surrounding a vertex. 
Voxel-based processing. The SPM12 algorithm (Wellcome Trust Centre for Neuroimaging, 
London, UK, www.fil.ion.ac.uk/spm), running under MATLAB 9.0 (Mathworks, Sherborn, MA, 
USA), followed the automated tissue classification in the “unified segmentation” framework (17), 
using an enhanced set of brain tissue priors for increased accuracy for subcortical structures (18). 
The resulting tissue probability maps were transformed non-linearly to standard MNI space using 
the diffeomorphic inter-subject registration algorithm (DARTEL) (19). Grey matter probability 
maps were scaled with the corresponding Jacobian determinants to preserve the initial total amount 
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of signal intensity followed by an isotropic Gaussian smoothing kernel of 8 mm full-width-at-half-
maximum (FWHM) (20; 21). 
 
Data analysis 
Z-scores for Head Circumference (HC) were estimated based on age- and sex-normed 
orbitofrontal HC measurements obtained using Swiss anthropometric normative data as a 
reference population (22; 23).  
Voxel-brain morphometry (VBM) analysis. An explicit masking of GM was used to ensure 
inclusion of the same number of voxels in all analyses. The mask was created by averaging 
smoothed (FWHM of 3 mm isotropic) Jacobian-modulated tissue probability maps in MNI space 
across all subjects. 
For visualization purposes, final brain maps were generated using BSPMVIEW MATLAB 
toolbox (http://doi.org/10.5281/zenodo.59461), and highlighted GM regions were identified and 
labelled by mapping the Neuromorphometrics human brain atlas (Neuromorphometrics Inc., 
http://neuromorphometrics.com). SPM T-maps were converted to Cohen d maps with CAT12 
toolbox (http://dbm.neuro.uni-jena.de/cat12/).  
Surface-based analysis. We used the Desikan-Killiany atlas (24) to label brain regions. All 
vertices in the fsaverage5 space were included in the analyses, except those that were part of the 
corpus callosum or medial wall, or those labeled as “unknown”. We visualized the results with the 
Connectome Workbench on the Human Connectome Project’s 32k vertex standard inflated mesh 
(25). 
Analyses on the covariates. We estimated the influence of several covariates on the regional 
pattern of gene-dosage dependency in the VBM analyses. For the influence of MRI sites, we 
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performed a ‘leave-one-out’ approach. We systematically removed one of the MRI sites from the 
statistical design to determine whether any of the sites were preferentially driving the effect. We 
also controlled for the effect of the 7 scanning “sites” including them as a random term in a linear 
mixed model. 
Furthermore, we interacted the genetic groups with different covariates, especially the age, the sex 
(male and female), the MRI parameters (single- vs multi-echo). We divided the dataset in 3 age 
bins to analyze the effect of the broad age range on the results: individuals below or equal to 12 
years of age (40 deletion carriers, 12 duplication carriers and 36 controls); individuals between 12 
and 21 years of age (22 deletion carriers, 11 duplication carriers and 68 controls); individuals 
above 21 years of age (16 deletion carriers, 48 duplication carriers and 108 controls). We also 
compared the results on a subset of 31 deletion carriers and 33 duplication carriers who underwent 
both single- and multi-echo protocols. Finally, we used two distinct methods to explore the 
contribution of the global GM volume to the regional brain differences between genetic groups. 
The local covariation approach (26) consisted in including the total GM volume of each participant 
as an additional covariate in the statistical design. Secondly, some regional volumes extracted with 
Neuromorphometric toolbox were plotted against the eTIV measures to determine whether the 
regional gene dosage-dependent differences were present across the full range of eTIV 
distribution. 
Meta-analytic functional decoding analysis. We used the NeuroSynth database 
(http://neurosynth.org), which contains activation coordinates for 5809 fMRI studies. The 
Neurosynth platform provides a quantitative inference about potential cognitive functions linked 
to patterns of activation. The database contains automatically generated meta-analysis maps for 
several thousand psychological terms and topics (27). Statistical inference is calculated using a 
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chi-square test to generate P value maps (28). Contrast maps for each term were computed by 
comparing studies that loaded highly on that term to all other studies where that term did not load. 
A correlation analysis was performed between each term and the peak of each anatomical cluster 
associated with the 16p11.2 alterations. The resulting coefficients were ranked to find the most 
associated psychological terms. 
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Figure S1. Correlation between the estimation of total intracranial volume, gray matter 
and white matter volumes computed with FreeSurfer and implemented in SPM 
Correlation between the estimation of the brain volumes in cubic centimeter, computed with FreeSurfer and 
implemented in SPM, for each genetic group (1st row), for each cohort (2nd row), and for both multi and single echos 
as MRI parameters (3rd row). eTIV, estimated total intracranial volume; GM, gray matter; WM, white matter; SVIP, 
Simons VIP; FS, FreeSurfer. 
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Figure S2. Developmental trajectory of mean cortical thickness per genetic group 
Relationship between age and mean cortical thickness in the control (A and B), deletion (A), and duplication (B) 
groups. The mean cortical thickness measurements were corrected for sex, NVIQ, and cohort. The fit lines (red = 
deletion group, green = control group, and blue = duplication group) and 95% confidence intervals are included for 
the regressions between mean cortical thickness and age (i.e., both age and age2 terms). The group differences in 
developmental trajectory were modeled with mean cortical thickness as the dependent variable and group, age, age2, 
group X age, and group X age2 as the independent variables. The relationship between age and mean cortical thickness 
did not differ between the three groups. We ran the multiple regression analyses after re-centering the age variable to 
the mean age (24.7 years) and one standard deviation above (39.1 years) and below the mean age (10.3 years). The 
duplication carriers' cerebral cortex was thinner than the age-matched control participants at 39.1 years (t = -3.47, p 
= 0.0006) but not 24.7 years (t = -1.43, p = 0.15) or 10.3 years (t = -0.89, p = 0.37). The deletion carriers’ mean 
cortical thickness did not differ from the control participants’ mean cortical thickness at any point in development.   
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Figure S3. Effects of gene dosage on regional cortical thickness and cortical surface area in 
EU and SVIP cohorts 
For every vertex in the cerebral cortex, the relationship between either cortical thickness or cortical surface area and 
the number of 16p11.2 genomic copies was estimated for the EU (A and B) and SVIP (C and D) cohorts, after 
controlling for age, age2, sex, MRI site, NVIQ, and either mean cortical thickness or total cortical surface area. The 
cool colors depict a positive relationship (i.e., Deletion<Duplication), and the warm colors depict a negative 
relationship (i.e., Deletion>Duplication) between cortical metrics and the number of 16p11.2 genomic copies. The 
results are corrected for multiple comparisons at a false discovery rate of q<0.05. Color bars represent Cohen d. EU, 
European; SVIP, Simons VIP; L, left; R, Right. 
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Figure S4. Effects of gene dosage on regional gray matter volume according to age category 
and sex 
Effects of gene dosage on regional gray matter volume separately in children, adolescents and adults (A), and in males 
and females (B). Results of voxel-based whole-brain maps with volume of regions showing negative 
(Deletion>Duplication) and positive (Deletion<Duplication) relationship with the number of 16p11.2 genomic copies, 
after controlling for age, age2, sex, cohort, total intracranial volume and non-verbal IQ. Results significant at a 
threshold of p<0.05 family-wise error corrected for multiple comparisons are displayed in standard Montreal 
Neurological Institute (MNI) space. Color bars represent Cohen d. L, left; R, Right. 
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Figure S5. Effects of gene dosage on regional gray matter volume according to MRI 
parameters 
A. Left panels (Deletion > Duplication) show voxel-based whole-brain maps with volume of regions showing a 
negative relationship with the number of 16p11.2 genomic copies, for single-echo and multi-echo images, after 
controlling for age, age2, sex, cohort, TIV and NVIQ. Right panels (Deletion < Duplication) present positive 
relationship with the number of 16p11.2 genomic copies. B. Same analyses on a subset of carriers (31 deletion, 33 
duplication carriers) that underwent both single- and multi-echo protocols. Results significant at a threshold of p<0.05 
family-wise error corrected for multiple comparisons are displayed in standard Montreal Neurological Institute (MNI) 
space. Color bars represent Cohen d. L, left; R, Right. 
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Figure S6. Relationship between global and regional differences associated with 16p11.2 
deletion and duplication 
Correlation of the raw and adjusted volumes (in cm3) in a group of regions obtained from the local brain gene dosage 
Deletion>Duplication, with respectively the unadjusted and adjusted eTIV. Adjusted volumes are estimated in a linear 
model including age, age2, sex and cohort as fixed covariates. Calcarine cortex, hippocampus and superior/middle 
temporal gyri present the same pattern. The bold line represents the linear regressions between the region of interest 
and the eTIV. eTIV, estimated total intracranial volume. 
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Figure S7. Linear and quadratic effect of gene dosage on regional gray matter volume 
Linear (A) and quadratic (B) effects of gene dosage on regional gray matter volume. Results of voxel-based whole-
brain maps with volume of regions showing negative (Deletion>Duplication) and positive (Deletion<Duplication) 
relationship with the number of 16p11.2 genomic copies, after controlling for age, age2, sex, cohort, total intracranial 
volume and non-verbal IQ. Results significant at a threshold of p<0.05 family-wise error corrected for multiple 
comparisons are displayed in standard Montreal Neurological Institute (MNI) space. Each bar plot represents the 
contrast estimate of a peak voxel in a brain regions showing significant linear effects (eg. insula) or in regions showing 
alterations predominantly associated with the deletion (superior, transverse and middle temporal gyri, calcarine 
cortex) or the duplication (caudate). Color bars represent Cohen d. L, left; R, Right. 
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Figure S8. Differential and overlapping contribution of deletion and duplication to the 
regional gene dosage-dependent differences on cortical thickness and cortical surface area 
For every vertex in the cerebral cortex, the relationship between the number of 16p11.2 genomic copies and either 
surface area or cortical thickness was estimated for deletion carriers compared to controls (respectively A and B) and 
for duplication carriers compared to controls (respectively C and D) after controlling for age, age2, sex, cohort and 
either mean cortical thickness or total cortical surface area. The cool colors depict a positive relationship (i.e., 
Control>Deletion or Duplication>Control), and the warm colors depict a negative relationship (i.e., Control<Deletion 
or Duplication<Control) between either cortical thickness or surface area and the number of 16p11.2 genomic copies. 
The results are corrected for multiple comparisons at a false discovery rate of q<0.05. Color bars represent Cohen d. 
L, left; R, Right. 
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Figure S9. Overlap between voxel-based and surface-based results for cortical alterations 
specific to deletion and duplication 
Significant voxel-based results (Family wise error correction, p<0.05) are projected on the significant surface-based 
maps (False discovery rate, q<0.05) for deletion carriers compared to controls (C,D), for duplication carriers 
compared to controls (E,F) and for the conjunction analysis between the 3 genetic groups (A,B). L, left; R, Right. 
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Figure S10. Functional associations of the deletion and duplication regional gene dosage-
dependent differences in volume 
Radar plot displaying functional associations between meta-analytic coactivation and (A) deletion- and (B) 
duplication-related structural brain alterations. Correlation values are shown between peaks within each anatomical 
cluster and the top 17 psychological terms used in publications using Neurosynth platform. TTG, transverse temporal 
gyrus; STG, superior temporal gyrus; MTG, middle temporal gyrus. 
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Figure S11. Global brain measures in familial controls and unrelated controls 
Boxplots of eTIV, GM, WM and ventricular volumes, cortical surface area and mean cortical thickness in each control 
group. Regression is estimated with a linear model using an ordinal variable including controls of deletion families = 
1, unrelated controls = 2, and control of duplication families = 3. Linear and quadratic expansions of age, sex, non-
verbal IQ and MRI site are fixed covariates. In each box, the bold line corresponds to the median. The bottom and top 
of the box show the 25th (quartile 1 [Q1]) and the 75th (quartile 3 [Q3]) percentile, respectively. The upper whisker 
ends at highest observed data value within the span from Q3 to Q3+1.5 times the interquartile range (Q3–Q1), and 
lower whisker ends at lowest observed data value within the span for Q1 to Q1 - (1.5 * interquartile range). Circles 
that exceed whiskers are outliers. eTIV, estimated total intracranial volume; GM, gray matter; WM, white matter; 
EU, European; SVIP, Simons VIP.  
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Figure S12. Grey matter volume differences between CNV carriers and the two different 
control groups (familial controls and unrelated controls) 
A,C. Results of voxel-based whole-brain maps showing regions which volume is higher in deletion carriers compared 
to controls without any deletion-carrying family members (Deletion > Unrelated controls), in deletion carriers 
compared to controls with a deletion-carrying family member (Deletion > Deletion familial controls). B,D. Results 
of voxel-based whole-brain maps showing regions which volume is lower in duplication carriers compared to controls 
without any duplication-carrying family members (Duplication < Unrelated controls), in duplication carriers 
compared to controls with a duplication-carrying family member (Duplication < Duplication familial controls). 
Results significant at a voxel level at threshold of p<0.05 family-wise error corrected for multiple comparisons are 
displayed in standard MNI space. Color bars represent Cohen d. L, left; R, Right. 
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Figure S13. Contribution of CNV carriers and familial controls to the regional gene dosage-
dependent differences in cortical surface area 
A, C, and E. Cortical surface area comparisons between the deletion carriers, controls with a deletion-carrying family 
member (i.e., deletion familial controls), and controls without any deletion-carrying family members (i.e., Unrelated 
controls). B, D, and F. Cortical surface area comparisons between the duplication carriers, controls with a duplication-
carrying family member (i.e., duplication familial controls), and controls without any duplication-carrying family 
members (i.e., Unrelated controls). Warm and cold colors represent negative and positive gene dosage throughout the 
figure. All comparisons controlled for age, age2, sex, cohort and total cortical surface area. All results are corrected 
for multiple comparisons at a false discovery rate of q<0.05. Color bars represent Cohen d. L, left; R, Right. 
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Figure S14. Contribution of CNV carriers and familial controls to the regional gene 
dosage-dependent differences in cortical thickness 
A, C, and E. Cortical thickness comparisons between the deletion carriers, controls with a deletion-carrying family 
member (i.e., deletion familial controls), and controls without any deletion-carrying family members (i.e., Unrelated 
controls). B, D, and F. Cortical thickness comparisons between the duplication carriers, controls with a duplication-
carrying family member (i.e., duplication familial controls), and controls without any duplication-carrying family 
members (i.e., Unrelated controls). Warm and cold colors represent negative and positive gene dosage throughout the 
figure. All comparisons controlled for age, age2, sex, cohort and mean cortical thickness. All results are corrected for 
multiple comparisons at a false discovery rate of q<0.05. Color bars represent Cohen d. L, left; R, Right.  
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